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Abstract  
Extrinsic regulation of fate choice in mouse haematopoietic stem cells 
The mechanisms regulating stem cell self-renewal, proliferation, and differentiation are still not 
fully understood. Improving our knowledge of these processes will not only provide greater 
insight into stem cell biology but will also have major implications in the understanding of 
cancer development, since numerous cancers can trace their origins back to single stem cells.  
It has previously been shown that variations in culture conditions can alter fate choice in 
haematopoietic stem cells (HSCs). For decades cytokines have been used to maintain and 
expand mouse and human HSCs in vitro, with a number of studies demonstrating that cytokines 
directly influence HSCs fate choice. In this thesis, I explored the extrinsic regulation of mouse 
HSCs fate choice using three different approaches:  
1) Modulation of cytokine concentration 
2) Establishment of minimal conditions to retain HSCs function in vitro 
3) Development of 3D matrices to provide physical support beyond liquid culture 
 
The first results chapter (3.1) identifies that the amount of Stem Cell Factor (SCF) signalling 
does not alter the number of functional HSCs retained, but may alter the degree of clonal 
expansion post transplantation. Chapter 3.2 demonstrates that minimal cell culture conditions 
depending solely on gp130 signalling can maintain HSCs as single cells for an extended period 
of time. These cells retain full functional repopulation potential but present with a myeloid 
differentiation bias. Finally, Chapter 3.3 represents a first proof-of-principle series of 
experiments showing that HSCs are better supported on soft substrates, implicating physical 
forces in influencing HSCs maintenance ex vivo.  
In conclusion, these findings further confirm that SCF is a key regulator of HSCs fate, but is 
not essential for the retention of HSCs function. The newly established minimal cell culture 
medium allows the specific investigation of various molecules affecting HSCs fate choice at 
the single cell level. Furthermore, it offers a new platform for studying exit from quiescence in 
a controlled manner over several days. This latter aspect could have major implications for the 
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1.1 Haematopoiesis and haematopoietic stem cells 
Haematopoiesis is the process by which all mature blood cells are produced1. In the bone 
marrow of a healthy adult, an estimated 1011–1012 blood cells are produced every day2,3.  
Maintaining the balance between continuous blood cell production and depletion is essential, 
as disruption of homeostasis can result in, among others, anaemia, myeloproliferative 
neoplasms, and leukaemia4.  
Blood is a tissue consisting of an aqueous plasma and a cellular component5. Blood plasma 
makes up 55% of the total blood volume. It consist mainly of water (95%) and contains soluble 
proteins, circulating nucleic acids, electrolytes as well as metabolites such as glucose, vitamins, 
and amino acids6. The cellular component is composed of erythrocytes, thrombocytes, and 
white blood cells (leukocytes) such as lymphocytes (B and T cells), monocytes/macrophages, 
and granulocytes. There are four types of granulocytes, which are neutrophils, eosinophils, 
basophils and mast cells. Erythrocytes are involved in gas exchange between tissue and lungs, 
mainly transporting oxygen to the tissues. Megakaryocytes in the bone marrow produce 
thrombocytes (platelets), which play an important role in haemostasis by mediating blood 
coagulation and tissue repair. Leukocytes function in the defence of the immune system against 
infectious agents1,5.  
All cellular blood components are derived from a very rare subset of haematopoietic stem cells 
(HSCs) at the apex of the haematopoietic hierarchy. HSCs are multipotent, therefore can give 
rise to cells of all blood lineages, and have the ability to self-renew, thus give rise to one or two 
equally potent daughter cells upon division2,7. 
In human, it is estimated that 1 in 3x106 bone marrow cells is an HSCs, which is > 2-fold more 
frequent than in peripheral blood. In cord blood 1 in 0.93x106 cells is an HSCs, as determined 
by limiting dilution analysis in a xenograft mouse model8. This differs from mouse, in which 
functional studies of whole bone marrow have shown, that approximately 1x105 of total bone 
marrow cells are HSCs9,10.  
 
1.1.1 Developmental haematopoiesis 
The majority of studies defining vertebrate developmental haematopoiesis have used mouse, 
chicken, and zebrafish as model organisms. However, the underlying processes are broadly 
applicable to other vertebrates including humans11,12. 
INTRODUCTION 
2 
In vertebrates, blood cell development occurs in two separate waves; the primitive wave and 
the definitive wave. In mice, during the primitive wave, erythroid progenitors appear in so-
called blood islands that line the extra-embryonic yolk sac at embryonic day E7.5 (E17 in 
human)11,13-15. Their main function is to oxygenate the surrounding tissue in the rapidly 
developing embryo11. These haemangioblast-derived primitive cells form large nucleated 
erythrocytes that lack self-renewal capacity and as a consequence, the primitive wave is of a 




Figure 1:  Comparison of developmental stages in haematopoiesis between the mouse and 
human embryo15.  
A) Mouse haematopoietic development. Mesoderm forms during gastrulation at E6.5, followed by the 
development of blood islands in the yolk sac at E7.5. At 10.5 HSCs emerge in the AGM region, 
placenta and arteries (only AGM shown). At E14.5 haematopoiesis has moved to the liver, followed 
by bone marrow colonisation shortly before birth at E18.5.  
B) Human haematopoietic development. At embryonic day 17, haematopoiesis originates in the yolk 
sack. The liver is first colonised around day 23. Arterial clusters appear between day 27 and day 40, 
3 days before a second hepatic colonisation by CD34+ progenitors. At 10.5 weeks the bone marrow 
is colonised. Figure taken from Baron et al. Blood (2012) 
 
The definitive wave begins at E8.25 in mouse and E21 in human with the establishment of 
circulation15,16. Definitive erythromyeloid progenitors first arise in the extraembryonic yolk sac 
followed by the placenta at E9.5. The aorta-gonad-mesonephros (AGM) region is the first 
intraembryonic region to harbour haematopoietic progenitors at E10 but vitelline and umbilical 
arteries are also sites of development11,13,14,16. 
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Starting at E9 in mice the foetal liver (FL) is colonised by haematopoietic cells that were 
generated in other tissues such as the placenta, yolk sac and AGM13,14,16. Between E11 and E12, 
the foetal liver becomes the main region for definitive haematopoiesis until the formation of 
bone marrow (BM) cavities shortly before birth around E15. In human, the first hepatic 
colonisation occurs at E23, followed by a second colonisation at E30. At around 10.5 weeks, 
the bone marrow is colonised11,15. Throughout adulthood the bone marrow is the primary 
haematopoietic organ13,14,16. 
 
1.1.2 The bone marrow niche 
In 1978, Raymond Schofield coined the term “niche” for the unique environment in which 
interactions of the stem cell with other cells ensures its ability to self-renew and stay in a largely 
dormant state17. As discussed above, shortly before birth, HSCs begin to migrate from the foetal 
liver to the bone marrow where they remain and continue to proliferate during adulthood13,14,16. 
 
The bone marrow is a highly vascularised organ comprised of a medullary cavity encased in 
cortical bone. The endosteum lines the inside of the bone. Trabecular bone, also referred to as 
spongy bone, forms the internal bone tissue. Protrusions create a honeycomb or sponge-like 
structure enlarging the bone surface and ensuring that cells in this area are in close proximity 
to the bone in this area18. Bone itself is produced by osteoblasts which are highly active in the 
trabecular region19,20. Longitudinal arteries in the cortical bone branch into radial arteries and 
arterioles in the endosteum, which in turn drain into sinusoids and eventually coalesce into a 
central sinus forming the venous circulation, which allows entry and exit of HSCs and other 
haematopoietic cells into and from the blood circulation18,21,22. 
Historically, it was thought that the endosteal zone was home to HSCs23,24, which was supported 
by findings that phenotypic HSCs associate with the bone surface in vitro25 and in vivo26, in 
addition to observed functional changes in HSCs upon ablation of osteoblasts or other bone 
components27-29. This view of the endosteal stem cell niche was first called into question by 
findings that showed that deletion of key cytokines such as CXCL12 and SCF in osteoblasts 
did not alter HSCs function30,31. In more recent years the potential existence of a vascular niche 
has been investigated. 
 
Besides osteoblasts20,27,32, the bone marrow contains a variety of different cell types such as, 
endothelial cells31,33, CXCL12-abendunt reticular (CAR) cells34, Leptin receptor-expressing 
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(LepR+) perivascular cells35, Nestin-expressing mesenchymal cells (Nes+)36, and NG2+ 
pericytes which overlap in their expression with LepR+ and Nes+ stromal cells37 (Figure 2).  
It has been shown that these cells are involved in the regulation of HSCs quiescence, 
proliferation, and differentiation through the production of cytokines and other molecules 
including stem cell factor (SCF)31,33,37, osteopontin20,27, stromal cell derived factor 1 (SDF1 or 
CXCL12)34-37 G-CSF (granulocyte colony stimulating factor)38, interleukin-639, and 
angiopoietin25,36.  
 
Immunophenotypic HSCs have been found to be in close proximity to sinusoids which are 
surrounded by perivascular cells that show high expression of SCF and CXCL12. A common 
observation is that upon ablation of these cells or disruption of their cytokine production, HSCs 
numbers are greatly reduced. This supports the notion that these cells play an important role in 
HSCs maintenance and challenges the view of specific and restricted geographical space for 
HSCs along the endosteal surface of the bone31,34-36,40,41. 
 
 
Figure 2:  The adult bone marrow niche42. 
HSCs in the bone marrow can be found around arterioles as well as sinusoids receiving cytokine 
signals such as SCF and CXCL12 secreted by endothelial cells and perivascular cells as well as 
TGF-β1 produced by Schwann cells and megakaryocytes.  
 
It remains unclear if there is one particular bone marrow niche location or if different niches 
can support quiescent and/or actively cycling HSCs32,43-45. A recent report suggests that 
phenotypically, HSCs seem to be randomly localised among the bone marrow with sinusoids 
being the sole site of egression into circulation46. Therefore, live in vivo imaging supported by 
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distinct and reliable HSCs markers is necessary to gain further insight into where HSCs localise 
under homeostatic conditions. Several reporters have recently been described (α-catulin47, 
Hoxb548, and Fgd549) with varying levels of success, however none of these mark HSCs 
exclusively. 
 
1.1.3 Early evidence for the existence of a haematopoietic stem cell 
In the early 1950s it was discovered that the intravenous injection of whole bone marrow cells 
could recover the irradiated haematopoietic system of a recipient mouse50,51. This research 
inspired the first successful human bone marrow transplant for the treatment of a leukaemic 
patient in 1956, where multipotency and self-renewal capacity of HSCs were formally 
demonstrated for the first time in a human7,50,51. 
 
In 1961, pioneering experiments by Till and McCulloch described the formation of colonies 
consisting of haematopoietic tissue in the spleens of mice that had previously been transplanted 
with isolated bone marrow. These colonies were termed colony forming unit-spleen (CFU-S), 
and each colony was suggested to be derived from a small number of cells or even one single 
cell. This represented the first formal evidence for the existence of an HSCs in the bone 
marrow52. Shortly after that, the same group established that the haematopoietic system consists 
of three compartments: i) the stem cell compartment with multipotent cells of extensive 
proliferative capacity, ii) the differentiated cell compartment containing cells with limited 
proliferative capacity and iii) a mature cell compartment consisting of specialised cells.  
Additionally, tritiated thymidine uptake experiments provided early evidence that colony-
forming cells are quiescent53, which will be further be discussed in 1.2. 
The clonality and self-renewal ability of CFU-S was further shown by serial transplantation of 
CFU-S. Interestingly, colony-forming cells gave rise to colonies with widely differing 
characteristics as judged by morphology and the distribution of colony-forming cells among 
colonies. This was early evidence for heterogeneity in the stem cell compartment54, which will 
be discussed at length in section 1.3.  
Complementing these in vivo studies, clonal in vitro assays were established to analyse function 
and differentiation capacity of single cells. Short-term semi-solid culture, based on agar or 
methylcellulose medium mixtures, were used to analyse single cell clonality and differentiation 
capacity55,56. Later, long-term cell initiating culture (LTC-IC) assays were developed to 
measure self-renewal potential and differentiation capacity of the input cell by their ability to 
produce myeloid and or lymphoid progeny for a minimum period of 5 weeks56-60.  
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For many decades since, the haematopoietic system has been intensely studied through in vitro 
limiting dilution colony formation assays as well as in vivo tracking of haematopoietic clones, 
using retroviral marking, cellular barcoding, fluorescently tagged cells or single cell 
transplantation7,61,62. Ultimately, this has resulted in the identification and characterisation of 
the HSCs, which is to date, the best characterised adult mammalian tissue specific stem cell2,7.  
 
1.1.4 Isolation of adult mouse and human HSCs 
The gold standard to definitively prove that a purified HSCs is indeed a long-term repopulating 
cell with durable self-renewal activity is serial transplantation into irradiated recipient mice 
with long-term multi-lineage reconstitution in primary (≥16 weeks) and secondary (≥16 weeks) 
recipient animals. This contribution is usually measured by the presence of granulocytes (G), 
monocytes (M), B- and T-cells in the peripheral blood. To be considered successfully 
reconstituted, the contribution of donor cells typically must account for at least 1% of the total 
whole blood count at the later stages of this assay63. Interestingly, some HSCs do not contribute 
to >1% of lymphoid lineages in primary transplants but can generate an adequate amount of 
GM, B- and T-cells in secondary recipients64. These findings, and the late appearance of some 
single cell-derived clones64,65 call the above mentioned gold standard into question. 
 
HSCs with different self-renewal potential and repopulating kinetics can be identified and 
isolated based on size, granularity, cell surface antigen profile and different enzymatic activity, 
such as the cells’ ability to efflux Rhodamine123 (Rho123) or Hoechst 33342 (Side population, 
SP)7,66. Antibodies most commonly used for HSCs identification include those raised against 
CD117 (c-Kit), Stem cell antigen-1 (Sca-1), CD201 (EPCR), the SLAM markers CD48 
(negative) and CD150, CD135 (negative, fms like tyrosine kinase 3 (Flt3) or Foetal liver kinase 
2 (Flk2)), CD49b (negative) and CD34 (negative)7,67,68. Notably, relatively few of the surface 
markers used for identification are required for HSCs function7. 
 
In the mouse system, several groups have reported HSCs purities of >50% through different 
sorting strategies10,41,69, with a recent report showing that single cell transplantation using HSCs 
defined by the surface marker combination CD45+CD150+CD48-EPCRhigHSCsa-1high yields a 




As mentioned above, novel gene reporter mice such as α-catulin47, Hoxb548, and Fgd549 have 
been generated to aid in the FACS (fluorescent activated cell sorting) isolation of HSCs and the 
detection of HSCs in their putative niche in vivo. HSCs are enriched in the positive population 
of each of these reporters, with estimated HSCs frequencies of 14.9%, 47.6% (in combination 
with other HSCs surface markers), and 31.2% for α-catulin, Hoxb5 and Fgd5 respectively, in 
primary transplantation. Only α-catulin+ cells were transplanted as single cells with 15.4% of 
recipients showing multi-lineage reconstitution, which could be improved by co-staining with 
c-Kit to 28.6%48. Recent single cell expression profiling of the HSPC compartment confirms 
that Hoxb5, Fgd5, and α-catulin are indeed predominantly expressed in the long-term HSCs 
cluster70.  
 
Even though these sorting strategies result in a relatively pure population of HSCs, they each 
exclude cells that are functional stem cells because some HSCs are detectable in the non-
phenotypic cell fraction – a striking example of which was described for CD15041,71,72. It 
therefore remains unclear whether HSCs transit between phenotypes, but irrespective of this, it 
is evident that there are less rigorous phenotypes that include more HSCs at lower purities. 
Differences in these contaminating cell fractions has a significant impact on the interpretation 
of gene expression studies, especially those at the single cell level.  
 
Mouse HSCs are more extensively characterised than their human counterparts. While both 
systems share many conceptual similarities (e.g. rare HSCs, hierarchically organised, stepwise 
differentiation into mature cells), there are a number of differences which make it challenging 
to translate all of the research findings. In particular, there are major differences in the cell 
surface marker combinations used for purification and the governing signalling pathway3. One 
such example is the expression of CD34 (absent on mouse HSCs), which is the primary marker 
for enriching human HSCs. CD34 expression enriches for LTC-IC, which for human cells is a 
reliable read out for multipotency but not necessarily in vivo repopulation potential3,73. 
However, similar to CD150neg in mouse71, it has been shown that cells lacking CD34 expression 
are capable of multi-lineage, long-term repopulation in recipient animals74,75. Interestingly, 
engraftment in mice with CD34negCD38neg HSCs, is detectable at later stages than that of 
CD34+CD38neg HSCs75, suggesting that the former represents a specific HSCs subtype similar 
to mouse alpha-HSCs, which will be discussed in 1.3. 
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In addition to the absence of lineage markers, another potent marker that enriches for human 
HSCs is CD90 (Thy-1), which is expressed on human foetal liver, cord blood, and bone marrow 
HSCs76-78. Absence of CD38 expression further enriches for LTC-ICs as well as cells capable 
of multi-lineage repopulation in nonobese diabetic/severe combined immuno-deficient 
(NOD/SCID) mice. CD38 expression is also correlated with increased differentiation and 
CD34+CD38+ contain a higher proportion of actively cycling cells than CD34+CD38neg 
Haematopoietic Stem and Progenitor cells (HSPCs)78-80. 
To date, the combined expression of Lin-CD34+CD38−CD45RA−CD90+CD49f+ is used to 
obtain a population of HSCs from umbilical cord blood, which are capable of reconstituting the 
haematopoietic lineages in nearly 10% of recipient immuno-deficient mice81. Notably, the 
xenograft setting of these experiments may restrict the ability of all LT-HSCs to successfully 
repopulate, thereby potentially under-estimating the frequency in various cell preparations. This 
is supported by the higher percentage observed in long-term multi-lineage in vitro assays81.  
 
1.2 The cell cycle and quiescence in haematopoietic stem cells 
1.2.1 Mammalian cell cycle regulation  
The mammalian cell cycle is tightly regulated through a network of cyclins, cyclin dependent 
kinases (CDKs), as well as their antagonists, the cyclin-dependent kinase inhibitors 
(CDKIs)82,83. Cyclins bind to CDKs leading to the phosphorylation of downstream target 
proteins involved in the progression of one cell cycle phase to the next83. The cell cycle can be 
subdivided into 4 phases: i) A Gap phase (G1) which proceeds to the ii) DNA synthesis (S) 
phase, followed by a iii) second Gap phase (G2), which in turn progresses to the iv) mitosis (M) 
phase84. Each phase is characterised by the specific families of cyclins and their corresponding 
CDKs, with different cyclin D family members playing a pivotal role in G1 to S phase 
progression84. Importantly, in each phase cell cycle checkpoints are in place to ensure proper 
cell division84,85. These checkpoints are mediated by CDKIs, which inhibit CDKs and in doing 
so cause cell cycle arrest. Depending on their target specificity CDKIs can be subdivided into 
two families, the Cip/Kip family and the Ink4 family. The former is able to inhibit several 
different CDKs, whereas the latter inhibits CDK4 and CDK6 specifically82,84.  
The checkpoint in G1 that needs to be overcome to progress into S phase and thus into the 
mitotic cell cycle, is referred to as the Restriction point (R)84,85. Here, the tumour-suppressor 
Retinoblastoma (Rb) becomes fully phosphorylated by CDK4/6. In its hyper-phosphorylated 
form, Rb no longer binds and inhibits, members of the E2F transcription factor family which in 
turn activate gene transcription84,86. Upon exit from M phase, Rb becomes hypo-phosphorylated 
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and regains its inhibitory role in G1
84. Differential levels of CDK6 in human HSCs have been 
implicated in the accelerated exit from quiescence in ST-HSCs compared to LT-HSCs87. 
 
1.2.2 Quiescence is a distinct protective cell cycle state 
If conditions are unfavourable, cells may remain in G1 prior to R and become non-cycling
85. 
Upon exiting the cell cycle, the cell is considered to reside in a state termed G0. In case of 
senescent or terminally differentiated cells this state is irreversible. Quiescent cells however, 
reside in G0 and are able to re-enter the cell cycle
84,85. Quiescence is suggested to be a protective 
mechanism for the cells to prevent potential mutagenic events occurring during DNA 
replication and cell division2,88-90, the accumulation of which in HSCs, could lead to 
haematological malignancies such as leukaemia91 or myeloproliferative neoplasms92,93. 
Nonetheless, due to the longevity of HSCs and a prolonged G0 phase, DNA damage still 
accumulates. Therefore, quiescent HSCs require distinct DNA damage responses, a specialised 
DNA repair machinery, and a high drugs efflux capacity90,94. 
Thus, the vast majority of HSCs remain in the metabolically inactive G0 phase of the cell cycle 
and in doing so preserves a rare population of quiescent HSCs under homeostatic 
conditions2,69,95-98. 
 
1.2.3 Loss of function mouse models allow analysis of cell cycle regulators 
Various mouse models have been generated to investigate key regulatory molecules that control 
HSCs cell cycle and quiescence88,99-104.  
p53 Is a key regulator of cellular responses to stress stimuli, including DNA damage, 
culminating in senescence, apoptosis or cell cycle arrest83,105. A knock-out study in mice has 
demonstrated that p53 also plays an important role in maintaining HSCs self-renewal and 
quiescence and p53 has been shown to be highly expressed in the HSCs-enriched fraction (LSK, 
LineagenegSca-1+c-Kit+) compartment99,106,107. Mice lacking p53 expression have 2-fold more 
phenotypic HSCs with a higher proliferation rate than their WT counterparts. p53-/- LSK cells 
have the ability to reconstitute an irradiated recipient mouse; however, recipients develop and 
die of lymphoma within 4 months99. It has previously been shown that KO of the ETS 
transcription factor MEF increases HSCs quiescence and number but does not affect their 
repopulation capacity108. To assess if p53 regulates the increased quiescence in Mef-/- double 
knock-out (DKO) p53-/-Mef-/- were generated. DKO LSK outcompeted WT bone marrow cells 
in transplantation assays similar to Mef-/-, thus demonstrating that p53 does not give Mef-/- cells 
INTRODUCTION 
10 
a self-renewal advantage. DKO mice do show a higher percentage of SP cells, pointing to the 
role of p53 in maintaining quiescence in Mef-/- mice99.  
 
One of p53’s downstream target is p2199,105. Ablation of p21 results in the expansion of the 
HSPC pool but subsequent exhaustion of mutant HSCs, as cell cycle entry is no longer 
inhibited88. However, under homeostatic conditions, no accelerated turn-over of labelled HSCs 
was seen in p21-/- HSCs which calls into question the importance of p21 as a key regulator of 
quiescence96. Similar results to these p21-/- experiments were obtained in mice lacking 
expression of the CDKI p57, which under homeostatic conditions is highly expressed in LT-
HSCs and to a lesser extent in ST-HSCs and MPPs. Lack of p57 reduced HSCs repopulation 
ability in serial transplantation indicating impaired self-renewal capacity100,101. p57-/- LSK cells 
show an increase in the cell fraction that has entered the cell cycle100, however no alteration in 
cell cycle was observed in the LT-HSCs compartment101.  
 
 
Figure 3:  Regulation of the cell cycle in HSCs. 
Adapted from Rossi et al., Cell stem cell (2012). 
 
Both p21100 and p27101 expression are increased upon p57 deletion, indicating a compensatory 
role for these CDKIs. Indeed, p57 knock-down (KD) in the LSK fraction of p27-/- mice results 
in an increase of cycling LSK, reduced repopulation activity in primary transplants 
accompanied by a reduction of the LSK pool in primary recipients101. Thus, both p27 and p57 
play an important role in the maintenance of quiescence and self-renewal. Co-
immunoprecipitation experiments have shown that this is mediated by the binding of p27 and/or 
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p57 to HSCs70, which is a member of the heat shock protein 70 family. HSCs70 acts as a 
chaperon for cyclin D1 nuclear translocation and accelerates its binding to CDK4/6. p27/p57 
binding to HSCs70 inhibit nuclear import of cyclin D1 and, in doing so, prevents 
phosphorylation of Rb in the nucleus101. 
In contrast to loss of p21 and p57, ablation of the INK4 family member p18 leads to a 
competitive repopulation advantage of mutant HSCs over WT without HSCs exhaustion in 
serial transplantation102. This suggest that extrinsic modulation of p18, possibly using a specific 
inhibitor, may be key for HSCs expansion in vitro. 
 
Other members of the INK4 family are p16 and p1982,109. Ectopic expression of p16 in HSCs 
largely inhibits proliferation, whereas p19 overexpression completely abrogates proliferation. 
Both p16 and p19 expression levels are elevated in Bmi-1-/- mice, which present with reduced 
phenotypic HSCs number and hypocellular bone marrow. Bmi-1-/- bone marrow cells fail to 
reconstitute recipient mice, suggesting that suppression of p16 and p19 by Bmi-1 is necessary 
for HSCs to enter the cell cycle109. 
 
Interestingly, disruption of expression of single members of the Rb family (Rb, p107, and p130) 
does not result in severely dysfunctional HSCs. Viatour et al. therefore generated triple knock-
out mice (TKO) to assess their role in haematopoiesis103. TKO mice died within 12 weeks of 
Cre-induction. Animals analysed displayed splenomegaly with extramedullary haematopoiesis, 
as well as increased numbers of HSCs, LSKs and GMPs accompanied by a substantial 
expansion of mature myeloid cells. Transplantation of TKO unfractionated BM resulted in 
short-term reconstitution (4 weeks), outcompeting all WT competitors. However, TKO HSCs 
were not capable of long-term reconstitution, with recipients dying within 5 weeks post-
transplantation. This indicates that TKO HSCs are primed to differentiate into cells of the 
myeloid lineage but are accompanied by loss of HSCs self-renewal. Interestingly, 
reintroduction of one WT allele of p107 repressed the excessive myeloproliferation seen in 
TKO but did not compensate for deficient lymphoid cell production103. This shows that 
members of the Rb family can partially compensate for the loss of another member, but also 
underscore the need to better understand the molecular mechanism driving cell cycle 
progression and differentiation.  
 
Functional redundancy can also be observed in cyclin D1-/-, D2-/-, and D3-/- mice which exhibit 
only a mild haematopoietic phenotype. Combined knock-out of all three cyclin D molecules is 
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embryonic lethal after E13.5. Conditional TKO mice present with reduction of HSCs and 
impaired repopulating ability, showing the importance of cyclin D for normal 
haematopoiesis104. Presence of cyclin D marks the G1 phase of the cell cycle, where cyclin  
A2 – cyclin A1 is testes specific – is present in S and G2 phase
84,110. Double knock-out of cyclin 
A1 and A2 in an A1-/-A2fl/fl mouse results in death within 30 days of Cre-induction. 
Administration of pI-pC after bone marrow transplantation of A1-/-A2fl/fl BM results in reduction 
of cells among all haematopoietic lineages, showing that cyclin A2 is required for normal 
proliferation in haematopoietic cells110.  
 
Aside from the molecules directly involved in the cell cycle progression with well-described 
roles in model organisms, a number of pathways have been implicated in modulating HSCs 
quiescence and proliferation83. These include, but are not limited to, the TGF-β pathway, the 
PI3K/PTEN/AKT pathway, and the Wnt pathway83,111-116. 
 
The Transforming Growth Factor-β (TGF-β) superfamily signals through binding of the ligands 
to TGF-β type receptor II which forms a complex with TGF-β receptor I. This is followed by 
the phosphorylation of SMADs (SMAD-1, -3, -5, and -8), which then form a heterodimer with 
SMAD4 before translocating into the nucleus, where the complex recruits transcriptional 
cofactors to activate gene expression111,117.  
Yamazaki et al. showed that that pre-treatment of HSCs with TGF-β1 in vitro inhibits lipid raft 
clustering and in doing so keeps the majority of HSCs in a hibernating state111,118. Upon removal 
of TGF-β1, the cells were able to generate colonies and 20% of the surviving cells were able to 
reconstitute recipient mice in single cell transplants. Interestingly, SMAD2 and SMAD3 are 
phosphorylated in HSCs but become dephosphorylated upon cytokine stimulation. Pre-
treatment with TGF-β seems to protect SMAD2/3 from dephosphorylation, indicating that 
SMAD2/3 regulate quiescence in HSCs111. The same group later showed that non-myelinating 
Schwann cells in the bone marrow secrete TGF-β and that HSCs lacking the TGF-β type II 
receptor have impaired long-term repopulation ability. Interestingly, Tgfbr2∆/- show a decrease 
in Smad2/3 phosphorylation and increased cell cycling, suggesting that pSmad2/3 is important 
for HSCs self-renewal and quiescence119. 
Other Smad molecules have been investigated as well, with conditional KO of Smad5 failing 
to result in a haematopoietic phenotype with HSCs that have reconstitution ability and lineage 
output comparable with wild type, suggesting that SMAD5 is functionally redundant117. 
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Deletion of Smad4 on the other hand results in a mild haematopoietic phenotype with impaired 
self-renewal activity but normal lineage differentiation and cell cycle regulation120.  
Altogether, these findings suggest that some, but not all SMADs, are functionally redundant in 
HSCs, activating the same downstream pathways. 
 
The PI3K (phosphatidylinositide 3-kinases)/AKT (Protein kinase B) pathway has been 
implicated in the regulation of cell proliferation, differentiation, resistance to stress, survival, 
and migration83,113. PTEN (Phosphatase and tensin homologue) is a negative regulator of 
PI3K/AKT112,113. Ablation of PTEN results in a reduction of phenotypic LT-HSCs, whereas the 
ST-HSCs pool is not significantly affected113. PTEN-/- LT-HSCs are more proliferative 
compared to WT control and can only transiently repopulate irradiated recipients112,113. 
Interestingly, multi-lineage reconstitution capacity of PTEN-/- HSCs can be restored using the 
drug Rapamycin, which selectively inhibits mTOR kinase activity, which is a downstream 
target of PI3K112. PTEN-/- does not affect the homing ability of HSCs but it does lead to an 
increase in mobilisation to the peripheral blood and spleen113. Loss of PTEN in HSCs results in 
decreased numbers of lymphoid progenitors and B220+ B lymphocytes, whereas the myeloid 
lineage is not affected113. These findings show that PTEN expression is necessary to maintain 
self-renewal in HSCs and plays a role in directing lineage choice.  
 
Downstream genes of PTEN include those encoding for AKT and Forkhead O (FoxO) 
proteins83. Akt1-/- and Akt2-/- mice only show a mild haematopoietic phenotype, suggesting 
functional redundancy. In contrast, DKO Akt1-/-Akt2-/- mice have defective haematopoiesis with 
mutant HSCs entering cell cycle less frequently and impaired differentiation potential114. 
AKT directly phosphorylates FOXO1, O3 and O4 and inhibits their activity resulting in their 
exclusion from the nucleus, where they can no longer act as transcription factors leading to cell 
cycle arrest through activation of p27, p130 and p21 as well as inhibition of cyclin D 
expression83,115,116. As seen before, single knock-out of FoxO1/3/4 does not yield a severe 
haematopoietic phenotype, suggesting functional redundancy116. However, upon serial 
transplantation of FoxO3a-/- bone marrow, an HSCs self-renewal defect becomes apparent115. 
Double knock-out of FoxO1/3 results in an increase in apoptosis116. FoxO3a-/- HSCs have 
elevated ROS levels, likely driving the observed increase in phosphorylation of p38MAPK115. 
FOXO1/3/4 deficiency increases myeloid cell production concomitant with a reduction in BM 
HSCs and LSK116. Mutant HSCs have impaired long–term repopulating capacity and proliferate 
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faster. This cell cycle phenotype is further reflected in the reduced expression levels of p21, 
p27, and p130 in these TKO HSCs, whereas Cyclin E1 and D2 expression is elevated116.  
 
1.2.4 Upstream regulators of proliferation 
Activation of above mentioned pathways is mediated by receptor binding of growth factors, 
insulin, or cytokines such as SCF (stem cell factor)121,122, TPO (thrombopoietin)121,123, Ang-1 
(Angiopoietin)101, and G-CSF124 each of which have been shown to promote HSCs proliferation 
in vivo and in vitro. In vitro, these are often used in conjunction with Interleukin (IL)-3125-127, 
IL-6126,128 and IL-11125,129 which have synergistic mitogenic effects on HSCs proliferation125,130. 
 
Furthermore, inflammatory signalling has been shown to stimulate HSCs proliferation131. These 
can involve type I132 or type II133 interferons (interferon-α and interferon-γ respectively), Tumor 
Necrosis Factor (TNF)134,135, and lipopolysaccharide (LPS)136. 
 
More recently, posttranscriptional regulation of genes through micro-RNA (miRNA) have been 
shown to alter gene expression through mRNA destabilisation and translational inhibition137. 
Ablation of miR-126 expands human and mouse HSCs and improves engraftment and homing 
ability137. In contrast, deletion of the global miRNA regulator Dicer results in the loss of 
functional HSCs138. Overexpression of miR-125a drives an increase in stem cell frequency and 
gives mouse HSCs a competitive advantage in reconstitution assay compared to wild-type139. 
This observation is in accordance with the finding that miR-125a deficient mice have reduced 
self-renewal capacity138. Inhibition of the micro-RNA Let7 leads to an increase in HMGA2 
expression concomitant with in an increased frequency of HSCs self-renewal as well breast 
cancer initiating cells140,141. In HSCs, it has been shown that this is regulated via the Let7 
inhibitor LIN28b and the Let7 negative target HMGA2, overexpression of both these molecules 
increase donor cell contribution in irradiated recipients over WT141.  
 
The above discussed regulatory molecules and pathways are only a small sample of the complex 
machinery that is the cell cycle. Much is still not understood and even less is known about cell 
type-specific mechanisms of action. Further gene perturbation studies are therefore necessary 
to gain a better understanding of how the cell cycle, and in particular the process of G0 exit, is 




1.3 HSCs heterogeneity 
The existence of heterogeneity within the HSCs compartment was shown as early as 1964, 
when Till et al. reported highly variable spleen-colony formation with respect to number and 
types of daughter cells within the colonies54,62. Subsequently, haematopoietic progenitor 
heterogeneity was also noted in in vitro colony forming assays62. In the 1980s, retroviral 
marking of HSCs derived from different haematopoietic tissues allowed the identification and 
tracking of clones in vivo over extended periods of time61,62. Through clonal tracking of 
transplanted single HSCs it was shown that HSCs are heterogeneous with respect to self-
renewal activity, life span, repopulation pattern, and fate commitment63,142. An HSCs can self-
renew through symmetric or asymmetric cell division143,144, it can undergo apoptosis or it can 
exit quiescence and differentiate, the latter two both leading to a decline in the HSCs pool  
(Figure 4)7.  
 
 
Figure 4:  Putative HSCs fate choices. 
HSCs can make different fate choices throughout their lifetime. An HSCs can remain in the G0 phase 
of the cell cycle or it can self-renew symmetrically leading to an expansion of the HSCs pool. 
Additionally, the HSCs can proliferate and give rise to a differentiated daughter cell and another 
HSCs through asymmetric cell division, with the HSCs returning to a quiescent state. Alternatively, 
the stem cell can produce two differentiated cells or undergo apoptosis leading to a decline in the 
HSCs pool.  
 
1.3.1 HSCs heterogeneity in self-renewal activity and life span 
The HSCs population is commonly subdivided into long-term HSCs (LT-HSCs), also referred 
to as long-term repopulating cells (LTRCs), and short-term HSCs (ST-HSCs)7. LT-HSCs are 
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considered to be more primitive, giving rise to larger clones with greater lineage potential and 
often associated with delayed detection of mature progeny in peripheral blood upon 
transplantation1,145. 
Most importantly, LT-HSCs but not ST-HSCs can repopulate mice in a serial transplantation 
setting68, a formal demonstration of their ability to create daughter HSCs.  
 
The proliferative stress exerted on LT-HSCs would be tremendous if all mature blood cells 
were directly derived from this rare population of cells. HSCs are relieved from this burden by 
multipotent, oligo-potent and lineage-restricted progenitor cells, which are highly proliferative 
and possess extensive developmental potential2,146. A recent study using in situ Doxycyclin 
(Dox) induced transposon labelling, has attempted to quantify the dynamics of lineage 
replacement by multipotent progenitors (MPPs) over time. Nearly 20% of erythromyeloid 
clones were derived from an MPP population at 8 weeks post Dox administration. However, 
the caveat of this tracking method is that not all progenitor populations are labelled, thus the 
actual number of contributing MPP may be underestimated. In addition, cell recovery and 
sequencing depths may not be equal among populations, introducing technical bias146. 
 
Another study estimated that that LT-HSCs divide approximately once every 145 days based 
on the computational modelling of BrdU (Bromodeoxyuridine) label retention95. Studies using 
doxycycline induced histone 2B-GFP reporter mice have shown 80% of HSCs have divided 
within a 24 week chase period; however 5% of stem cells retain the label past 72 weeks. Using 
a model in which 80% of HSCs cycle fast and 20% of cells divide less often, it was estimated 
that 5.3–11.1% of fast proliferating HSCs divide daily and only 0.8–1.8% per day of the slow 
population divide96. The former observation is in agreement with findings from other groups in 
which 4.7%147 or 6%148 of BrdU-labelled HSCs divided daily. However, as BrdU incorporation 
over the 10-day treatment time was linear, the authors concluded that all HSCs proliferate at a 
similar rate. This conclusion however, does not consider the extent of functional heterogeneity 
in the HSCs population. Of note, only 45.9% of phenotypic LT-HSCs (LSK SLAM CD41neg) 
incorporated the label at 10 days148. Another report found 87.8% BrdU-labelled HSCs (LSK 
cKit+) at day 10 and >99% labelling after 180 days of continuous BrdU administration147. Thus, 





The proliferation rate of the slow population mentioned above would be equivalent to once 
every 55–125 days in the slow cycling HSCs population, which is consistent with the lower end 
estimate of the previously reported 145 days95,96. In contrast, ST-HSCs exhibit finite self-
renewal and cannot repopulate a mouse past the primary transplantation. ST-HSCs divide 
approximately 4 times more often than LT-HSCs and exit cell cycle faster87,95,142. 
Since BrdU has been shown to have a mitogenic effect on HSCs95,148, another study employed 
CFSE (carboxyfluorescein succinimidyl ester) labelling, which is diluted to undetectable levels 
after 5 cell divisions. Using this method, transplanted cells were tracked for 3–21 weeks. The 
authors found that only few cells had not divided by at the end of the chase period. Serial 
transplantation of non-divided LSK or LSK that had divided >5x between 12–14 weeks post 
primary transplantation were able to engraft secondary recipients. Interestingly, cells that had 
divided >5x as early as 3 weeks post primary transplantation failed to repopulate. These 
findings show that serially transplantable LT-HSCs are present in both the cycling and 
quiescent fraction. Extrapolating from their data the authors estimate that HSCs divide every 
39 days on average totalling in 18 cell divisions during the lifetime of a mouse149. It is important 
to note that this estimation relies on the reliable and comprehensive labelling of all stem cells 
prior to the primary transplant. Therefore, it is currently impossible to conclude with absolute 
certainty what the average life span of an HSCs is and how many cell division it will undergo 
before exhaustion of its progeny as labelling and recovery of all HSCs is not feasible with the 
presently available technology.  
 
1.3.2 HSCs heterogeneity in numbers and cell types produced post-transplantation 
The spleen colony formation assays described above inferred heterogeneity, but in the 21st 
century, clonal and single cell approaches in purified stem and progenitor cell populations 
revolutionised the field by formally documenting HSCs heterogeneity. These started with the 
work of Muller-Sieburg et al., who showed through serial transplantations of HSCs clones from 
limiting dilution assays (LDA) that daughter HSCs behave similarly to their parents with regard 
to self-renewal, primitiveness and lineage contribution142. Interestingly, it was observed that 
approximately 30% of all clones expressed a lineage bias towards the myeloid or lymphoid 
lineage, which was maintained through serial transplantation. These findings led to the 
conclusion that the lineage dominance is due to an “inherited”, cell intrinsic mechanism142,150. 
The HSCs clones were classified as myeloid biased (my-bi), lymphoid biased (ly-bi) or 
balanced (bala) based on the ratio of lymphoid to myeloid lineage142. 
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Similar findings were classified differently in a large study of single HSCs transplantations64 
where the inaccurate term of “myeloid-biased” was avoided since it which incorrectly implies 
that the myeloid output from the my-bi clones differed from that of balanced clones. Rather, 
these cells produce the same amount of myeloid cells but are deficient in lymphoid potential7,64. 
Dykstra et al. present this unbiased categorisation of HSCs based on the relative amounts of 
mature cell production, with HSCs giving rise to primarily myeloid cells as alpha-HSCs and 
those clones that have a balanced lymphoid and myeloid lineage output as beta-HSCs. Both 
populations are characterised by robust self-renewal and a constant repopulation pattern in 
primary and secondary transplantations64. The lymphoid progenitor cells (CLPs) derived from 
alpha-HSCs are quantitatively and qualitatively deficient when compared to CLPs generated 
from beta-HSCs64,151. This is consistent with accounts from Muller-Sieburg et al., which 
reported that lymphoid progeny generated from my-bi HSCs have impaired responses to IL-7, 
a cytokine important for B- and T-cell development150. Single HSCs with finite  
self-renewal activity (e.g., those that could not repopulate secondary recipients) were classified 
as gamma and delta-HSCs. Gamma-HSCs are largely lymphoid biased but can produce myeloid 
cells, whereas delta-HSCs only produce lymphoid cells 16–20 weeks post transplantation64,151. 
Benveniste et al. suggested that these should be categorized as intermediate HSCs (IT-HSCs), 
a transitional HSCs between LT- and ST-HSCs, since these cells show prolonged (>8 months) 
reconstitution after transplantation152. There is significant overlap between the HSCs 
subcategorisation used by different labs as summarised by Ema et al. and shown in Table 1 and 
Figure 5, emphasising the need of a unified standard to detect and describe HSCs subtypes63. 
 
Table 1:  Variations in HSCs subcategorisation 
HSCs subtype 
Repopulation in weeks post 
transplantation 
Ratios of mature progeny 
Long-term >52 weeks not assessed 
intermediate-term >32 weeks <52 not assessed 
short-term <24 weeks not assessed 
   
myeloid-biased 20 weeks Lymphoid:Myeloid: <3 
balanced 20 weeks Lymphoid:Myeloid: <10, >3 
lymphoid-biased 20 weeks Lymphoid:Myeloid: >10 
   
alpha 16 weeks Myeloid:Lymphoid: >2 
beta 16 weeks Myeloid:Lymphoid: >0.25, <2 





Figure 5:  HSCs subtypes classified by different labs largely overlap.  
Adapted from Ema et al., Exp Hematol (2014). Venn diagram shows the relationship between the 
different classified HSCs subtypes. Data was used from 30 single cell transplantations. A) 14 My-bi 
HSCs, 8 LT-HSCs, and 10 α-HSCs were identified. B) 4 Bala-HSCs, 10 IT-HSCs, and 7 β-HSCs 
were categorised. C) 12 ST-HSCs, 12 Ly-bi HSCs, and 13 γ-HSCs were identified. My-bi=myeloid 
biased. Ly-bi=lymphoid biased. Bala=balances. LT=Long-term HSCs. IT=Intermediate-term HSCs. 
ST=Short-term HSCs. α=alpha-HSCs. β=beta-HSCs. γ=gamma-HSCs. Numbers indicate positive 
transplant outcomes categorised in accordance to the criteria displayed in Table 1.  
 
Interestingly, the relative proportion of alpha and beta-HSCs changes throughout mouse 
development. In the mouse foetal liver (E14.5) beta-HSCs account for the majority of HSCs, 
with only 5−10% being alpha-HSCs. Both populations increase at similar rates until E18.5 with 
alpha-HSCs becoming more frequent in the postnatal and young bone marrow. In the older 
adult bone marrow (>1 year) alpha-HSCs (ESLAM) are the dominant cell type151 and this 
accumulation continues into old age. This is consistent with previous findings that my-bi HSCs 
are enriched in aged mice89,153-155 and that myeloid chimaerism is increased in mice transplanted 
with donor HSCs derived from aged (18 months) mice155,156. The phenotypic HSCs (pHSCs) 
frequency increases with age in the mouse bone marrow89,151,155,157. However when this 
population is further subdivided into CD150+CD41neg, the HSCs compartment is significantly 
decreased157, whereas a vast increase is observed in the CD150+CD41+ population154,157,158. 
This is also reflected in the recent finding by Yamamoto et al. where aged HSCs produced a 
significantly lower amount of T lymphoid cells in both primary and secondary transplantation 
when compared to young HSCs indicating that aged HSCs may become lymphoid-deficient157. 
 
1.3.3 HSCs heterogeneity in fate commitment 
Currently available methods for HSCs isolation are unable to prospectively discriminate 
between distinct HSCs subtypes, which makes the study of their differences at the molecular 
level particularly difficult62. With emerging tools in the field of single cell biology, many 
studies have now attempted to uncover what mechanisms and molecules link transcriptional 
and phenotypic variations in HSCs159-161.  
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In a high-throughput single cell gene expression analysis of 18 key haematopoietic transcription 
factors, Moignard et al. found that transcription factor expression is heterogeneous in HSCs and 
progenitors, with some genes exhibiting a bimodal expression, thus potentially generating three 
different expression states: i) high, ii) medium or iii) no expression162. This confirmed previous 
findings by Glotzbach et al. who used microfluidic-based high-throughput single cell qPCR to 
analyse the gene expression state of LT-HSCs163. The authors reported that some genes 
displayed asymmetric transcriptional gene distribution, which may be due to transcriptional 
bursts. Using their approach, Glotzbach et al. could provide evidence for subpopulations within 
the LT-HSCs compartment based on their transcriptional fingerprint163. However, a unique 
molecular signature that identifies a distinct functional HSCs state, such as an alpha or beta-
HSCs, has yet to be identified68,164. 
 
1.4 Refining the haematopoietic hierarchy 
Historically, it was thought that the differentiation into mature blood cells was achieved in a 
stepwise fashion through multiple rounds of differentiation via a large number of increasingly 
more committed progenitor cells63. The classical bifurcation model proposed that apical LT-
HSCs give rise to ST-HSCs, which in turn give rise to restricted progenitor cells of the lymphoid 
or myeloid lineages via common lymphoid progenitors (CLPs) and common myeloid 
progenitors (CMPs) respectively (Figure 6A). The latter progenitor pool then bifurcates into 
granulocyte/macrophage progenitors (GMPs) and megakaryocyte/erythrocyte progenitors 
(MEPs). CLPs give rise to dendritic cells (DCs), pro-B, pro-T, and pro-natural killer (NK) cells 
which then mature into various specialised B-cells, T-cells and NK cells91,165,166.  
 
This classical model was first challenged by Adolfsson et al. who reported a multipotent 
progenitor population that failed to produce cells of the erythrocytic/megakaryocytic lineage. 
These were termed lymphoid-primed multipotent progenitors (LMPP)167. The revised model 
proposed that HSCs give rise to a megakaryocyte/erythroid progenitor (MkEP) cell and 
alternatively, loss of the Mk and E potential would generate an LMPP. Another possibility is 
that the ST-HSCs give rise to CMPs and LMPPs followed by bifurcation of CMPs into MkEPs 
and GMPs, while the LMPPs would give rise to GMPs and CLPs (Figure 6B)63,167.  
This model received further input by Arinobu et al., who suggested that lineage commitment 
takes place at the MPP stage through the differential expression and mutual inhibition of PU.1, 
and GATA-1, a transcription factor required for megakaryocyte and erythrocyte development, 
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thereby regulating the generation of CMPs and progenitors or both myeloid and lymphoid 
lineage (GMLPs). Multipotent progenitor cells (MPPs) which upregulated PU.1 would give rise 
to GMLPs which then in turn bifurcate into CLPs and GMPs, while MPPs with increased 
GATA-1 expression generate exclusively CMPs that then generate MEP and GMP  
(Figure 6D)168. The observation that dendritic cells can be derived from both myeloid and 
lymphoid origin implied that they originate from both GMPs and CLPs, supporting the 
hypothesis that a progenitor exists with both lymphoid and myeloid differentiation potential 
such as the GMLP91,169.  
 
However, second generation cellular barcoding experiments have shown that the LMPP 
compartment is in fact also heterogeneous and is largely comprised of unipotent progenitors 
generating predominantly dendritic cells (DC, ~50%), and to a lesser extent B-lymphocytes and 
myeloid cells. Only 3% of LMPP were observed to have a multi-lineage outcome, although 
barcoding experiments are always limited by their detection ability, due to low sampling. Paired 
daughter transplantations of LMPPs have shown that the heterogeneity in lineage output is 
largely maintained suggesting a cell intrinsic or “imprinted” mechanism170. Using a Gata1-GFP 
reporter mouse line, Drissen et al. investigated lineage potential in both the phenotypic LMPP 
and preGM/GMP compartment. Gata1-GFP+ pre-GMs do not give rise to B- and T-
lymphocytes and only produce few monocytes but have high mast cell out and generate Mks, 
erythrocytes and eosinophils171. Interestingly, 2–3% of LMPP do express Gata1 which 
corresponds to a similar percentage of Mks generated from LMPPs167,171. The authors 
concluded that lineage segregation occurs as early as the HSCs/MPP stage based on Gata1 
expression171. In contrast to this finding, recent work using long-term, continuous single cell 
quantification of GATA1 and PU.1 expression has shown that cells that differentiated into the 
GM lineage increased PU.1 expression over time but never expressed GATA-1 during the 
differentiation process172. This implies that GATA-1 does not play a significant role in GM 
lineage commitment. It was furthermore shown that cells differentiating into the MegE lineage 
always expressed GATA-1 independent of PU.1 levels, leading to the conclusion that lineage 
choice is reinforced by transcription factor expression but not initiated172 and disputing the 
mutual inhibition hypothesis previously stated by Arinobu et al168. 
 
Using a combination of index-FACS and MARS-seq, Paul et al. aimed to unravel the 
heterogeneity within the myeloid progenitor compartment. Transcriptional profiling showed 
that the CMP pool could be subdivided into subpopulations primed to adopt one of 7 myeloid 
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cell fates, namely erythrocytes, megakaryocytes, dendritic cells, monocytes, neutrophil, 
eosinophil or basophil. Surface marker expression of CD135 and CD115 (both positive) 
identified cells that did not give rise to cells of the Mk/E lineage173. This is partially consistent 
with previous single cell qPCR data generated by Guo et al., showing that phenotypic CMPs 
are shared between the Mk/E and lymphomyeloid differentiation trajectory. CD55 is a potent 
marker to enrich for cells differentiating towards the Mk/E lineages, with CD115 subdividing 
the CD55+ CMP compartment further. CD115 also subdivides the GMP compartment but no 
functional studies on these subpopulations were performed so it is unclear whether the 
molecular subsets described relate to functionally heterogeneous cell populations174.  
Overall, the generally accepted model has been that restricted progenitors are derived from 
more multipotent progenitors, which originate from the HSCs compartment. However, recent 
experiments have also called this concept into question, suggesting that the differentiation of 
HSCs into certain lineages does not always occur via stages of progenitors, but that HSCs could 
give rise to lineage-restricted progenitors directly, such as repopulating common mega-
karyocyte progenitors (rCMP), which retain limited self-renewing potential (Figure 6C)175,176. 
Of late, the existence of a long-term repopulating megakaryocyte restricted stem cell (LT-
MkSC) has been discussed. However, the frequency of this putative cell is lower than 10-6 and 
its reconstitution never exceeds 0.1% donor chimaerism, i.e. 50 cells if 5x104 platelets were 
acquired157. Thus, it is challenging to draw firm conclusions from such low numbers of cells. 
This putative LT-MkSC was not detected in aged animals157, even though >80% of single aged 
HSCs show a platelet bias177. This is also reflected in increased Mk/E lineage specific genes 
compared to HSCs obtained from young mice177. Yet, no secondary transplants on these 
supposed platelet-biased aged HSCs were performed. Thus, it is unclear if these putative HSCs 
were in fact HSCs or were contaminated with MkP177. The latter possibility is supported by an 
in vitro single cell tracking experiment, which showed that ~15% of phenotypic LT-HSCs give 
rise to megakaryocytes largely without prior cell division, suggesting that the input cells were 
in fact MkP178.  
 
To address the existence of a purely megakaryocyte restricted long-term self-renewing HSCs 
in situ, Rodriguez-Fraticelli et al. made use of a Sleeping Beauty lineage tracing model 
combined with TARIS, an improved transposon integration sequencing technique. Eight weeks 
after in situ labelling, cells of different lineages were isolated and their transposon tags 
analysed. Only ~10% of tags found in megakaryocyte progenitor (MkPs) were shared with 
multiple other lineages, suggesting that the vast majority of the megakaryocyte lineage arises 
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independently from other blood lineages. Interestingly, none of the isolated MkP clones shared 
tags solely with erythroblasts, suggesting that the MEP lies downstream of a progenitor with 
erythromyeloid and/or lympho-erythromyeloid potential. However, it needs to be taken into 
account that MkPs may be far more numerous than other cell types, thus detection limits need 
to be adjusted accordingly and conclusions are difficult to make without deeper sampling.  
To assess long-term repopulation potential of Mk-restricted HSCs, cells were transplanted and 
their progeny assessed at four and 30 weeks post transplantation. Six out of eight recipients 
contained donor-derived multi-lineage progeny. This suggests that the majority of 
megakaryocyte producing clones within the phenotypic LT-HSCs compartment are not MkP 
lineage restricted. However, the findings of a Mk-primed cluster within the phenotypic LT-
HSCs population as well as the detection of in situ labelled Mk clones lacking overlapping 
labels with other lineages, suggest that the megakaryocyte lineage is the earliest to branch off. 
Notably, MPP2 also produce Mks suggesting that there may be two distinct pathways for Mk 
production146.  
 
Distinct CD45 isotypes are commonly used to distinguish between donor and recipient cells in 
peripheral blood, however this does not allow for the assessment of erythrocytes and platelets 
as these do not express this surface marker. Carrelha et al. have overcome this limitation by 
using transgenic mice co-expressing Gata1-eGFP and Vwf-tdTomato, which fluorescently label 
erythrocytes and platelets respectively, as donor mice. Following single cell transplantation 
~11% of mice showed only platelet reconstitution. These donor cells were termed platelet-
restricted (P-restricted). Of note, few subsequent secondary transplants were carried out, with 
recipients showing low levels of erythrocyte, myeloid and lymphocyte lineage reconstitution. 
In addition, isolated Vwf+ HSCs (LSK SLAM) from primary recipients showed multi-lineage 
potential in in vitro assays179. This argues against an exclusive platelet-restricted HSCs but is 
in accordance with previously discussed findings146. However, it is possible that these tools 
simply track platelets and erythrocytes in alpha-HSCs. In addition to P-restricted donor cells, 
the authors also found platelet+erythrocyte, platelet+erythrocyte+myeloid, and platelet+ 
erythrocyte+myeloid+B cell restricted repopulation patterns. This indicates that 
megakaryocytes are situated higher up in the haematopoietic hierarchy than previously thought 
and may indeed be derived via two separate developmental pathways146,179.  
 
Transcriptional overlap between the megakaryocyte and the LT-HSCs population is a consistent 
feature arising in single cell transcriptomic analysis, through multiplexed qPCR or single cell 
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RNA sequencing (RNA seq) profiling of the HSPC compartment. Different clustering methods 
suggest a close relationship between the Mk/E and long-term HSCs branch70,146,174,180. It is 
important to note however, that many genes are shared between megakaryocytes and HSCs, 
again highlighting their close connection70. Yet, the possibility cannot be excluded that shared 
gene expression between MKs and HSCs may be due to contaminating MkPs within the HSCs 
branch.  
 
Interestingly, similar observations of an early exclusive Mk differentiation branch separating 
from the HSCs pool were also made within the human system181,182. Human haematopoiesis is 
considered to follow a similar developmental pattern as seen in mouse, with MPPs 
(CD34+CD38negCD90negCD45RAnegCD49fneg) giving rise to multi-lymphoid progenitors 
(MLP) that have both lymphoid and myeloid potential171. Notta et al. aimed to improve 
resolution by subdividing the MPP pool using the surface markers CD71 (Transferrin receptor) 
and CD110 (Thrombopoietin receptor, MPL). Only MPPs negative for these markers (termed 
MPP1) and long-term HSCs (CD34+CD38negCD90negCD45RAnegCD49f+) were able to give rise 
to multi-lineage progeny. By comparing lineage output from progenitors derived from foetal 
liver, cord blood and adult bone marrow, the authors were able to show that the ratio of 
progenitors with multi-lineage or uni-lineage capacity changes throughout development, with 
more cells adopting a uni-lineage fate in adult bone marrow (82% uni-lineage) compared to 
foetal liver and cord blood (60% and 73%, respectively). Additionally, within the putatively 
unprimed HSCs/MPP compartment, a subset of cells expressing both CD71 and CD110 was 
detected identifying cells seemingly primed to adopt megakaryocyte/erythroid fate. These 
findings suggest an early branching point for the Mk/E lineage separating from the multipotent 
cell compartment181.  
 
This is also in line with recent finding by Velten et al. where human bone marrow cells from 
two individuals were index-sorted and RNA sequencing was performed. Clustering of the 
libraries showed that progression from a multi-lineage state to a distinct primed population is 
concurrent with the upregulation of CD38 on the cell surface. Functionally, the majority of 
phenotypic oligopotent progenitor populations gave rise to uni-lineage progeny, which was also 
reflected in their gene expression profiles. Based on gene expression clustering, the authors 
suggest that priming for the earliest lineage segregation occurs within the HSCs compartment 
between the lymphoid/myeloid and megakaryocyte/erythrocyte lineage. The cells then 
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transition through a CMP stage and bifurcate into GMP and MEP with CD71 enriching for cells 
of the erythroid lineage182.  
 
 
In contrast to Velten et al. who used an unbiased sorting approach with retrospective lineage 
assignment built on gene expression data, Karamitros et al., immuno-phenotypically isolated 
HSCs, MPPs and several oligopotent progenitor populations from both human cord blood and 
bone marrow. As observed by others, most progenitors had only uni-lineage progeny, although 
 
Figure 6:  Different models depicting the haematopoietic hierarchy. 
A) Bifurcation model. B) LMPP model. C) Direct lineage differentiation model. A-C) modified from 
Ema et al., Exp Hematol (2014). D) Lineage differentiation into lymphoid or myeloid lineage is 
dependent on reciprocal activation of Gata-1 and PU.1. Pink background reflects increase in Gata-
1 expression, while blue depicts the increase of PU.1 in progenitors. Overlapping region represents 
progenitor priming. Modified from Arinobu et al., Cell stem cell (2007). E) Continuum of differentiation 
model. Modified from Laurenti, E. & Göttgens, Nature (2018)183. MPP = multipotent progenitor; CMP 
= common myeloid progenitor; CLP = common lymphoid progenitor; MEP = megakaryocyte and 
erythrocyte progenitor; LMPP = lymphoid-primed multipotent progenitor; GMP = granulocyte and 
macrophage progenitor; IT-HSCs= intermediate HSCs; MyB = myeloid progenitor with B cell 
potential; ST-HSCs= short-term HSCs; MyT = myeloid progenitor with T cell potential; DC = Dendritic 
cell; NK = Natural Killer cell; ILC = Innate Lymphoid cells. 
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bi-lineage and multi-lineage outcomes were observed. GMP and MLP lacked erythroid output 
and MLP only generating unilineage lymphoid cells. LMPP had the capacity to generate 
monocytes, granulocytes and lymphoid cells but failed to generate erythrocytes and 
megakaryocytes, with high expression of CD10 enriching for LMPPs with lymphoid potential. 
Single cells of the LMPP, MLP and GMP compartment were sequenced and, like Velten et al., 
the authors found that cells typically defined as the above mentioned progenitor populations do 
not segregate from each other but rather are part of a continuum of lympho-myeloid 
differentiation (Figure 6E)184. However, in the interpretation of this data it is important to 
remember that due to the greater resolution of inter-cell differences and technical drop-outs, 
single cell RNA seq data is likely to present as a continuum in contrast to data obtained from 
bulk RNA seq. 
 
Since cell surface marker expression does not faithfully reflect the transcriptional state of a 
given cell174, unbiased approaches capturing vast numbers of cells without predefining them by 
phenotype, with possible retrospective lineage assignment through either functional outcome 
or gene expression profile, may aid in the understanding of lineage priming and 
differentiation70,185. For instance, Dahlin et al. has shown that single cell sequencing of 
> 44,000 mouse HSPC can determine the entry point of 8 individual lineage trajectories186.  
 
With recent findings in mind and the advances of single cell profiling technologies, several 
groups have proposed a more fluent continuum of transitional stages in blood cell development 
to replace the binary commitment model. Major amendments to the old models are that  
lineage priming occurs earlier than previously thought in both the mouse and human 
system70,171,181,182,184,187, and that the hitherto believed oligopotent progenitor pools in fact give 
rise to mainly uni-potent progeny146,173,182,184. However, as shown for seemingly Mk-primed 
HSCs, when submitted to the stress of transplantations, these cells did reveal multi-lineage 
potential146,179. It is therefore necessary to keep in mind that just because a progenitor is 
observed to produce a single lineage, it is not necessarily true that this cell does not have oligo-
lineage potential.  
 
In this context, “potential” encompasses several lineage outcome possibilities, whereas “fate” 
insinuates that the cell is irreversibly committed to differentiate into a particular lineage guided 
by external stimuli. Hence, it is important to consider if a terminally differentiated blood cell 
has adopted its fate because it only possessed uni-potential capacity or because it was stimulated 
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to do so by extrinsic factors. In vivo, it still needs to be determined if fate commitment is a 
stochastic event or if location within the niche is an essential factor. In particular because many 
external stimuli are soluble factors, which may make niche location partially irrelevant. One of 
the external stimuli known to be produced by cells from the bone marrow niche and extensively 
studied for its effects on HSCs is the cytokine stem cell factor, further described in 1.5.  
 
1.5 Stem cell factor, a cytokine involved in regulating haematopoiesis 
Stem Cell Factor (SCF), also known as Mast Cell Growth Factor (MGF)188, Kit-Ligand (KL)189, 
and Steel Factor (SF)190, is a cytokine encoded by the Steel (Sl) locus on mouse chromosome 
10 and human chromosome 12191. In the bone marrow, SCF is produced by endothelial and 
mesenchymal stromal cells, including LEPR-expressing perivascular cells and adipocytes31,192.  
 
SCF is the ligand of the proto-oncogene c-Kit, a transmembrane receptor tyrosine kinase and 
member of the Platelet Derived Growth Factor (PDGF) receptor subfamily188,189,193,194. In 1956, 
it was first hypothesised that SCF and c-Kit may be complementary to each other based on the 
striking similarities between the phenotypes of both mutant Steel (Sl) and white-spotting (W) 
mice195, the latter locus encoding Kit196,197. Mutant Steel mice are characterised by anaemia, 
reduced gonad size, and diluted hair pigmentation including white spotting. The majority of 
homozygous mutant mice die perinatally due to macrocytic anemia195. Similarly, the few 
surviving W homozygous mutant mice have white coats with black eyes, are severely anaemic, 
have a reduced number of mast cells and are sterile198,199. These findings implicate that both c-
kit and SCF play an important role in the regulation of haematopoiesis, gametogenesis as well 
as melanogenesis195. SCF has moreover been found to be important for development of the 
interstitial cells of Cajal in the intestine where it is produced by smooth muscle cells200,201. 
Furthermore, research suggests a role for secreted SCF in neurogenesis by stimulating the 
proliferation of neuronal precursor cells in vitro and in vivo202. 
 
1.5.1 The SCF-KIT complex 
SCF is encoded by 9 exons in human, mouse and rat191. It exists in both a membrane-anchored 
and a soluble form as the result of alternative splicing of exon 6 and proteolytic processing191,203-
205. SCF binds Kit with high affinity and in a species-specific manner. Human SCF (HSCsF) 
does not bind mouse Kit (dissociation constant Kd >700nM), while rat SCF binds to human Kit 
(hKit) with 100-fold lower affinity than HSCsF to hKit (Kd 10-50nM vs. 0.5-1nM 
respectively)206. This is likely due to structural discrepancies between human and murine SCF.  
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SCF is a noncovalent homodimeric glycoprotein consisting of four-helix bundles, or 
protomers206,207. Soluble SCF contains 165 amino acids, with the first 141 residues being 
essential for receptor binding207. SCF forms a dimer through polar and nonpolar head-to-head 
interactions between the protomers207,208. SCF binding to Kit is driven by charge 
complementarity, and both human SCF/KIT and mouse SCF/KIT are expected to display the 
same overall binding configuration. However, the interspecies incompatibility is possibly due 
to the highly hydrophobic patches in mouse SCF (Ile50, Leu54, Val87, and Leu88), binding to 
the hydrophobic mouse KIT (Pro124 and Phe126), not being complementary to the less 
hydrophobic Ser123 and Tyr125 in human KIT208. Another report has argued that the 
substitution of Tyr125 by phenylalanine in mouse substituted may have resulted in the loss of 
a hydrogen bond leading to diminished binding affinity209.  
 
 
Figure 7:  Stem cell factor binding to its receptor c-Kit. 
Stem cell factor monomers form a homodimer and bind as such to extracellular domains 1-3 of two 
Kit monomers, bringing domain 4 and 5 in close proximity and causing a conformational change. 
Both Kit monomers bind bivalently to each other leading, enabling auto-phosphorylation on Kit.  
 
The KIT protein is a type III tyrosine kinase receptor, which are characterised by a split tyrosine 
kinase domain210. Its glycosylated extracellular region contains five immunoglobulin-like (Ig-
like) domains. KIT is anchored in the cell membrane by a single transmembrane domain, 
flanking the first of the bisected tyrosine kinase domains, which is separated from the second 
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domain by a kinase-insert region (Figure 7)209,210. In vitro binding analysis of SCF to a truncated 
KIT lacking both the transmembrane and cytoplasmic domains, have shown that KIT receptor 
binding is dependent on the ectodomain alone210.  
 
1.5.2 The SCF-KIT signalling pathway 
Upon ligand binding, individual SCF protomers bind to the immunoglobulin-like domains D1, 
D2 and D3 of an individual KIT protomer208,209. In doing so, the monomeric KIT receptor 
undergoes a conformational change, allowing the interaction between the Ig-like domains D4-
D4 and D5-D5 to allow dimerisation with another KIT monomer209, followed by the bivalent 
binding of the ligand and in doing so stabilising the conformation (Figure 7)209,210. This 
dimerisation facilitates auto-phosphorylation of KIT 206,209. This is followed by ubiquitination 
of the receptor, marking it for internalisation and lysosomal degradation211. Binding of soluble 
SCF causes a rapid and transient activation of c-KIT, while the membrane-bound isoform 
activates the receptor in a more sustained manner. This might be because the complex cannot 
be internalised as rapidly in this case211,212. 
 
Upon activation of the receptor, intracellular proteins bind the kinase domains of Kit directly 
and undergo tyrosine phosphorylation. Several groups have demonstrated that members of the 
STAT (Signal Transducer and Activator of Transcription) family (STAT1, STAT3, STAT5), 
the PI3K family (AKT, RSK1, RPS6) as well as the MAP (mitogen-activated protein) kinase 
family (ERK, MEK, p38, c-RAF) are phosphorylated as a result of SCF/KIT complex 
formation191,206,210,213,214. 
 
1.5.3 SCF directly affects HSCs and can act synergistically with a variety of other 
growth factors  
Transplantation experiments performed by McCulloch, Siminovitch and Till in the early 1960’s 
provided the earliest evidence that SCF may act directly on HSCs. Bone marrow and spleen 
derived haematopoietic cells of the genotype Sl/Sld or Sld/Sld, carrying heterozygous or 
homozygous mutations in the region encoding stem cell factor, were transplanted into wild type 
mice and vice versa and their spleens were examined shortly after for colony forming units 
(CFU-S). It was found that upon transplantation into wild type recipients no differences in 
colony forming efficiency could be observed. However, the opposite was true for the 
transplantation of wild-type (WT) cells into mutant recipients. Upon examination, spleens were 
significantly smaller and had only few colonies when compared to a wild-type recipient. Thus, 
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the defect exerted by the Sl mutation is not intrinsic to the colony-forming cells but affects the 
haematopoietic microenvironment215.  
 
Transplantation of WT foetal liver cells into the c-Kit mutant W/Wv recipients can partially or 
entirely cure the anaemic phenotype, with red blood cell counts returning to normal levels. 
Changes of the haemoglobin pattern to that of the donor cells, proves that the implanted cells 
are indeed the source of the newly generated erythrocytes216. Transplantation of Sl/Sld bone 
marrow cells into W recipients also restored blood values to normal215. 
McCulloch and Till also showed that W/Wv recipient mice do not require irradiation prior to 
transplanting haematopoietic cells derived from non-mutant litter mates (ww). They 
hypothesized that the WWv cells either are deficient in their colony-forming ability or require a 
stimulus for colony formation217. It is now known that the loss of Kit function, thus the inability 
to respond to environmental stimuli, is the cause for WWv cells’ inability to compete with wild 
type cells218. These results strongly suggest that SCF, produced by cells of the haematopoietic 
microenvironment, directly acts on HSCs, whereas the W mutation affects the stem cells 
directly215,216. 
 
SCF has been shown to stimulate proliferation of human, non-human primate, and mouse 
haematopoietic stem and progenitor cells219-221. When SCF stimulated bone marrow cells are 
transferred into medium lacking SCF, clones that have already begun to proliferate will stop 
proliferating and die. This suggests that SCF has a direct effect on the colony initiating cells in 
the bone marrow128. In both humans and mice, SCF acts as a radioprotective agent when 
administered in vivo prior to chemotherapy (human) or irradiation (mice)213,222-224. However, 
due to its functional pleiotropy, SCF also activates melanocytes and mast cells leading to 
hyperpigmentation and severe allergic or anaphylactic responses, respectively199,213,225.  
Colony formation is greatly enhanced when SCF is used synergistically with a number of other 
growth factors and cytokines, such as IL-3, IL-6, IL-11, Erythropoietin (EPO), granulocyte-
macrophage colony-stimulating factor (GM-CSF), granulocyte-colony stimulating factor  
(G-CSF)125-128,219,220. 
 
When SCF is administered in vivo, peripheral blood and bone marrow cellularity increases 
within the first 7 days in both mice126 and baboons220 but returns to baseline levels by week 
three of treatment. This effect is enhanced in mice when G-CSF is used synergistically but not 
with G-CSF alone126. Contrary to these findings, it has also been reported that SCF does not 
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synergise with GM-CSF, macrophage colony stimulating factor (M-CSF), IL-1, IL-4, Il-5, 
tumour necrosis factor (TNF), and leukaemia inhibitory factor (LIF)226. Colony formation 
assays performed on HSCs (Lin-Rho123loSca-1+) only stimulated with SCF failed to generate 
any colonies. However, in combination with IL-3, IL-6 or G-CSF, colonies could be 
obtained226. When used alone, SCF increased survival compared to medium without any 
cytokines. SCF in synergy with other cytokines stimulates cell proliferation and retains HSCs 
repopulating ability in vitro for up to 7 days. However, when competitively transplanted with 
fresh bone marrow, stimulated cells repopulated a significantly lower amount of recipient 
mice125,226. Thus, SCF clearly affects haematopoietic cells in vivo and in vitro, although its 
effects on cell division, survival and differentiation needs to be teased apart and further 
investigated. 
 
Since these experiments (which spanned several decades), it has been of great interest to 
establish cytokine cocktails that could selectively expand HSCs by stimulating self-renewal, 
proliferation, and survival whilst inhibiting differentiation ex vivo. Several groups have shown 
that a combination of IL-3, IL-6 and SCF expands HSPCs in culture and maintains engrafting 
capability for up to 14 days227-230. Similar results have been published for IL-11 and SCF129,231-
233. Interestingly, IL-3 has also been reported to have a negative effect on proliferation and the 
reconstitution capacity of HSCs when used without IL-6229,230. Conflicting reports have been 
published whether or not SCF synergizes with Flt3-ligand (FL)231,232. Failure to reconstitute the 
haematopoietic system after 14 day culture of LSK cells with SCF and FL alone232 suggests 
that IL-6 or IL-11 is necessary to retain HSCs stemness. Contrary to this, observations have 
been made that stimulation of single cells (LSK) with FL and SCF leads to colony formation, 
which was not enhanced by IL-6 addition. However, transplantation data to confirm 
engraftment capabilities of these cells are missing from this study231. Subsequent research by 
the same group has shown that IL-11 and SCF in combination have a significant positive effects 
on the number of colony forming cells (CFC), long-term culture initiating cells (LTC-ICs), total 
cellular output, and most importantly competitive repopulating units (CRU). Addition of FL to 
these two cytokines does not change CRU expansion124, suggesting that FL is not essential, 
which is consistent with the absence of the FLT3 receptor (CD135) on the surface of mouse 
LT-HSCs.  
 
Yet, all studies listed above mainly have used bulk population of haematopoietic stem and 
progenitor cells (i.e. LSK or LinnegSca-1+CD34neg). Thus, any effect SCF may have on HSCs 
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cannot necessarily be distinguished from its effect on progenitor cells. Single cell in vitro 
studies have addressed this problem. While Audet et al. and Miller et al. both used very low 
cell numbers to initiate colonies, the sorted populations of LS+ and LSK only contain 
approximately 0.053% and 0.397% stem cells respectively124,234. 
 
Single cell studies with LT-HSCs have shown that the concentration of SCF differentially 
affects HSCs (LinnegCD45midRhonegSP) in their engrafting capabilities. A high concentration 
promotes HSCs self-renewal with 25% of cells being able to engraft, whereas HSCs cultured 
in 30-fold lower amount of SCF show a 3-fold reduction in reconstitution capacity from as early 
as 16h in culture. This reduction is maintained in 4-day clones. Interestingly, cell cycle kinetics 
and survival were not affected10. Another study showed that inhibition of lipid raft clustering 
of c-Kit results in the abrogation of SCF/KIT signalling, with HSCs (LSK CD34neg) remaining 
as single cells in vitro for up to 10 days. Interestingly, some of these cells retained the ability 
to reconstitute all lineages in primary transplantation recipients121. These finding suggest that 
SCF may not be necessary for the maintenance of “stemness” per se, but rather it is required 
for HSCs proliferation and self-renewal.  
 
1.6 In vitro expansion of haematopoietic stem cells 
The ability to self-renew while retaining multipotency makes HSCs an ideal candidate for the 
treatment of haematologic disorders such as leukaemia. Since the patient’s own haematopoietic 
system has been severely compromised by chemo- or radiotherapy, in an effort to eliminate all 
malignant cells, a bone marrow transplant is necessary to rebuild the blood system. Common 
sources of HSCs for transplantation are bone marrow (BM), mobilised peripheral blood (mPB) 
and umbilical cord blood (UCB) from human leukocyte antigen (HLA) matched donors. 
However the availability of HLA compatible donors is limited, with only 60–70% of patients 
finding a suitable donor and UCBs do not always contain sufficient numbers of HSCs for 
transplantation into an adult patient235,236. Developing a quality- controlled protocol for the in 
vitro expansion of (autologous) HSCs would guarantee on-demand availability of HSCs for the 
treatment of haematological disorders. In order to do this, we need to understand the 
mechanisms driving symmetric self-renewal divisions of HSCs and apply them outside the 
body236.  
Extensive research has been conducted into intrinsic and extrinsic regulators of HSCs 
expansion236,237 (some of which were described above). The strongest intrinsic determinants to 
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date include Hox genes, epigenetic regulators such as the Polycomb-group proteins and 
miRNAs139,236,237. However, introduction of genetic material is undesirable in clinical protocols 
since the potential of malignant transformations or stem cell exhaustion cannot be excluded236. 
Therefore, much research in HSCs expansion has focused on extrinsic regulators including 
cytokines and developmental regulators such as known players in the Wnt signalling pathway, 
Shh signalling pathway, and the Notch pathway236-238. In addition, small molecules have 
recently been shown to modulate in vitro HSCs expansion236,239, most notably are 
StemRegenin1 (SR1)123,235 and UM171 which lead to a 2-fold and 13-fold increase in human 
LT-HSCs respectively after 7 day culture and in combination lead to a nearly 30-fold expansion 
of LT-HSCs measured by their frequency at 20 weeks following transplantation compared to 
uncultured BM235. Another promising molecule for the expansion of human HSCs is 
Prostaglandin E2 (PGE2). Pretreatment of cord blood cells with PGE2 prior to transplantation 
into patients has been shown to improve multi-lineage engraftment over those transplanted with 
untreated cord blood. However, its efficacy on in vitro expansion on human HSCs has not yet 
been assessed240,241. 
 
One of the major reasons for this may be that most HSCs expansion efforts take place in 
isolation, ignoring any potential contribution of the physical niche in which they typically 
reside. Adult HSCs reside in the bone marrow microenvironment, where they encounter 
cytokines, growth factors and chemokines, which are largely but not exclusively produced by 
niche cells18,242. These factors can be present in either soluble form or as insoluble, tethered 
transmembrane receptor ligands and extracellular matrix (ECM) molecules. The 
microenvironment therefore is a combination of differentiated cells, key soluble molecules and 
a tissue specific matrix, all potentially influencing stem cell fate choice in a complex spatially 
and temporally controlled manner243,244. Whereas the effects of soluble factors on HSCs self-
renewal and differentiation have been extensively studied, very little is known about how 
mechanical forces within the stem cell niche instruct HSCs fate choice and only a few studies 
have attempted to answer these questions242,244. What is clear, is that HSCs express surface 
adhesion receptors (e.g., integrins) and are able to sense mechanical forces through cytoskeletal 
components244. Moreover, the bone marrow microenvironment is relatively soft with an 
elasticity measured at approximately 300 Pa245 compared to tissue culture plastic which ranges 
in stiffness between 2–4 GPa, several orders of magnitude stiffer246. One study has suggested 
that stiffness affects HSCs fate choice as measured by HSCs (LSK CD150+) to progenitor 
(LSK) ratio, which was maintained or increased on soft tropoelastin coated plates when 
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compared to non-coated controls247. Another pioneering study in human HSCs reported that 
Myosin II (MyoII) is involved in adhesion and matrix sensing, as its polarisation is supressed 
in CD34+ stem and progenitor cells cultured on soft substrate but promoted on stiff matrices. 
MyoII is asymmetrically segregated upon cell division and remains high in CD34+ cells 
whereas the MyoII low daughter cells differentiates245. Overall however, this remains a 
significantly under-explored area of HSCs expansion efforts.  
 
This is in contrast to a number of other stem and progenitor cell systems where substrate 
stiffness has been shown to influence lineage differentiation243,244. Mesenchymal stromal cells 
(MSCs) are multipotent with osteogenic, chondrogenic and adipogenic potential. On stiff 
substrate MSCs preferentially differentiate into cells of the osteogenic lineage, whereas culture 
on a soft matrix leads to adipocyte differentiation244,248. In the liver, hepatocyte differentiation 
has been shown to be regulated by the composition of the extracellular matrix249 and reports 
show that hepatic stellate cells remain quiescent on soft matrices and differentiate into 
myofibroblasts when cultured on stiff substrates similar to that of a fibrotic liver243. In skin, 
keratinocytes grown on small, circular ECM islands, which restrict cell spreading, terminally 
differentiated, whereas those seeded on larger island remained immature. This was due to 
impaired actin disassembly and remodelling, indicating cell shape is the key factor determining 
cell fate250. The same group later reported that keratinocyte morphology, spreading and 
differentiation was influenced by substrate stiffness. Keratinocytes on soft matrices failed to 
form focal adhesions necessary for the activation of downstream pathways such as the ERK 
pathway251. However, it is important to note that the anchoring points for collagen were the 
main determinants for these differences as opposed to matrix stiffness itself. The authors found 
that differentially spaced anchoring points for collagen lead to changes in cell behaviour 
comparable to changes when cultured on matrices of varying stiffness251. It is therefore 
necessary to consider not only the composition of the matrix itself but also the geometry (two 
dimensional or three-dimensional (3D)) and elasticity, all of which impact cytoskeletal 
tension242,244.  
 
HSCs traditionally have been cultured in a two-dimensional fashion on rigid tissue-culture 
plastic sometimes coated with ECM proteins such as collagen or laminin, on feeder cell layers 
or on ECM derived hydrogels such as Matrigel242. To tease apart the mechanical effects from 
the biochemical stimulus on HSCs fate choice, cells need to be grown in a 3D matrix of defined 
composition mimicking the natural tissue as closely as possible. Thus, naturally derived 
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hydrogels such as Matrigel and co-culture on feeder layers are undesirable due to the undefined 
nature of the material itself242,244. In addition, the substrate needs to allow for sufficient gas 
exchange and nutrient supply to guarantee maximal cell viability and the matrix must not be 
physically constraining thus inhibiting proliferation, migration and morphogenesis242. The 
development of scalable, artificial 3D niches would allow for high-throughput screening of 
optimal conditions supporting HSCs self-renewal in vitro leading to the expansion of human 




1.7 The aims of this PhD thesis 
Haematopoietic stem cells have been studied for more than half a century but only in the last 
two decades have major advances in technology allowed us to begin studying HSCs at the single 
cell level in extreme detail. These advances include index-FACS, single cell RNA sequencing, 
single cell in vivo imaging, single cell transplantation, and the construction of microfluidic 
devices. 
 
Yet, much of what has been described on the population level has never been verified on the 
single cell level and at the purity level that we can investigate today. For instance, it has been 
shown on the population level that SCF increases cell survival but does not stimulate self-
renewal when not used in synergy with other cytokines. Yet, virtually all culture conditions 
aimed at the maintenance and expansion of HSCs include SCF under the premise that it 
enhances self-renewal.  
 
Therefore, the first aim of this PhD thesis was to investigate if short-term SCF stimulation alters 
HSCs fate choice on the functional as well as the transcriptional level in single HSCs and if any 
changes occur in a dose dependent fashion. The second objective was to assess how the absence 
of SCF/KIT signalling affects HSCs functionality in vitro. Finally, I explored how alterations 







C57BL/6-Ly5.2 (WT) were purchased from Charles River Laboratories (Saffron Walden, 
Essex, UK) and maintained at the University of Cambridge animal facility. Congenic C57BL/6-
Ly5.1 (WT-CD45.1) and C57BL/6w41/w41-Ly5.1 (W41) were bred and maintained at the 
University of Cambridge. All mice were housed in specified pathogen-free microisolator cages 
and were continuously provided with sterile food, water, and bedding. All procedures 
performed in this thesis were in compliance with the guidance on the operation of ASPA 
(Animals Scientific Procedures Act 1986) and performed under project license PPL 70/8406. 
 
2.2 Phenotypic mouse haematopoietic stem cell isolation 
2.2.1 Bone marrow harvest 
Mice were sacrificed by cervical dislocation. Bone marrow was harvested from femur and tibiae 
of both hind legs, pelvic bones, sternum and the spine. All of the following procedures were 
carried out under sterile conditions. Bone marrow (BM) was obtained by crushing the bones 
using mortar and pestle in PBS (phosphate-buffered saline, Sigma-Aldrich, St. Louis, MO, USA 
(Sigma)) supplemented with 2% foetal calf serum (FCS, Sigma or STEMCELL Technologies, 
Vancouver, CA (SCT)) and 50mM EDTA (Ethylenediaminetetraacetic acid, Sigma), from now 
on referred to as PBSFE.  
 
2.2.2 Erythrocyte depletion 
Erythrocyte depletion was achieved using ammonium chloride (NH4Cl, SCT). 3 mL cell 
suspension in PBSFE was treated with 5 mL NH4Cl and incubated on ice for 10 minutes (min), 
vortexing the sample after 5 min. Cells were then washed with 7 mL PBSFE and resuspended 
in 500 µL PBSFE per mouse in preparation for lineage depletion. 
 
2.2.3 HSPC enrichment 
The red blood cell depleted cell suspension was subsequently enriched using either the 
discontinued 3-step or the currently available 2-step negative EasySep Mouse Hematopoietic 
Progenitor Cell Isolation Kit (1976A SCT) with the following modifications:  
Per mouse, cells were resuspended in 500 µL PBSFE and incubated with 10 µL (1/50) EasySep 
Mouse Hematopoietic Progenitor Cell (HSPC) Isolation cocktail for 15 min. on ice.  
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20 µL (1/25) EasySep Streptavidin RapidSpheres 50001 were added and the cell suspension 
incubated for 15 min. on ice.  
For the discontinued 3-step kit, EasySep Biotin Selection Cocktail was added (1/10), followed 
by a 15 min. incubation on ice. Subsequently, magnetic particles were added (1/20) and the mix 
incubated on ice for another 10 min. PBSFE was added to a total of 2500 µL followed by a 3 
min. incubation in the EasySep Magnet at room temperature (RT). The supernatant was 
transferred into a new tube and the magnet incubation step was repeated one additional time.  
 
2.2.4 Fluorescence-activated cell isolation 
HSCs were isolated from the HSPC enriched cell suspension using fluorescence-activated cell 
sorting (FACS) following antibody staining. The cell suspension was incubated with antibody 
solution for 30 min. on ice, followed by a 20 min. incubation on ice with streptavidin (SAV) 
labelled secondary antibodies when necessary. The DNA intercalating dye 7-AAD (7-amino-
actinomycin D, Life Technologies, Carlsbad, CA, USA, (Life Technologies)) was used to 
exclude non-viable cells. Antibodies used for HSCs isolation are listed in Table 2, p. 39. HSCs 
were defined as EPCRhigh, CD45+, Sca-1high, CD48low/neg, CD150+. HSCs were sorted on a BD 
Influx cell sorter (BD Biosciences, San Jose, CA, USA (BD)) using the following filter sets 488 
530/40 (for FITC), 561 585/29 (for PE), 405 460/50 (for BV421), 640 670/30 (for APC),  
561 750LP (for PE/Cy7), 640 750LP (for APC/Cy7), 405 520/35 (for BV510), 640 720/40 
(for AF700), and 561 670/30 (for 7-AAD). Cells were sorted in either purity or single sort mode. 
Single HSCs were isolated using the single-cell deposition unit of the sorter placing 1 cell into 
the wells of round bottom 96-well plates, each well having been preloaded with 50 µL medium 
(described below). Cells were sorted at the Cambridge Institute for Medical Research Flow 
Cytometry Core Facility. 
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Table 2: Antibodies used for phenotypic mouse HSCs isolation.  
Antibody Clone Fluorophore Manufacturer 





CD150 TC15-12F12.2 PE/Cy7 Biolegend 
CD34 RAM34 Alexa Fluor 700 Biolegend 
CD45 30-F11 FITC Biolegend 
CD48 HM48-1 APC Biolegend 
CD117/c-Kit 2B8 APC/Cy7 Biolegend 
EPCR RMEPCR1560 PE SCT 
SCA-1 D7 BV421 Biolegend 
SCA-1 D7 BV605 Biolegend 
Streptavidin NA BV510 Biolegend 
 
2.3 Phenotypic human haematopoietic stem cell isolation 
2.3.1 Isolation of mononuclear cells 
Cord blood was obtained from Cambridge Blood and Stem Cell Biobank with informed consent 
from healthy donors and collected in accordance with regulated procedures approved by the 
relevant Research and Ethics Committees. Mononuclear cells (MNC) were isolated by using 
Pancoll lymphocyte separating medium (Pancoll, PAN Biotech, Aidenbach, Germany). Cord 
blood was mixed with equal parts of PBS and layered on Pancoll. Layered blood was then 
centrifuged at 500 g for 25 min. at RT with the brake turned off. The MNC layer was 
subsequently carefully aspirated and transferred to a new tube.  
 
2.3.2 Erythrocyte depletion 
The MNC cell fraction was subsequently treated with red blood cell lysis buffer (Biolegend, 
San Diego, CA, USA (Biolegend)) for 15 min. at 4°C to deplete erythrocytes.  
 
2.3.3 CD34 enrichment 
Erythrocyte depleted cord blood MNCs were enriched for CD34 using the human CD34 
microbead kit (Miltenyi Biotec, Bergisch Gladbach, Germany) with the following quantity 
modifications: 30 µL/108 cells CD34 Microbeads, FcR Blocking Reagent 30 µL/108 cells, 
PBS+3% FCS 90 µL/108 cells. Cells were separated using the AutoMACS cell separation 




2.3.4 Fluorescent-activated cell isolation 
CD34+ enriched cells were subsequently stained for the antibodies listed in Table 3 for 20 min. 
at RT. Cells were then washed and taken up in PBS + 2% FCS. Zombie Aqua (Biolegend) was 
used as a cell viability marker. HSCs (CD34+CD38negCD45RAnegCD19negCD49f+CD90+) were 
then sorted on a BD FACS Aria III or on BD FACS Aria Fusion sorters available at the NIHR 
Cambridge BRC Cell Phenotyping Hub facility.  
 
Table 3: Antibodies used for phenotypic human HSCs isolation.  
Antibody Clone Fluorophore Manufacturer 
CD19 SJ25-C1 Alexa Fluor 700 Biolegend 
CD34 561 APC/Cy7 Biolegend 
CD38 HIT2 Pe/Cy7 Biolegend 
CD45RA HI100 FITC Biolegend 
CD45RA HI100 PE Biolegend 
CD90 5E10 APC Biolegend 
CD90 5E10 PE Biosciences 
CD49f GoH3 Pe/Cy5 Biosciences 
 
Cells were sorted in single sort mode. Single HSCs were isolated using the single-cell 
deposition unit of the sorter placing 1 cell into the wells of round bottom 96-well plates, each 
well having been preloaded with 50 µL StemSpan medium (described below). 
 
2.4 In vitro culture of HSCs  
2.4.1 Liquid cell culture 
Phenotypic HSCs were sorted and culture into StemSpan serum-free expansion medium 
(StemSpan SFEM, SCT) supplemented with 20 ng/mL human Interleukin-11 (IL-11, R&D 
Systems, Bio-Techne, Minneapolis, MI, USA, (R&D)), 300 ng/mL Stem Cell Factor (SCF, 
R&D or SCT), 2 mM L-Glutamine (Sigma), 1000 U/mL-100 µg/mL Penicillin-Streptomycin 
(Sigma), 100 µM 2-Mercaptoethanol (Life Technologies).  
Standard SCF concentration was 300 ng/mL unless stated otherwise. In SCF-free conditions, 
StemSpan SFEM was additionally supplemented with 10% FCS.  
As FCS is of undefined nature and has been shown to differ significantly from batch to batch, 
a serum-free alternative medium was implemented: Cells were sorted into Ham’s F12 nutrient 
mixture (Gibco, ThermoFisher, Waltham, MA, USA (Gibco)) supplemented with 20 ng/mL 
human IL-11 (R&D), 300 ng/mL SCF (SCT or R&D), 2 mM L-Glutamine (Sigma), 1000 
U/mL-100 µg/mL Penicillin-Streptomycin (Sigma), 1% ITS-X (Insulin-Transferrin-Selenium-
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Ethanolamine, Gibco), 100 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 
Sigma), 100 mg/mL human serum albumin (HSA, Albumin Bioscience, Huntsville, AL, USA).  
 
2.4.2 Single cell kinetics and clone size determination 
Single phenotypic HSCs were sorted and cultured as described above. Cells were counted by 
visual inspection every 22–24 h to assess kinetics of cell division. On day 10 of culture, clone 
size was scored as follows: Very small (VS, <50 cells), small (S, 50–500 cells), medium  
(M, 501–5,000 cells), large (L, 5,001–10,000), and extra-large (XL, >10,001 cells), and the 
clone size estimation was previously validated using fluorescent counting beads as described in 
Kent et al. 2013252. 
 
2.4.3 Short-term liquid culture for RNA sequencing  
To minimise cell transferring steps, which would lead to loss of cells, phenotypic HSCs were 
sorted into a 5 mL polypropylene tube containing 500 µL of StemSpan supplemented with 
either 30 ng/mL or 300 ng/mL SCF in addition to 20 ng/mL human IL-11, 2 mM L-Glutamine, 
1000 U/mL-100 µg/mL Penicillin-Streptomycin, and 100 µM 2-mercaptoethanol. The tube was 
closed with a blue filter cap allowing air exchange. The 5 mL tube was subsequently placed 
into a 50 mL tube containing 5 mL of prewarmed PBS.  
A lid was loosely placed on the larger tube and it was 
subsequently placed into a humidified incubator at 37°C for 16h 
(Figure 8). 15 min. prior to the end of incubation, CD45-FITC 
antibody was added to the cells. After the incubation time, the 
cells were washed with 2 mL PBS. The remaining cells were 
resuspended in PBSFE containing DAPI (4′,6-diamidino-2-
phenylindole, Cambridge Bioscience, Cambridge, UK) and 
resorted for viable CD45+ cells into a 96 well PCR plate 




Figure 8: Schematic of 
16h culture method prior 
to RNA sequencing. 
METHODS 
42 
Table 4: Antibodies used to analyse colony forming units. 
Antibody Clone Fluorophore Detected lineage 
CD41 MWReg30 FITC Megakaryocytes/Platelets 
CD61 2C9.G2 (HMβ3-1) PE Megakaryocytes/Platelets 
Ter119 TER-119 PE/Cy7 Erythrocytes 
CD45.2 104 APC/Cy7 Haematopoietic cells 
Ly6G/Gr1 1A8 BV421 Granulocytes 
CD11b/Mac1 M1/70 APC Monocytes/Granulocytes 
 
2.4.4 Colony-forming assays 
To assess viability and multi-lineage differentiation capacity of single cells, cells were 
transferred from liquid culture into 600 µL of semi-solid MethoCult GF M3434 (SCT).  
Cells were cultured for 14 days and colony type scored either manually by morphology or by 
antibody staining. Antibodies used are listed in Table 4. All antibodies were purchased from 
Biolegend). Samples were acquired on BD LSRFortessa cell analysers. Laser and filter 
configurations for analysers used are listed in Table 5. Flow cytometry data was analysed using 
FlowJo v10 (FLOWJO LLC, Ashland, OR, USA).  
 
Table 5: Laser and filter configurations of LSRFortessa cell analysers. 
Fluorophore LSRFortessa 1 LSRFortessa 2 
7-AAD 561 670/30 532 710/50 
AF700 640 730/45 640 730/45 
APC 640 670/14 640 670/14 
APC/Cy7 640 780/60 640 780/60 
BV421 405 450/50 405 450/50 
BV605 405 610/20 405 610/20 
FITC 488 530/30 488 515/20 
PE 561 585/15 532 585/15 
PE/Cy7 561 780/60 532 780/60 
 
2.4.5 Culture in agarose-based gels.  
Hydrogels were made by heating SeaPrep agarose (Lonza, Basel, CH) in IMDM (Iscove's 
Modified Dulbecco's Medium, Gibco) until dissolved and adding thrombin from human plasma 
(Sigma) to the agarose solution once cooled down to 40oC. The mixture is then kept at 40oC. 
Fibrinogen from human plasma (Sigma) dissolved in IMDM was added to IMDM and mixed 
with either Laminin (Sigma) or human plasma Fibronectin (Merck Millipore, Burlington, MA, 
USA). All mixtures were made at 2X concentration. The thrombin containing solution was then 
quickly added to the fibrinogen containing solution in a 96 well plate and left to polymerise  
on ice. Figure 9 shows the layout of the 96 well plate to produce 96 individual gels. The gels 
were subsequently topped up with 50 µL of culture medium. Single or multiple cells were sorted 
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as described onto the gels and cultured for up to 21 days. Cells were isolated from the gels by 
digestion with trypsin (Gibco) at 37°C for 30 min. The trypsin reaction was stopped with 




Figure 9:  Plate layout for the production of agarose based hydrogels. 
Combination of agarose, Fibrinogen, Thrombin and ECM proteins are used to generate 96 different 
hydrogels. 
 
2.5 Atomic force microscopy 
Bone marrow plugs were obtained by flushing the bone marrow of Nestin-GFP+ mice (gifted 
by Mendez-Ferrer lab36) with a 21 gauge hypodermic needle and 3 mL IMDM. Bone marrow 
plugs were mounted in a well in a 10% agarose plate and covered with IMDM.  
Stiffness measurements of bone marrow plugs were carried out using an atomic force 
microscope (AFM, JPK Instruments, Berlin, Germany). Samples of exposed bone marrow were 
transferred onto an x/y motorised stage (AxioObserver A1, Zeiss, Jena, Germany) under an 
inverted microscope onto which the AFM was mounted. Tipless silicon cantilevers (0.1 to 0.3 
N/m, Sicon-tl, Nanosensors, Neuchâtel, Switzerland) with a polystyrene bead glued at their tip 
(radius r = 18.64 µm ± 0.17 µm, microParticles GmbH, Berlin, Germany) were used to perform 
indentations on the bone marrow, with an approach speed of 10 µm/s and a set force of 10 nN. 
Cantilever position relative to the tissue was monitored using a CCD camera (The Imaging 
Source, Bremen, Germany) mounted on top of the setup. Indentations were converted into 
stiffness values (K) by applying the Hertz model to the recorded force-distance curves:  
F = 4/3 K r1/2 δ3/2, for an indentation depth of δ = 2 µm; using a custom written automated 
algorithm based in Matlab (Mathworks, Natick, MA, USA). 
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2.6 Generation of haematopoietic chimaeras 
Donor cells were obtained from either WT or WT-CD45.1 mice. All donor mice were between 
8 and 16 weeks of age. Recipient mice were either WT or W41. All singe cell transplants were 
carried out using W41 as recipient mice. The mice carry a mutation in the SCF receptor c-Kit, 
giving WT donor cells a competitive advantage218. 
Recipient W41 mice were sublethally irradiated with a single dose 400cGy using a caesium 
source. Recipient C57BL/6-Ly5.2 were lethally irradiated with split doses of 550 cGy  
(total = 1100 cGy), with at least 3h between doses. All recipients were >8 weeks of age.  
Transplantations were performed by intravenous tail vein injection using a 29.5G insulin 
syringe. Limiting dilution transplantations were carried out into WT recipients by mixing the 
desired amount of WT-HSCs with 200,000 CD45.1/.2 whole bone marrow helper cells and 
subsequently transplanting the cell suspension.  
For single cell transplants, single cells were sorted into 100 µL of medium in a 96-well U-
bottom plate. 100 µL of PBS is mixed with the well content, all liquid is subsequently aspirated 
into the insulin syringe avoiding any air bubbles and injected into the tail vein.  
For secondary transplantations, bone marrow was harvest from the primary recipient by 
flushing tibiae and femurs with PBSFE followed by red blood cell lysis. An equivalent of one 
femur was transplanted per mouse. Each primary donor mouse was transplanted into at least 
two secondary recipients.  
In case of early death or sacrifice of the primary recipient, bone marrow was obtained from 
tibiae and femurs by crushing or flushing and subsequently frozen in 10% DMSO (Dimethyl 
sulfoxide, Fisher Scientific, Hampton, NH, USA) in FCS. On the day of transplantation, frozen 
cells are gently thawed in a water bath set to 37°C. The freshly thawed cell suspension is then 
added to 20 mL prewarmed IMDM in a dropwise fashion. Cells were washed to remove any 
DMSO and all remaining cells were transplanted into two recipients.  
 
2.7 Peripheral blood analysis 
Recipient mice were considered successfully repopulated when overall donor chimaerism >1% 
in the peripheral blood at 16 weeks post transplantation or later.  
To assess donor chimaerism in recipient mice, peripheral blood (PB) samples were obtained 
from the tail vein every 4 weeks, starting 8 weeks post transplantation up to 28 weeks, unless 
otherwise stated. Blood was collected in EDTA coated microvette tubes (Sarstedt AG & Co, 
Nuembrecht, Germany). Blood samples were treated with NH4Cl to deplete erythrocytes and 
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subsequently stained for lineage markers using the antibodies listed in Table 6 p.45. All 
antibodies were obtained from Biolegend. Samples were acquired on BD LSRFortessa cell 
analysers. Filter configurations for analysers used are listed in Table 5, p. 42. Cells of the B cell 
lineage were defined as viable single cells, myeloid negative (CD11bneg, Ly6gneg), CD3eneg, 
B220+. Cells of the T cell lineage were defined as viable single cells, myeloid negative 
(CD11bneg, Ly6gneg), B220neg, CD3e+. Cells of the myeloid lineage (GM, Granulocyte/ 
Monocyte) were defined as viable single cells, lymphoid negative (B220neg, CD3eneg), CD11b+, 
Ly6g+ or CD11b+, Ly6glow/neg. All flow cytometry data was analysed using FlowJo v10. An 
example of the gating strategy is displayed in Figure 10, p. 46. 
 
Table 6: Antibodies used to analyse donor chimaerism in peripheral blood. 
Antibody Clone Fluorophore Detected lineage 
B220 RA3-6B2 APC B cells 
CD11b/Mac1 M1/70 PE/Cy7 Monocytes/Granulocytes 
CD11b/Mac1 M1/70 BV605 Monocytes/Granulocytes 
CD3e 17A2 PE T cells 
CD45.1 A20 AF700 Recipient/Donor 
CD45.2 104 FITC Recipient/Donor 










2.8 RNA sequencing 
2.8.1 Single cell RNA sequencing analysis 
Single cell RNA sequencing (scRNA seq) analysis was carried out as previously described in 
Picelli et al. 2014 (Smart-seq2). Briefly, single cells were sorted by FACS directly into 96-well 
PCR plates containing lysis buffer. Lysis buffer contained 0.2% Triton X-100 (Sigma) and 
Rnase inhibitor (SUPERase, Thermofisher) in nuclease-free water (Thermo Fisher).  
Libraries were prepared using the Illumina Nextera XT DNA preparation kit. Libraries were 
pooled and run on the Illumina Hi-Seq4000 at the CRUK Cambridge Institute Genomics Core.  
scRNAseq data was analysed by Dr. Fiona Hamey, Rebecca Hannah, and Evangelia Diamanti 
(all Goettgens’ lab), and Hugo Bastos (Kent lab). Quality control settings for single cell data 
was as follows:  
To exclude cells from which low quality libraries with insufficient sequencing depths were 
generated, the threshold of number of mapped reads was set to >2*105, with mapped reads 
encompassing nuclear genes, mitochondrial genes and ERCCs. Empty wells and dead cells 
were excluded by setting a minimum threshold of 20% for reads mapping to known genes. 
Additionally, the threshold for reads mapping to mitochondrial genes was >0.2 ensuring that a 
minimum of 20% of reads map to non-mitochondrial genes. As shown by in Appx-A Figure 1 
and Appx-A Figure 2 in Appendix A, setting further threshold using other parameters would 
not eliminate any more cells than those mentioned above and thus were not applied. For 
example, setting the threshold ratio of “ERCC” to “mapped genes” to <1 was not necessary as 
to exclude more empty wells and dead cells than those excluded by above used parameters.  
 
2.8.2 Bulk RNA sequencing analysis 
Bulk RNA sequencing was carried out at the Genomics core facility of the Cambridge Stem 
Cell Institute upon submission of sample RNA. Libraries were prepared as described above 
using the Smart-seq2 protocol.  
RNA was extracted from the samples using the PicoPure RNA Isolation Kit (Thermo Fisher) 
according to protocol. RNA sequencing data was analysed by Dr. Fiona Hamey (Goettgens lab) 
and Hugo Bastos (Kent lab). 
 
2.9 Normalisation of single cell index-sorting data 
Surface marker intensity of single HSCs across different experiments were normalised and 
batch corrected using the flowCore (version 1.42.3) and sva (version 3.24.4) R packages. Single 
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HSCs were sorted in 96-well format and each plate was classified as an independent batch prior 
to batch correction. All recorded surface markers were arranged in a flow frame and 
subsequently subject to logicle transformation prior to batch correction. The analysis and all 
resulting figures were computed in R (version 3.4.2).  
Normalisation was performed by Daniel Bode (Kent lab). The original script was developed by 
Blanca Pijuan Sala in Elisa Laurenti's lab.  
 
2.10 Statistical analyses 
Extreme limiting dilution analysis (ELDA) was carried out using the ELDA software provided 
by the Walter and Elisabeth Hall Institute of Medical Research Bioinformatic resources, as 
described in Hu, Y, and Smyth, GK (2009)253. Gene ontology annotation was carried out using 
Enrichr254,255. Statistical data visualisation through violin plots was carried out using Python 
Seaborn. All other statistical analyses was performed using Graphpad Prism 6.07 for Windows 




3.1 Differential SCF stimulation in vitro does not affect engraftment capability 
but alters HSCs expansion in vivo 
Stem cell factor (SCF) is a cytokine widely used as part of various cytokine and growth factor 
cocktails aimed at human and mouse haematopoietic stem cell (HSCs) maintenance and 
expansion10,256,257. Research has shown that SCF independently can alter HSCs fate choice10.  
In 300 ng/mL supplemented with human Interleukin-11 (IL-11), nearly 20% of 4-day single 
cell derived clones are able to long-term reconstitute the haematopoietic system of recipient 
mice, whereas 10 day clones fail to repopulate secondary recipients64. Interestingly, the 
concentration of SCF has been shown to affect maintenance of HSCs activity, with a 30-fold 
reduction in SCF resulting in a 3-fold reduction of repopulation ability in 4-day clones. 
Importantly, this change in stem cell activity appears to occur prior to the first division between 
8 and 16h of culture (Figure 11), without concurrent changes in division kinetics or survival10. 
Notably, a low concentration of SCF was shown to promote differentiation whereas a high 
concentration stimulated HSCs self-renewal. These experiments were performed on HSCs 




Figure 11:  Differential Stem Cell factor stimulation alters HSCs activity. 
Single cell HSCs (CD45midLin-Rho-SP) were transplanted directly harvested from the bone marrow 
or following 8h, 16h or 96h in culture. A 30-fold reduction of SCF reduces HSCs activity 3-fold within 
16h of culture, when compared to unstimulated, uncultured HSCs. This reduction is maintained 




It is of interest to advance our understanding of the underlying molecular mechanisms driving 
these different fate choices. Furthering our knowledge about molecular drivers of HSCs self-
renewal may be applied to human HSCs leading to the establishment of culture conditions 
aimed at the expansion of human HSCs. These can ultimately be used in HSCs transplantation 
for the treatment of malignant or non-malignant blood disorders such as leukaemia or 
anaemia235,239.  
In addition, understanding the involvement of key molecules instructing specific lineage 
differentiation may aid in the targeted generation of mature blood types such as erythrocytes 
and megakaryocytes from either human embryonic stem cells, induced pluripotent stem cells 
or primary HSCs258.  
Therefore, my aim was to assess how HSCs self-renewal and differentiation is controlled by 
stem cell factor signalling. For this purpose an improved HSCs isolation phenotype was used 
as input material: Sca-1highEPCRhighCD45+CD48lo/-CD150+ (Figure 12), isolating HSCs at 67% 
purity in primary68 and ~50% secondary (unpublished) transplantations. This more highly 
purified HSCs population did not respond in the same way, resulting in significant differences 
in cell cycle kinetics and lower overall survival of HSCs. SCF concentrations were therefore 
adjusted to accommodate only a 10-fold difference between the high and low SCF dose. To 
assess functional differences between HSCs, single cell transplantations of differentially 
stimulated HSCs were carried out. The functional data was complemented by single cell RNA 
sequencing to detect any alterations in the cell’s transcriptome. All transplanted HSCs were 





Figure 12: Representative gating layout to purify phenotypic S-ESLAM HSCs. 
Sca-1highEPCRhighCD45+CD48lo/-CD150+ HSCs are isolated from lineage-depleted bone marrow 
using FACS. The dotted line indicates that further gating is not part of the standard gating strategy 
for E-SLAM HSCs.  
 
3.1.1 Low concentration of stem cell factor negatively affects cell survival and division 
kinetics of highly purified HSCs in vitro 
FACS isolated single HSCs were cultured for a period of 10 days in serum-free medium (SFM) 
containing human IL-11 and mouse stem cell factor (SCF). SCF was used at three different 
concentrations: 10 ng/mL, 30 ng/mL and 300 ng/mL. To assess the effect of alteration of SCF 
concentration on single HSCs clone survival, cell division kinetics, and clone size were 
monitored daily for 10 days.  
 
In contrast to a previous report using a less purified HSCs populations (~30% vs 67%), 
differences in cell survival were observed across the three SCF concentrations. Day 10 clone 
survival was 1.3x and 2.6x higher in medium containing 300 ng/mL mSCF (35.6% ± SD 
15.83%) when compared to 30 ng/mL (25.6%, ± SD 12.8%) and 10 ng/mL (13.6%, ± SD 3.9%) 
respectively (Figure 13A). While these differences were not significant, they did represent a 
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nearly 3-fold reduction in cell survival, making future molecular experiments more challenging 
and potentially introducing an element of cell selection. Supporting this latter possibility, the 
surviving HSCs treated with 10 ng/mL SCF were significantly delayed in the time to first 
division and subsequent divisions showed significant delays at day 3, day 4, and day 7. In 
contrast, divisional kinetics between 300 ng/mL and 30 ng/mL were similar at all time points 
(Figure 13B, C, D). Consequently, single HSCs stimulated with 10 ng/mL almost exclusively 
made very small (VS) and small (S) clones, at the expense of larger clones (Figure 13E and 
Table 7). While HSCs treated with 30 ng/mL did give rise to a significantly higher proportion 
of VS clones than those stimulated with 300 ng/mL (p=0.0248, see Table 7), the percentages of 
small, medium, large, and very large clones did not differ between the two treatments  
(Figure 13E).  
As there were virtually no differences in cell survival, cell cycle entry and cell cycle kinetics in 
HSCs stimulated with 30 ng/mL and 300 ng/mL SCF, these conditions were chosen to further 
investigate the molecular and functional changes in HSCs following differential SCF 
stimulation.  
 
Table 7: Percentage of very small and small clones after SCF treatment. 
Clone size 300 ng/mL SCF 30 ng/mL SCF 10 ng/mL SCF 
VS 21.6%, ± SEM 5.0%) 45.1%, ± SEM 6.0% 65.2%, ± SEM 10.3% 




Figure 13:  A 10 fold reduction in stem cell factor concentration does not alter HSCs kinetics 
or survival in vitro.  
A) Survival of clones treated with different concentration of SCF. B-D) Division kinetics of cells treated 
with different concentration of SCF: E) Clone size distribution of 10 days after treatment with different 
concentration of SCF, n= 4 exp. F) Exemplary micrographs of different clone sizes. Scale bar = 100 
µm. Error bars show standard error of the mean (SEM). 2way ANOVA, Tukey’s multiple comparison 
test. Dashed line represents non-linear regression fit, [Agonist] vs. response, variable slope (four 
parameters). VS=very small, S=small, M=medium, L=large, XL=very large. 300ng: n=180, 4 exp; 




3.1.2 Limiting dilution analysis does not reveal significant functional differences 
between short-term differentially stimulated HSCs. 
To investigate the effect of different concentrations of SCF on the functional output of HSCs, 
50 LT-HSCs were bulk sorted followed by a 16h treatment with high (300 ng/mL) or  
low (30 ng/mL) concentrations of SCF. Sublethally irradiated W41 mice were transplanted with 
3 cells or 6 cells of the culture from each treatment and compared post-transplantation for their 
contribution to mature cell production. As seen in Figure 14A,B in both conditions 2 of 3 mice 
transplanted with 3 cells and 3 of 3 mice transplanted with 6 HSCs showed donor chimaerism 
>1% up to 20 weeks post transplantation, equivalent to an estimated stem cell frequency of 1 
in 2.64 (i.e. 37.9%). At 16 weeks, all mice show multi-lineage repopulation (Figure 14C,D) 
with a possible tendency to have a less balanced lineage output from HSCs stimulated with a 
low concentration of SCF. In both mouse m1.4 and mouse m1.8 a biased lineage production 
towards myeloid cells can be observed, in contrast to mouse m1.9 which seems to generate 
exclusively lymphoid cells.  
 
 
Figure 14:  Primary transplantation of differentially treated HSCs. 
A-B) Donor chimaerism in peripheral blood of W41 recipient mice over the course of 20 weeks post 
primary transplant. Blue: treatment with 300 ng/mL SCF. Red: treatment with 30 ng/mL SCF. Star 
indicates that this mouse was sacrificed for non-experimental reasons. C-D) Ratio of myeloid (GM) 
to lymphoid (B:T) lineage at 16 weeks post primary transplantation. All ratios were determined from 
peripheral blood samples. 
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As these results are not conclusive, a limiting dilution assay was performed at a 1, 3 and 10 
donor cell doses.  
At 20 weeks post transplantation, none of the mice transplanted (0 of 5) with 1 cell equivalent 
doses showed any repopulation (Figure 15A), whereas 2/6 (high SCF) and 2/7 (low SCF) mice 
that received 3 cells were repopulated (Figure 15B). All mice transplanted with 10 cells showed 
repopulation at 20 weeks (3/3, high SCF. 2/2 low SCF, Figure 15C). These results represent a 
non-significant (p=0.592) 1.2-fold difference in stem cell frequency between cells that were 
treated with 300 ng/mL SCF (1/6.69) and 30 ng/mL SCF (1/8.18, Figure 15D). 
 
 
Figure 15:  Limiting dilution transplantation of 16h stimulated HSCs.  
A-C) Peripheral blood donor chimaerism in WT recipient mice. Recipients were transplanted with 
different cell doses of either 300 ng/mL or 30 ng/mL 16h treated HSCs in addition to 2*105 whole 
bone marrow helper cells. Chimaerism at 4, 8, 12, and 20 weeks post primary transplant is displayed. 
D) Extreme Limiting Dilution Analysis (ELDA) plot, estimating stem cell frequency. 
 
When comparing the lineage composition of the two differentially treated input HSCs, in both 
treatments unbalanced lineage contribution could be observed, independent from the cell dose 
(Figure 16A-D). In a bulk transplantation setting it is probable that multiple HSCs contribute 
to the repopulation in the recipient mouse and a balanced repopulation pattern should be 
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observed. Therefore, in mice receiving 10 HSCs, a balanced lineage output (like m3.3 in Figure 
16C) would be expected as the pooled contribution of multiple HSCs subtypes. Yet, only 1 of 
3 mice in high SCF and 1 of 2 mice in low SCF (m3.3 and m3.20, Figure 16C-D) display a 
balanced lineage output suggesting that one or a few HSCs dominate the lineage production in 
the other recipients.  
 
From these data it can be concluded that low cell dose transplantations do not offer a high 
enough resolution to assess any functional changes between highly purified HSCs treated with 
different doses of SCF. This is likely due to the high reconstitution capabilities of Sca-1high-
ESLAM HSCs as well as their cell intrinsic heterogeneity64,68. Furthermore, transplanting 2% 
of the total culture as an equivalent of a single cell may result in none of the cells being 
physically transplanted. Therefore, it was necessary to perform single cell transplantation of 
HSCs to eliminate the possibility of comparing recipients that have multiple or only one 
dominant HSCs contributing to the lineage production. 
 
 
Figure 16:  Ratio of lineage contribution in recipients of 16h stimulated HSCs.  
A-B) Ratio of myeloid (GM) to lymphoid (B:T) lineage 20 weeks post primary transplantation in 
recipient of 3 treated HSCs. C-D) Ratio of myeloid (GM) to lymphoid (B:T) lineage 20 weeks post 




3.1.3 Single cell transplantation shows that SCF does not alter HSCs frequency but may 
impact clonal expansion post-transplantation.  
For the single cell transplants, single HSCs were sorted and stimulated for 16h with a high or 
low concentration of SCF in individual wells of a 96 well plate and presence of a single cell 
was confirmed prior to transplant. This approach removes the uncertainty associated with 
transplanting a proportion of total liquid and ensures that 1 single cell is delivered per recipient 
animal. The number of recipients successfully repopulated in primary transplantation does not 
differ between those from HSCs treated with 300 ng/mL SCF to those treated with 30 ng/mL 
with 14/40 (37.5%, Figure 17A and B) and 15/40 (35%, Figure 17C and D) respectively, from 
two separate experiments. In both settings, one mouse showed >0.5% and <1.0% donor 
chimaerism but was also serially transplantable, indicating the presence of functional HSCs. In 
secondary recipients 8 of 40 and 10 of 40 mice for high and low dose treated HSCs respectively, 
displayed multi-lineage repopulation. Notably the levels of donor contribution were 
significantly higher (p=0.0274) in secondary recipients of HSCs receiving a high dose of SCF, 
suggesting that more (or more potent) daughter HSCs were generated in the primary recipient 
compared to cells treated with a low dose of SCF (Figure 17E). In both treatments, one mouse 
retrospectively determined to have been transplanted with a gamma-HSCs (m7.14 and m10.23) 
showed repopulation in secondary recipients. However, only lymphoid lineages were detected 
and chimaerism steadily decreased over time (Figure 17A&D). It can therefore be assumed that 
the secondary engraftment is due to lymphocyte progenitors and long-lived lymphocytes. 
This data does not reflect previous findings in that low SCF reduces HSCs frequency however, 
it does suggest that the concentration of initial SCF stimulation alters HSCs biology resulting 
in differential stem cell expansion post-transplantation. It is possible that this has not been 
observed previously due to the less pure population of HSCs. Alternatively, the lower dose of 
10 ng/mL may exacerbate the reduction in HSCs activity not only resulting in lower HSCs 
expansion (as seen in 30 ng/mL) but also leading to loss of self-renewal activity. This may 
indicate that 30 ng/mL SCF is sufficient to maintain HSCs activity but not enough to stimulate 
HSCs expansion. To fully understand the impact of SCF signalling on HSCs fate choice, it 




Figure 17:  Stem cell activity but not secondary donor chimaerism is nearly identical between 
recipients of differentially treated HSCs. 
A-B) Peripheral blood donor chimaerism in W41 mice transplanted with 300 ng/mL, 16h treated 
HSCs. 14/40 mice were positive in primary transplantation >1% (35%), 8/14 repopulated secondary 
recipients. C-D) Donor chimaerism in mice transplanted with 30 ng/mL, 16h treated HSCs. 15/40 
mice were positive in primary transplantation >1% (37.5%), 10/15 engrafted in secondary recipients. 
n=80, 2 experiments. Star indicates recipient animal was sacrificed for non-experimental reasons. E) 
Donor chimaerism in primary and secondary recipients of differentially treated HSCs. Unpaired t-test, 




3.1.4 Single cell transplantations reveal that in vitro SCF stimulation does not alter 
HSCs subtype  
Single cell transplantation allows the classification of donor HSCs based on their lineage 
outcome at 16 weeks. According to findings from the Eaves lab, HSCs can be categorised into 
alpha, beta, gamma and delta, as determined by the ratio of GM to B/T-cells. Alpha-HSCs are 
lymphoid deficient, whereas beta-HSCs give rise to an equal amount of myeloid and lymphoid 
cells. Both alpha and beta-HSCs subtypes are capable of long-term lineage reconstitution in 
secondary recipients. In contrast, gamma and delta-HSCs primarily produce lymphoid cells 
with delta-HSCs completely lacking myeloid lineage contribution past 16 weeks in primary 
transplantation. These two HSCs subtypes typically fail to reconstitute the haematopoietic 
system in secondary recipients64.  
As can be seen from Table 8 and Figure 18 both treatments result in a similar distribution of 
HSCs subtypes with a tendency of a more balanced lineage production from those HSCs treated 
with a low concentration of SCF. More single cell transplants will be necessary to confirm this 
trend. Interestingly, in the low SCF treated mice 3 out of 6 retrospectively assigned beta-HSCs 
failed to reconstitute secondary recipients which would be expected. This is again supports the 
hypothesis that a high SCF concentration stimulates more self-renewal divisions. 
 
Table 8: HSCs subtype distribution in primary recipients of differentially stimulated single 
HSCs 
HSCs subtype 
16h stimulation of single HSCs 
300 ng/mL SCF 30 ng/mL SCF 
Alpha 5 5 
Beta 2 6 
Gamma 2 2 
Delta 5 2 
 
At present, from the data it can be concluded that there are no significant differences in primary 
lineage reconstitution ability and lineage production between HSCs stimulated with a high or 
low concentration of SCF. This shows that the amount of 30 ng/mL is sufficient to retain HSCs 
stemness within the first 16h of culture. Longer time-courses will be necessary to determine if 





Figure 18:  Peripheral blood donor cell ratio of myeloid to lymphoid progeny from single cell 
primary and secondary recipients at 16 weeks post transplantation. 
A) Recipients of single 300 ng/mL, 16h treated HSCs. B) Recipients of single 30 ng/mL, 16h treated 
HSCs. <1% indicates unsuccessful secondary transplants. X indicates sacrifice of the recipient for 
non-experimental reasons before any data could be obtained. Legend continued on next page. 
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Figure 18: Peripheral blood donor cell ratio of myeloid to lymphoid progeny from single cell 
primary and secondary recipients at 16 weeks post transplantation.  
α (alpha), β (beta), γ (gamma), δ (delta) indicate the HSCs subtype determined at 16 weeks based 
on peripheral blood myeloid (M) to lymphoid (L) ratio. M/L>2 = alpha-HSCs. M/L>0.25,<2 = beta-
HSCs. M/L<0.25 = gamma/delta-HSCs. Gamma HSCs that fail to contribute to the myeloid lineage at 




3.1.5 Single cell RNA sequencing of cultured and stimulated HSCs shows that cell cycle 
activation signature drives main differences between cell populations  
To assess transcriptional changes between freshly isolated HSCs and those that were stimulated 
with a high or low dose of SCF, single cell RNA sequencing was carried out. 191 freshly 
isolated cells were sequenced of which passed 127 quality control. For both 300 ng/mL and  
30 ng/mL SCF treated conditions 96 cells were processed of which 63 and 80 passed the 
thresholds set for quality control (Figure 19, Appx-A Figure 1 and Appx-A Figure 2). 
 
Figure 19:  Quality control of raw read data in single cells. 
RNA sequencing ran in two lanes SLX-12565 and SLX-12566 with libraries prepared from single 
freshly isolated HSCs divided up into both lanes at molarity equal to that of the libraries from treated 
single HSCs (SLX-12565= 300 ng/mL treatment, SLX-12566= 30 ng/mL treatment). Red depicts cells 
that did not pass thresholds set for the respective QC criteria listed on the y-axis of each graph. A-
B) Mapped reads including nuclear genes, mitochondrial genes and ERCC (>2*105). C-D) Reads 
mapping to genes (>0.2). E-F) Reads mapping to mitochondrial genes (<0.2). Cells that did not pass 
quality control were excluded from analysis. The black dots depict cells that passed quality control.  
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A total of 21,616 gene transcripts were analysed, with 2480 genes being differentially expressed 
(p<0.01) between freshly isolated and 300 ng/mL SCF stimulated cells (1780 upregulated, 700 
downregulated). Gene expression of 2103 transcripts was altered between naïve HSCs and 
those stimulated with 30 ng/mL SCF (951 upregulated, 1152 downregulated). 
Of note, 824 upregulated and 554 downregulated genes were found significantly differentially 




Figure 20: Venn diagram of differentially expressed genes between freshly isolated HSCs 
and SCF stimulated HSCs.  
Freshly isolated BM HSCs were sorted directly into lysis buffer. Cultured HSCs were stimulated 16h 
with high (300 ng/mL) or low (30 ng/mL) concentration of SCF. The top left cluster shows that 33 
genes were differentially expressed (DEX) between HSCs treated with 300 ng/mL and 30 ng/mL 
SCF. Of these 33 DEX genes, 30 were upregulated and 3 downregulated. 20 of those upregulated 
genes were also upregulated when compared to freshly isolated HSCs in the top right cluster. The 
top right cluster shows 2480 DEX genes between freshly isolated and 300 ng/mL SCF treated HSCs. 
Of those genes 1780 transcripts were upregulated in high SCF treated HSCs and 700 were 
downregulated. The bottom cluster displays the differential gene expression between freshly isolated 
HSCs and 30 ng/mL SCF treated HSCs. Of the 1378 DEX genes, 824 are found upregulated and 
554 downregulated in treated HSCs.  
 
Not surprisingly, gene ontology (GO) terms observed in SCF stimulated cells upregulated genes 
functionally clustered were mostly involved in initiation of proliferation, such as DNA 
replication initiation, DNA synthesis and repair, G1/S transition and DNA repair (Figure 21, 
Appx-B Table 1, and Appx-B Table 2). In contrast, none of the downregulated genes in SCF 
stimulated genes were significantly enriched in any GO terms. This indicates that SCF treated 
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cells are stimulated to divide, preparing the necessary machinery to do so, while shutting down 
other cellular processes that might be related to preserving the quiescence programme. 
 
  
Figure 21: Clustergram of gene ontology displaying biological processes upregulated in 
treated HSCs.  
The first 10 significant enriched terms are displayed in the columns, and the first 20 enriched genes 
in the rows. Red matrix indicate the association of the input gene with the respective ontology term. 
 
When comparing the transcriptome of high and low SCF treated HSCs 33 genes were 
differentially expressed (Figure 20). 30 if these 33 genes being significantly upregulated and 3 
downregulated (Table 9 and Table 10) in HSCs treated with a high dose of SCF compared to a 
low dose. As shown in Table 10, all significantly upregulated genes in HSCs treated with 30 
ng/mL SCF encompassed predicted genes. Therefore, the analysis was restricted to protein 
coding annotated genes leaving 12,831 transcript to be analysed. However, following exclusion 
of pseudogenes, no transcripts were found to be significantly overexpressed in low SCF treated 
HSCs. This suggests that the activation from quiescence is a much more dominant set of 
molecular changes than differential SCF signalling. 
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Table 9: Upregulated genes in HSCs stimulated with 300 ng/mL SCF for 16h compared to 
HSCs stimulated with 30 ng/mL SCF for 16h. 
Gene name ENSEMBLE gene ID Adjusted P-value Log2 fold change 
Zfp385a ENSMUSG00000000552 0.00596 3.08476 
Nabp1 ENSMUSG00000026107 0.00581 2.56111 
Gm12420 ENSMUSG00000081775 0.00001 2.04650 
Fahd2a ENSMUSG00000027371 0.00002 1.90934 
Cav2 ENSMUSG00000000058 0.00752 1.65520 
Tmem120a ENSMUSG00000039886 0.00012 1.47429 
Tubb6 ENSMUSG00000001473 0.00415 1.46703 
Plek ENSMUSG00000020120 0.00752 1.30837 
Gem ENSMUSG00000028214 0.00021 1.28827 
Pidd1 ENSMUSG00000025507 0.00626 1.26505 
Ash2l ENSMUSG00000031575 0.00596 1.10319 
Zdhhc13 ENSMUSG00000030471 0.00862 1.04585 
Lyn ENSMUSG00000042228 0.00720 1.03073 
Tap1 ENSMUSG00000037321 0.00720 1.02628 
Myadm ENSMUSG00000068566 0.00596 0.97459 
Hmgcr ENSMUSG00000021670 0.00596 0.97231 
Naa40 ENSMUSG00000024764 0.00752 0.96858 
Galk1 ENSMUSG00000020766 0.00752 0.96756 
Ndrg3 ENSMUSG00000027634 0.00539 0.90353 
2810474O19Rik ENSMUSG00000032712 0.00596 0.86782 
Lypla1 ENSMUSG00000025903 0.00720 0.84400 
Ctnna1 ENSMUSG00000037815 0.00563 0.81197 
Serinc1 ENSMUSG00000019877 0.00720 0.79858 
Pafah1b2 ENSMUSG00000003131 0.00720 0.74582 
Vps35 ENSMUSG00000031696 0.00539 0.68410 
Kdelr2 ENSMUSG00000079111 0.00752 0.65759 
Rnf187 ENSMUSG00000020496 0.00596 0.49646 
Msn ENSMUSG00000031207 0.00019 0.45594 
Bzw1 ENSMUSG00000051223 0.00626 0.41193 
Serinc3 ENSMUSG00000017707 2.75E-07 0.37956 
 
Table 10: Differential gene expression in cells treated 16h with 30 ng/mL compared to 
300 ng/mL SCF 
Gene name ENSEMBLE gene ID Adjusted P-value Log2 fold change 
Gm3511 ENSMUSG00000105031 0.002582 0.163444 
Gm28437 ENSMUSG00000101111 0.00744 0.335708 
Gm12967 ENSMUSG00000080944 0.008061 0.547697 
 
The close relationship between these two treated cell populations is visualised in Figure 22A 
by principle component analysis (PCA). Here, differentially treated single cells clearly cluster 
together and away from freshly isolated cells. To test if the short culture period drives this 
separation, a total of 1378 genes with shared differential expression in treated and freshly 
isolated HSCs were excluded from the PCA. However, cultured cells still clustered together 
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Figure 22:  PCA clustering of freshly isolated BM HSCs and cultured, SCF treated HSCs. 
Freshly isolated, untreated HSCs are depicted in grey and cluster away from HSCs treated for 16h 
with 300 ng/mL SCF (blue) and 30 ng/mL SCF (red). A) Highly variable genes are plotted without 
additional filtering. B) Clustering of cells following exclusion of genes differentially expressed in 
treated cells compared to untreated.  
 
Of the 30 genes upregulated in high vs. low SCF treated HSCs, 20 were also upregulated in 
high vs freshly isolated HSCs (Appx-B Table 3). Analysis of transcription factor occurrence 
shows that Lyn, Tubb6, Cav2, Plek, and Msn are significantly associated with the transcription 
factor Elf4 (Table 11 and Figure 23). 
 
Table 11: Transcription factor-gene occurrence of genes upregulated in high SCF treated 
HSCs 
Term P-value Adjusted P-value Input genes 
ELF4 9.31E-06 0.00421 LYN;TUBB6;CAV2;PLEK;MSN 
ETS1 0.000196 0.01775 LYN;TUBB6;CAV2;MSN 
ELK3 0.000196 0.01775 TUBB6;CAV2;MSN;GEM 
NFKB2 0.000196 0.01775 LYN;TUBB6;PLEK;GEM 
STAT3 0.000196 0.01775 LYN;TUBB6;CTNNA1;MSN 
KLF6 0.003123 0.042776 TUBB6;MSN;GEM 
PRDM1 0.003123 0.042776 LYN;PLEK;GEM 
REL 0.003123 0.042776 LYN;PLEK;GEM 
CBFB 0.003123 0.042776 TUBB6;MSN;BZW1 





Figure 23: Clustergram of transcription factor-gene occurrence of genes upregulated in high 
SCF treated HSCs. 
The transcription factor Elf4 has the strongest association with the input genes that were upregulated 
in high SCF treated HSCs compared to low SCF treated and unstimulated HSCs. 
 
As seen in Figure 24 Plek, Tubb6, and Cav2 but not Msn and Lyn are indeed higher expressed 
in the majority of cells treated with a high dose of SCF.  
Plek encodes for the phosphoprotein Pleckstrin, which is the main substrate for phosphorylation 
by protein kinase C in thrombocytes, following platelet activation. Over-expression of 
Pleckstrin in cell lines has been shown to alter their actin cytoskeleton and cell spreading259-261. 
Little is known about its role in haematopoiesis although its expression seems to be enriched in 
myeloid progenitor cells262. 
The class V β-tubulin subtype 6 is encoded by Tubb6. It is a vital component of the cell’s 
cytoskeleton and required for orchestrating DNA segregation during cell division. β6 Tubulin 
is thought to be restricted to megakaryocytes and platelets, however not much is known about 
its expression in HSCs263,264. 
Caveolin-2 (Cav2) is a component of the caveolae, which are situated within lipid rafts and 
mediate signal transduction to intracellular space and in doing so facilitate signal activation of 





Figure 24:  Violin plots displaying gene expression distribution among differentially treated 
HSCs.  
 
The ETS transcription factor Elf-4 (E74-like factor, also known as Myeloid Elf-1-like factor 
(MEF) is known to play a crucial role in HSCs cell cycle entry and proliferation show increased 
quiescence and radioprotection108,266,267. The common co-occurrence of Plek, Tubb6, and Cav2 
with Mef suggests that these genes are activated upon entry into cell cycle. This is in congruent 
with the finding that HSCs are stimulated to proliferate which may occur in a dose dependent 
fashion (Figure 24). 
 
Overall, in this chapter my aim was to investigate how differential SCF stimulation alters HSCs 
fate choice on a functional and molecular level. Functionally, I was able to show through single 
cell transplantation of differentially stimulated HSCs that a higher concentration of SCF results 
in an increased level of donor cell contribution in secondary but not primary recipients. This is 
RESULTS 
69 
suggests that HSCs are programmed to undergo more self-renewal divisions when stimulated 
with a high concentration of SCF in vitro. To assess if a high concentration indeed stimulates 
more self-renewal divisions in vivo, the transcriptome of freshly isolated single HSCs was 
compared to that obtained from single differentially treated HSCs. The results clearly show that 
SCF stimulates HSCs to enter cell cycle regardless of the concentration tested. However, treated 
HSCs were transcriptionally very similar thus only few genes were differentially expressed. 
Genes that were upregulated in HSCs treated with a high concentration of SCF associated with 
the transcription factor Mef, known to positively regulate exit from quiescence and cell 
proliferation and differentiation108. Therefore, it is necessary to investigate if Mef regulates self-
renewal and differentiation in a dose dependent manner or if a negative regulator of Mef is 
overrepresented in high SCF treated HSCs. 
Additionally, further self-renewal regulators need to be identified and their putative differential 
expression analysed. Furthermore, downstream activation of SCF/KIT signalling needs to be 
investigated to evaluate if differential SCF treatment modulates the response, for instance by 
activation of different members of the STAT family. It would also be interesting to assess how 
cell cycle regulators are altered in response to differential SCF stimulation. In conclusion, for 
statistically relevant analysis, more biological replicates need to be processed to provide insight 




3.2 HSCs remain in state of hibernation in vitro in the absence of stem cell factor 
The results above have shown that stimulation of HSCs with different doses of SCF prior to 
first division does not impact HSCs retention, but instead alters their expansion capacity post-
transplantation. A previous study has also shown that single phenotypic HSCs can be 
maintained as single cells for 5–7 days in the presence of SCF when lipid-raft clustering is 
inhibited resulting in abrogated SCF signalling. In this same study and supported by additional 
studies, it has been demonstrated that complete absence of cytokines resulted in HSCs death 
within 24h111,121. Collectively, these findings suggest that SCF signalling is necessary for HSCs 
self-renewal and proliferation but it is potentially dispensable for maintenance of stemness. 
Understanding the molecular mechanisms underlying HSCs dormancy and exit from 
quiescence may aid in the optimisation of HSCs maintenance and expansion ex vivo. 
Additionally, these findings may be applied to therapy resistant leukaemic cells termed minimal 
residual disease, which is often cause for relapse after a patient went into remission268.  
Therefore, I set out to investigate whether SCF was essential for retaining HSCs function in 
vitro. To this end, I established a minimal cytokine culture medium without SCF in which HSCs 
function and survival can be maintained for an extended period of time. As it has previously 
been shown that gp130 signalling is indispensable for effective haematopoiesis and that 
activation of the gp130 receptor by IL-6 or IL-11 augments HSCs expansion in vitro, IL-11 was 
chosen as the sole stimulatory cytokine in this minimal culture set up231,269. In this chapter, I 
was able to show that fully functional serially transplantable HSCs can be maintained for up to 
7 days in vitro in the absence of SCF signalling. These HSCs can serially reconstitute recipient 
mice but display a bias towards myeloid differentiation. Gene expression analysis indicates that 
the majority of known HSCs regulators are expressed in these cultured HSCs, validating their 
stem cell identity on the molecular level. Yet, differences can be observed making this culture 
condition an intriguing system to investigate several biological questions. 
 
3.2.1 In vitro maintenance of single HSCs in the absence of SCF 
To assess the importance of SCF for HSCs self-renewal and survival, single HSCs were 
cultured in the absence of SCF but in presence of human IL-11. In standard culture conditions, 
none of the cells survived past 3 days in culture. The medium was therefore supplemented with 
10% FCS (serum-supplemented medium, SSM) resulting in 25.5% (± SD 18.9%) survival 
despite continuous cell death (Figure 25A-B). Modified serum-free medium (SFM) conditions 
yielded 32.6% (± SD 3.6%) survival (Figure 25B), compared to 94.8% (± SD 5.2%) in SCF, 
IL-11 and serum containing culture. Survival in SCF-deprived conditions was exclusive to 
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HSCs, as single sorted progenitor fractions (LSK or SLAM (CD48-CD150+)) cells did not 
survive past 2 days in culture (data not shown). Together, this shows that a proportion of 
phenotypic HSCs are more resilient in culture, demonstrating that the HSCs population is 
heterogeneous in cell survival in stressed conditions. 
The average clone size in standard SCF containing conditions would amount to ~400 cells after 
7 days in culture252. Interestingly, 99.3% of surviving HSCs did so without undergoing cell 
division. Any cell that did divide would either remain as 2 cells or subsequently die. Altogether 
this minimal culture condition allows the culture of single HSCs for an extended time in the 
absence of any notable proliferation. Thus, these HSCs from here on referred to as hibernating 
HSCs.  
 
3.2.2 Heterogeneity in HSCs cell cycle kinetics is maintained in minimal cytokine culture 
At the time of bone marrow isolation, the vast majority of HSCs are in G0 of the cell cycle and 
are subsequently activated by cytokine stimulation in vitro95. Time to first division typically 
comprises 24–48h252. 
To investigate the viability of these hibernating HSCs and to assess if SCF deprivation leads to 
synchronisation of the cell cycle state, cell division was stimulated by reintroduction of SCF on 
day 7 of culture. Surprisingly, heterogeneity in time to first division, cell division kinetics, and 
clone size distribution is maintained and close to identical to that of freshly stimulated HSCs 
(Figure 25C-D). Thus, these hibernating HSCs are not synchronised and do not selectively 
survive based on cell cycle state.  
 
To test if these cells maintain multipotency, single cells were transferred into cytokine-rich 
semi-solid medium supporting colony formation. 67.9% (± SD 13.9%) and 81.4% (± SD 
17.2%) of single cells from SSM and SFM culture respectively, generate clones. This is 
comparable to HSCs cultured for 20h (prior to first division) in standard conditions 85.4%9 (± 
SD 2.9%) (Figure 25E). The vast majority (79.4% ± SD 6.6% in SSM and in 83.5% ± SD 5.8% 
SFM) of cells retain multipotency and generate clones of at least three different lineages as seen 
in Figure 25F. These results provide the first evidence that phenotypic HSCs can be cultured 




Figure 25:  HSCs remain viable single cells and retain their multipotency in minimal cytokine 
culture. 
A-B) SCF deprivation decreased HSCs survival in culture but ~25-35% remain viable single cells up 
to 7 days in culture. C) Cell division kinetics following cell division directly after sort (day 0, n=418, 5 
exp.) or following 7 days of culture (day7, n=180, 5 exp.). Lines show non-linear regression fit, 
[Agonist] vs. response, variable slope (four parameters). D) Heterogeneity in clone size on day 10 
following SCF addition is maintained throughout 7 day of SCF deprivation. E) ~65-80% of single cells 
can generate a clone in CFU assays after 7 days of SCF deprivation (-/- n=121, 5 exp., -/+ n=230, 6 
repeats, +/+ n=48, 2 exp.). F) The majority of single cells (~80%) make colonies of at least three 
lineages in CFU assays showing their retention of multipotency (-/-, n=70, 4 exp., -/+ 166, 5 exp.). 
Paired t-test. Error bars represent SEM.  
 
3.2.3 Hibernating single HSCs retain full in vivo functionality 
The CFU assay does not measure the cell’s capacity to differentiate into the lymphoid lineage 
and has limited capacity to assess self-renewal. Therefore, hibernating HSCs were transplanted 
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into sublethally irradiated mice either as single cells or at a 3-cell dose (3 pooled single cells). 
Figure 26 shows the experimental set up for the transplantation. 
 
 
Figure 26:  Experimental design for the transplantation of one or three hibernating HSCs. 
HSCs were cultured 7 days in minimal cytokine conditions and subsequently transplanted into W41 
recipients as either single cells or three pooled unstimulated single cells or three pooled single cells 
that were stimulated 16h with SCF. 10 mice per condition. 
 
4 of 10 mice transplanted with 3 cells showed donor chimaerism of >1.0% in peripheral blood. 
One of the mice transplanted with 3 cells (m6.6) presented exclusively lymphoid lineage 
reconstitution at 16 weeks and failed to engraft a secondary recipient, as would be expected. 
Overall, 2/10 mice successfully engrafted secondary recipients. Similarly, 3/10 mice were 
successfully engrafted from primary recipients of single HSCs. All of these (3 of 3) were 
serially transplantable. This demonstrates that at least 30% of cells surviving 7 days in culture 
without SCF stimulation are indeed stem cells capable of multi-lineage long-term reconstitution 
and durable self-renewal.  
 
Interestingly, all three secondary repopulating single HSCs predominantly exhibited myeloid 
lineage output 16–28 weeks post primary transplant and would be classified as alpha-HSCs 
based on the definition published by Dykstra et al. Importantly, this potential lineage bias was 
retained in 2/3 secondary transplants, in accordance with the 50% rate of alpha programme 
retention observed in Dykstra et al. Possible bias towards the myeloid lineage is partially 
obscured in the 3 cell transplants since multiple HSCs would contribute but even so, the myeloid 
cell bias is observed in 2/5 recipients, suggesting an over-representation of alpha-HSCs. 
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Of note, m6.25 (Figure 27E-F) did not show any donor chimaerism >0.5% at 16 weeks post 
transplantation and therefore would have been excluded from further analysis and serial 
transplantation by many standard definitions of LT-HSCs. By week 28 however, 13.6% donor 
chimaerism was observed in the primary recipient and subsequent secondary animals were 
successfully reconstituted. This emphasises the need for longer term assessment of donor 
chimaerism in single cell transplantation studies in particular.  
 
To investigate if short-term SCF stimulation after 7 days of minimal culture alters HSCs 
chimaerism, mice were also transplanted at a 3-cell dose with HSCs that were stimulated 16h 
with SCF. As seen in Figure 27C, 4/10 mice showed donor chimaerism >1.0% in peripheral 
blood, comparable to the reconstitution efficiency seen from non-stimulated cells. However, 
the overall chimaerism was higher in mice reconstituted with 3x16h stimulated HSCs compared 
those transplanted with 3 non-stimulated HSCs in both primary (32.2% ± SD 32.7% vs. 12.8% 
± SD 9.1%) and secondary recipients (41.2% ± SD 46.0% vs. 15.0% ± SD 13.0%). The 
possibility cannot be excluded, that any of the recipients have not received all 3 cells however. 
Therefore, single cell transplants of stimulated compared to non-stimulated HSCs would need 





Figure 27: Donor chimaerism in W41 recipients of 7 day cultured HSCs.  
Donor chimaerism in peripheral blood of primary and secondary recipients of 3 pooled HSCs cultured 
for 7 days in the absence of SCF. B) Donor myeloid to lymphoid ratio at 16 weeks in primary recipients 
of A. C) Donor chimaerism in primary and secondary recipients of 3 pooled HSCs cultured for 7 days 
in absence of SCF followed by 16h stimulation of SCF. D) Donor myeloid to lymphoid ratio at 16 
weeks in primary recipients of C E) Donor chimaerism in primary and secondary recipients of single 
HSCs cultured for 7 days in the absence of SCF. F) Donor myeloid to lymphoid ratio at 16 and 28 
weeks in primary recipients and at 16 weeks in secondary recipients of E. Error bars represent SEM. 




3.2.4 HSCs that tolerate SCF deprivation are predominantly alpha subtype HSCs 
Despite low numbers, these results suggest that SCF deprivation selects for HSCs with a robust 
myeloid lineage output in both primary and secondary transplants, which may need longer than 
average to contribute significantly to the production of all lineages. This would be in accordance 
with previous data reporting a delayed onset of lineage production by alpha-HSCs64,65. To test 
this hypothesis, further single cell transplants were carried out of HSCs cultured for 7 days in 
both serum containing (SSM) and serum free (SFM) conditions as depicted in Figure 28. 
 
 
Figure 28:  Experimental design for the transplantation of single serum-free or serum-
supplemented, cultured HSCs. 
HSCs were cultured 7 days in minimal cytokine conditions in either serum-supplemented StemSpan 
(21 recipients) or serum-free Ham’s F12 (22 recipients) base medium.  
 
12/21 Mice (57.1%) transplanted with SSM cultured HSCs, successfully repopulated primary 
recipients (Figure 29A) with >1% overall donor contribution at some point post transplantation. 
One mouse (m12.10) was culled for non-experimental reasons before 16 week data could be 
obtained but serial transplantation of its bone marrow showed secondary reconstitution. At 8 
weeks in the primary transplantation, this mouse displayed an exclusively myeloid phenotype. 
5/11 (45.4%) transplanted HSCs were classified as alpha-HSCs, with a predominant myeloid 
lineage output, which is a significantly higher ratio of alpha-HSCs compared to freshly isolated 
HSCs. 4/11 were characterised as beta-HSCs, displaying a balanced lineage production of both 
myeloid and lymphoid cells (Figure 29B). Data from secondary transplants (16 weeks) show 
that 10/21 (47.6%) mice are successfully engrafted. As expected, gamma and delta-HSCs did 
not serially transplant. Again, one recipient (m12.22) did not exhibit donor chimaerism >1% at 
16 weeks (0.52%) in the primary recipient and very low contribution (4.4%) at 20 weeks.  
Yet, this mouse successfully serially engrafted (16 weeks: 29.2% ± SD 6.9%, 3 secondary 
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recipients). Out of 22 mice transplanted with SFM cultured HSCs, 14 (63.6%) showed >1% 
donor contribution at 16 weeks (Figure 29C). Again, the majority (9/14, 64.2%) were classified 
as alpha-HSCs (Figure 29D). In secondary recipients, 11/22 (50%) successfully engrafted at 12 
weeks. Overall, half of single cultured HSCs (50.2%, ± SD 14.6%) repopulated primary 
recipients. Since one of the caveats of single cell transplantation is that the cell may remain in 
the syringe at the time of transplantation, this percentage may even be slightly higher. These 
results show that the established minimal cytokine culture is able to maintain fully functional 
HSCs for an extended period of time, allowing the manipulation at the single cell level as well 
as providing a platform to study exit from quiescence.  
 
 
Figure 29:  Donor chimaerism in W41 recipients of single 7 day cultured HSCs. 
A) Overall donor contribution in peripheral blood of primary and secondary recipients of single HSCs 
cultured for 7 days in SSM without SCF. The star indicates that this mouse had to be sacrificed for 
non-experimental reasons. Recipient bone marrow was then secondary transplanted. n=22 primary 
recipient mice. B) Donor myeloid to lymphoid ratio at 16 weeks in primary recipients, subdividing the 
input HSCs into α (alpha), β (beta), γ (gamma), δ (delta) based on myeloid to lymphoid ratio. C) Overall 
donor contribution in primary and secondary recipients of single HSCs cultured for 7 days in SFM 
deprived of SCF. n=21 primary recipient mice D) Donor myeloid to lymphoid ratio at 16 weeks in 
primary recipients, subdividing the input HSCs into the classes discussed in B. Error bars represent 
SEM. Star indicates that this mouse was culled for non-experimental reasons and bone marrow was 
successfully serially transplanted.  
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Interestingly, repopulated recipients predominantly displayed an alpha-HSCs lineage output 
(54.9%, ± SD 13.3%, Figure 30B-C). All mice received HSCs that were obtained from mice 
between 8 and 16 weeks of age. Strikingly, when comparing the frequency of alpha-HSCs 
present in our recipients, it resembles the lineage output of HSCs derived from aged mice  
(38–46 weeks) as seen in Figure 30B-E. Cultured HSCs consists of significantly more alpha-
HSCs at the expense of beta-HSCs (p=0.031), whereas the ratio to gamma/delta-HSCs 
remains unchanged (p=1.0). This indicates that the alpha-HSCs subtype is more resilient both 
in vitro and in vivo. Possibly, alpha-HSCs represent the most primitive stem cell that only 
convert to beta-HSCs when lymphoid cell production is required. This hypothesis can only 
be investigated by comparing purified alpha and beta-HSCs, which to date is not possible 
based on their surface marker profile.  
 
 
Figure 30:  Lineage differentiation of 7 day cultured HSCs is more similar to those derived 
from aged mouse HSCs. 
A) Distribution of HSCs subtypes in mice transplanted with freshly isolated HSCs obtained from mice 
aged 8–12 weeks. B) Distribution of HSCs subtypes in mice transplanted with 7 day HSCs cultured 
in serum-supplemented minimal medium and obtained from mice aged 8–16 weeks. C) Distribution 
of HSCs subtypes in mice transplanted with 7 day HSCs cultured in serum-free medium and obtained 
from mice aged 8–16 weeks. D) Combined data from B and C. E) Distribution of HSCs subtypes in 
mice transplanted with freshly isolated HSCs obtained from mice aged 38–46 weeks. A/E) modified 




3.2.5 High CD150 expression enriches for HSCs able to tolerate SCF deprivation 
Since all HSCs were index-sorted, it was possible to analyse their surface marker profile in 
order to try and prospectively isolate alpha-HSCs with robust in vitro survival. Most 
strikingly, higher levels of CD150 expression correlated with surviving HSCs. Other markers 
that were modestly but significantly different on hibernating HSCs include higher CD45 and 
EPCR expression, as well as lower CD48 expression. Interestingly, expression levels of the 
SCF receptor c-Kit did not select for surviving HSCs (Figure 32). 
To verify the use of CD150 as a selective marker for hibernating HSCs, Sca-1high-ESLAM 
HSCs were sorted from CD150mid or CD150high population (Figure 31A) and cultured in 
absence of SCF. As seen in Figure 31B, day 7 survival of CD150high HSCs is significantly 
higher (44.2% ± SD 14.6%) than that of CD150mid HSCs (18.2% ± SD 17.7%), confirming 
that adjustment of the sorting gate selects for HSCs with a higher propensity to survive in 
minimal culture conditions. These results and the correlating enrichment in alpha-subtype 
HSCs after 7 day culture suggest that alpha-HSCs may prospectively be so isolated based on 
their higher than average expression of CD150. This would also be agreement with previous 
findings by two other groups65,270 who demonstrated an enrichment of alpha-HSCs in 
CD150high cell fractions. To assess if these cultured alpha-HSCs are different from those 
freshly isolated, more single cell bone marrow transplantations will need to be performed.  
 
 
Figure 31:  CD150high expression correlates with higher survival of single HSCs in minimal 
culture. 
A) Gating strategy for the isolation of CD150mid or CD150high ESLAM Sca-1high HSCs. First gate 
shows viable single lineage depleted bone marrow cells. B) Survival of prospectively sorted 






Figure 32:  Surface marker expression on single HSCs at time of sort. 
Normalised fluorescent intensity for the respective cell surface markers at the time of sort. Cells 
surviving 7 days in culture have elevated expression of CD150, EPCR and CD45 and lower 
expression of CD48. 
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Higher expression of CD150 is also observed in cells that survive 7 days in culture and are 
ultimately candidates for transplantation, as shown in Figure 33A-B. When investigating 
CD150 expression on transplanted HSCs, no bias can be observed between those that 
successfully repopulate the recipient and those that do not. Equally, no evident clustering in the 
CD150 high fraction can be observed of those HSCs that are retrospectively determined to be 
an alpha-HSCs (blue diamonds). In both conditions, mice repopulated with short-term 
gamma/delta-HSCs have a CD150 expression below average (squares), potentially indicating 
their lower self-renewal potential. 
 
 
Figure 33:  Normalised CD150 expression on single HSCs at the time of sort. 
Surviving HSCs (green) generally have a higher than average expression of CD150 in both serum 
supplemented (A) and serum free culture (B). Repopulating (blue) and non-repopulating cells (black) 
do not cluster to a specific region of CD150 intensity. Blue diamonds represent repopulated alpha-
HSCs. Dark blue squares represent HSCs that were retrospectively assigned a gamma or delta 
subtype.  
 
3.2.6 Human HSCs can be maintained as single cells in minimal culture conditions 
Altogether, these findings demonstrate that the cytokine stem cell factor is not essential for the 
maintenance of HSCs in culture but enhances survival in vitro and promotes proliferation. In 
the absence of SCF HSCs remain in a hibernating state retaining full in vivo functionality as 
shown by single cell transplant. These hibernating HSCs can be induced to proliferate and self-
renew and may be isolated based on a higher than average expression of CD150. Transcriptional 
analysis of these hibernating HSCs may provide insight into the underlying mechanisms of exit 




These results may have major clinical implications if they can be applied to human HSCs, with 
regard to HSCs isolation and retention, and study of exit from quiescence. A better 
understanding of what drives human HSC proliferation and differentiation may aid in the 
development of culture conditions aimed at the expansion of HSCs for bone marrow 
transplantation as well as contribute to establishing protocols for the ex vivo production of 
specialised mature blood cells.  
Therefore, human HSCs (CD34+CD38negCD45RAnegCD19negCD49f+CD90+, at 10% purity81) 
were single-cell sorted and cultured in StemSpan with or without serum supplementation. 
Preliminary results depicted in Figure 34A-B show that 79.1% survived in FCS supplemented 
minimal culture conditions, with 97.3% remaining single cells. As expected, survival was lower 
in serum-free conditions (33.3%) but 100% of surviving cells remained undivided. Notably, 
even in SCF stimulated culture a small proportion of cells did not enter the cell cycle (Figure 
34C-D). Next, I assessed cell cycle kinetics following SCF stimulation after 7 days of 
deprivation in HSCs cultured in serum-supplemented minimal conditions. HSCs did enter cell 
cycle within the first 24h of stimulation, albeit at a slower rate than the control which received 
SCF from day 0. This indicates that human HSCs need a longer stimulation period to become 
activated than mouse HSCs. However, minimal culture conditions will need to be optimised 
and more repeats carried out to confirm and validate this observation. These results may provide 
an exciting opportunity to study exit from quiescence in human HSCs, without the need for 
induction of quiescence through chemical inhibitors such as the specific CDK4-CDK6 inhibitor 
PD033299 (PD). PD blocks G1 to S phase transition, however these non-dividing HSCs are not 
truly reflective of quiescent HSCs87. 
 
In conclusion, I was able to show that single mouse HSCs can be cultured for a period of up to 
7 days without undergoing cell division while maintaining the capacity to self-renew and 
serially repopulate recipients with multi-lineage reconstitution. The majority of these 
hibernating HSCs exhibit an alpha phenotype and may be prospectively identified using high 
CD150 expression. These findings may allow the study of how extrinsic stimulants effect cell 
survival and exit from quiescence on the single cell level. In addition, molecular changes within 
freshly isolated and cultured HSCs can be assessed including transcriptional changes using 
RNA sequencing. The latter may allow the identification of genes that are dispensable for HSCs 
stemness and possibly detect genes that are overrepresented in the alpha-HSCs subtype. Finally, 
a proof-of-principle experiment in human HSCs demonstrates that this phenomenon may not 
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be restricted to mouse HSCs, making it particularly important to validate whether single human 
HSCs maintained in culture still retain the functional properties of input HSCs. 
 
 
Figure 34: Distribution of quiescent and proliferating human HSCs in minimal culture 
conditions.  
A) Percentage of cells that remain undivided in serum-supplemented minimal culture conditions. B) 
Percentage of cells that remain undivided in serum-free minimal culture conditions. C) Percentage 
of cells that remain undivided in serum-supplemented standard conditions. D) Percentage of cells 
that remain undivided in serum-free standard conditions. E) Cell division kinetics following cell 
division directly after sort (dashed curve, n=30, 1 exp.) or following 7 days of culture (solid line, n=35, 




3.2.7 RNA sequencing of cultured HSCs reveals genes potentially driving myeloid 
lineage choice and maintenance of HSCs activity 
Functionally, the results have conclusively shown that the majority of hibernating HSCs retain 
their stem cell activity and thus are able to reconstitute the haematopoietic system of primary 
and secondary recipients. Investigation of the transcriptome of these cells may aid in the 
identification of genes that are indispensable for HSC function, under the premise that those 
genes shared between freshly isolated HSCs and hibernating HSCs are essential for the 
maintenance of stemness.  
To this end, RNA sequencing was performed on a small bulk population (200–300 cells) of 
hibernating HSCs and compared to freshly isolated cells. In total 17,860 gene transcripts were 
analysed of which 2,067 were significantly differentially expressed (p<0.01). 1107 genes were 
upregulated in the cultured cell population, which clustered mainly with GO terms usually 
associated with synaptic signalling activity such as excitatory extracellular ligand-gated ion 
channel activity, acetylcholine receptor activity, neurotransmitter:sodium symporter activity, 
and acetylcholine-gated cation-selective channel activity (Table 12). GO analysis of the 960 
downregulated genes indicates that the majority are involved in protein and small molecule 
binding (Table 13). 
 
Table 12: Gene ontology associated terms based on upregulated genes in hibernating 
HSCs compared to naïve BM HSCs. 
Annotation cluster Gene count P-value elimFisher 
calcium ion binding 695 9.10E-06 
actin binding 370 0.00168 
heme binding 170 0.01830 
motor activity 136 0.00918 
excitatory extracellular ligand-gated ion channel activity 52 0.00128 
calcium channel activity 98 0.00803 
peptide hormone binding 38 0.00204 
acetylcholine receptor activity 24 0.00134 
neurotransmitter:sodium symporter activity 21 0.00070 




Table 13: Gene ontology associated terms based on downregulated genes in hibernating 
HSCs compared to naïve BM HSCs. 
Annotation cluster Gene count P-value elimFisher  
protein binding 504 0.00028 
organic cyclic compound binding 261 0.00630 
heterocyclic compound binding 260 0.00415 
metal ion binding 189 8.50E-05 
transferase activity 117 0.00085 
GTP binding 29 0.00017 
carboxylic acid binding 13 0.00192 
protein kinase inhibitor activity 8 0.00830 
transferase activity, transferring pentosyl groups  6 0.01341 
peroxidase activity 6 0.00257 
 
As GO terms are inconclusive and meant to guide research questions rather than answer them 
directly, normalised tag counts were also compared between freshly isolated and hibernating 
HSC samples in two biological replicates. Most significant differences were due to very low or 
undetectable gene transcripts in one of the replicates, which may be true absence, but could also 
be due to RNA degradation prior to library preparation. Upon exclusion of these genes, a list 
was generated with the most reliably differentially expressed genes listed in Table 14.  
 
Table 14: Manually curated list of genes that are downregulated in hibernating HSCs  
Gene ID BaseMean log2FoldChange P-value Adjusted P-value 
Fos 21784.53 -14.24 -5.16044 2.46E-07 
Jun 11497.15 -16.76 -5.01921 5.19E-07 
Ier2 10827.07 -11.72 -4.27136 1.94E-05 
Ifi44 2804.25 -14.72 -4.40949 1.04E-05 
Adck5 2794.90 -14.72 -4.40575 1.05E-05 
Fes 2609.28 -14.62 -4.37729 1.20E-05 
Hn1 2006.60 -14.24 -4.26249 2.02E-05 
Cx3cl1 1984.74 -14.22 -4.25883 2.06E-05 
Dfna5 1802.99 -14.08 -4.21785 2.47E-05 
Prdx4 1735.20 -14.03 -4.197 2.70E-05 
Anxa1 1672.70 -13.98 -4.17868 2.93E-05 
Retnlg 1488.00 -13.81 -4.13012 3.63E-05 
Atl3 1438.01 -13.76 -4.11912 3.80E-05 
Ptger3 1432.09 -13.75 -4.11715 3.84E-05 
Slc25a13 1356.67 -13.67 -4.08802 4.35E-05 
Sestd1 1350.56 -13.67 -4.08552 4.40E-05 
Slc25a24 1298.69 -13.61 -4.07234 4.65E-05 
 
The two most downregulated genes in this list are Fos and Jun whose gene products form the 
transcription factor complex Activator Protein-1 (AP-1). Little is known about the role of  
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AP-1 in the regulation of HSCs fate choice. c-Fos-/- mice have severe defects in bone formation, 
and by proxy aberrant deficient haematopoiesis. Jun-B has more intensively been studied and 
has been shown to be involved the regulation of myelopoiesis and HSCs expansion. 
Overexpression of JunB in mouse HSCs leads to loss of HSCs and vice versa, loss of JunB 
results in the expansion of HSCs and myeloid progenitors ultimately leading to the development 
of myeloproliferative disease. However, JunB deficiency does not affect HSCs self-renewal 
activity in vivo271,272. These findings indicate that AP-1 activity may be essential to drive HSCs 
proliferation in vitro. However, more extensive gene analysis need be carried out to verify these 
findings and potentially uncover the network in which AP-1 plays a regulatory role. Potential 
targets need to be verified by qPCR and single cell RNA seq could be employed to provide a 
greater resolution into the transcriptional networks that drive myeloid differentiation.  
 
As hibernating HSCs retain their long-term, multipotent lineage engraftment abilities, 
investigating genes that are not expressed in this population may provide insight into the genes 
that are not essential for HSCs self-renewal. Since α-catulin47, Hoxb548, and Fgd549 are used as 
in vivo HSCs reporters, their differential expression was assessed in freshly isolated BM HSCs 
and HSCs cultured for 7 days in minimal cytokine conditions. Both Ctnnal1 and Fgd5 are not 
differentially expressed, while Hoxb5 is significantly downregulated in cultured HSCs  
(log2fold change 12.1506, p-adj. 0.005024) suggesting that Hoxb5 may not be suitable for the 
identification for HSCs in vitro or at least not the alpha-HSCs subtype. 
 
Wilson et al. recently identified a gene signature shared between phenotypic HSCs isolated 
based on different isolation strategies. These HSCs were termed MolO (Molecular overlapping) 
cells. The MolO signature was proposed to identify LT-HSCs on the molecular level and 
comprises transcription factors involved in differentiation and self-renewal, epigenetic 
regulators, as well as surface markers. Therefore, the expression data of cultured HSCs was 
probed for the presence or differential expression of MolO genes. 
 
As can be seen in Table 15, normalised tag counts widely differ between biological replicates 
in some samples. This may be due to RNA integrity or read depth during sequencing. However, 
this data is indicative of significant transcriptional changes occurring in cultured HSCs without 
a change in their functional output, thereby allowing us to better resolve the key molecules 
involved in the self-renewal machinery.  
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Table 15:  Tag counts and log2fold change of MolO genes in hibernating HSCs 
Gene 
ID 





tag counts tag counts 
Repeat 1 Repeat 2 Repeat 1 Repeat 2 
Ets1 1.456 0.000 653.527 0.000 8.411 0.1060 
Etv6 6320.094 2890.007 31397.328 665.283 1.666 0.9941 
Vwf 3387.897 6059.953 38414.486 150.164 1.588 0.9998 
Tal1 1131.240 5796.241 15291.860 818.774 1.319 0.9998 
Pbx1 4519.137 6656.346 16027.903 1725.935 1.229 0.9998 
Mecom 1485.026 7309.539 12763.571 1393.293 1.209 0.9998 
Cbfa2t3 11022.675 12137.487 24395.022 2754.273 0.838 0.9998 
Kit 34406.005 76182.844 184013.921 7165.575 0.779 0.9998 
Lyl1 28206.751 10809.463 47360.868 2850.263 0.643 0.9998 
Nfe2 35352.345 27032.448 65367.504 4256.862 0.446 0.9998 
Erg 8610.237 3030.653 13108.488 643.899 0.422 0.9998 
Fli1 22879.586 5715.100 18716.273 1681.741 0.041 0.9998 
Gata2 10917.850 19067.011 20133.897 1646.576 -0.085 0.9998 
Mpl 125234.247 76769.771 132221.945 9628.549 -0.148 0.9998 
Lmo2 78483.603 89618.603 158273.888 3730.338 -0.205 0.9998 
Meis1 22141.441 20063.705 29184.249 1490.234 -0.307 0.9998 
Tet2 2330.908 2357.174 1113.966 117.850 -1.359 0.9998 
Procr 26705.710 15603.601 16966.934 159.668 -1.607 0.9998 
Prdm16 2153.287 2270.623 670.030 97.892 -1.732 0.9775 
Ets2 5372.299 490.909 0.000 139.234 -2.185 0.9846 
Gata3 1595.675 2489.706 1.650 19.483 -4.611 0.3110 
Hoxb4 69.884 0.000 0.000 0.000 -6.310 NA 
Gfi1b 5183.031 5539.292 0.000 2.851 -8.799 0.0230 
 
The transcription factor Ets1 is upregulated in HSCs cultured in minimal culture condition, 
although it was only detected in one replicate in each condition making it difficult to make 
robust claims about its involvement. Conversely, the Ets transcription factor family members 
Fli-1 and Erg273 were not differentially expressed. Ets1 plays a known role in megakaryocyte 
differentiation and is highly expressed in embryonic endothelial cells where it potentially is 
involved in co-regulation the endothelial to haematopoietic transition via Runx-1. Little is 
known about Ets1 function in HSCs274. 
 
On the other hand, the negative transcriptional regulator Gfi1b is significantly downregulated 
in cultured HSCs, suggesting that this gene is not necessary for the maintenance of stem cell 
identity. This is in accordance to published data that shows Gfi1b is predominantly expressed 
in MEP and not the HSCs population, which suggests that Gfi1b is involved in driving 
differentiation in HSCs70,275. This is in agreement with reports suggesting that Gfi1b is involved 
in megakaryocyte/erythrocyte lineage specification68. It cannot be excluded however, that bulk 
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RNA sequencing does not provide a high enough resolution to detect changes in certain cells, 
despite the low amount of input cells.  
 
These first data from HSCs cultured in minimal conditions demonstrate that transcriptional 
differences can be observed between naïve and hibernating HSCs with fully retained functional 
capacity. Targets identified through RNA sequencing would need to be verified using RT-qPCR 
and potentially modulated to demonstrate their role in HSCs biology. Single cell RNA 
sequencing could further provide intercellular differences in cultured HSCs, where only 20-
40% retain a beta-HSCs programme. scRNA seq would also provide a better understanding of 
the molecular drivers of HSCs activity and exit from quiescence if performed in a defined time 
course post 7 day culture. Most intriguingly, it will enable the investigation of the 
transcriptional program of myeloid biased HSCs, potentially identifying novel markers for the 
specific isolation of alpha-HSCs. This may also be of clinical interest as myeloid cancers are 
suspect to arise from HSCs which are deregulated in their ability to generate lymphoid cells.  
 
3.2.8 Optimisation of serum-free culture to ensure single cell survival in absence 
of SCF 
As virtually no cells survived in StemSpan based medium without SCF stimulation in absence 
of foetal calf serum (FCS), I sought to improve survival in serum-free culture conditions to 
exclude the possibility that the described phenomenon is due to an unidentified molecule 
present in FCS. Literature searches showed that the addition of Collagen I (Col I) and nerve 
growth factor (NGF) to the standard conditions commonly used in our lab resulted in 97% 
viability of clones over a period of 7 days, with 74% or 9% of clones retaining short-term or 
long-term repopulating activity after transplantation respectively164. However, I was unable to 
replicate these findings in multiple experiments. HSCs were cultured as single cells in 
StemSpan supplemented with either 10% FCS (SSM) or NGF plus 10% Collagen I (NCM).  
By day 4, only 21.4%, ± SEM 6.8% of cells had generated viable clones in NCM compared 
nearly 80% in SSM (79.1%, ± SEM 10.3%) as seen in Figure 35A. From day 1 in culture, cell 
cycle entry of HSCs in NCM was delayed compared to SSM, with entry into second and third 
division being significantly later on day 2 and 3 respectively (Figure 35B-D). To assess if NGF 
is in fact cytotoxic, cells were cultured in SSM with the addition of NGF but not Collagen I. 
Only 16.5% of clones survived in these conditions, compared to 80-90% in SSM (data not 
shown). Thus, it seems that NGF adversely affects HSCs survival and proliferation in vitro. 
These findings do not exclude the possibility that Col I still has beneficial effect on cultured 
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HSCs, concealed by the overpowering negative effects of NGF. I therefore opted to test 
conditions suggested by Adam Wilkinson (Nakauchi lab, unpublished) which are described in 
3.2.1, p. 70. 
 
 
Figure 35:  NGF and Collagen supplementation does not improve HSCs survival or 
proliferation in vitro. 
A) 4 Day clonal survival in medium either supplemented with serum or NGF+Collagen I. B) 
Percentage of cells that have undergone a1st division. C) Percentage of cells that have undergone 
a 2nd division. D) Percentage of cells that have undergone a 3rd division. Serum: 10% FCS in standard 
medium supplemented with SCF and IL-11. n=274, 3 exp. NGF+Collagen I: 10% Collagen I + 250 
ng/mL NGF in standard medium + SCF + IL11. n=282, 3 exp. *=p<0.05, **=p<0.001. Error bars 





3.3 Investigating physical forces supporting HSCs survival and expansion 
ex vivo 
Adult HSCs reside in the bone marrow niche, which is a complex microenvironment comprising 
soluble factors, transmembrane receptor ligands and extracellular matrix molecules, as well as 
differentiated cells18,242. Besides collagen type II and III, collagen type I is part of the of the 
extracellular matrix in the bone marrow276, suggesting that mimicking the mechanical 
properties of the HSCs microenvironment is likely to influence HSCs survival and proliferation 
in vitro. Additionally, defined conditions that mimic the 3D architecture of the bone marrow 
niche in vitro would allow the teasing apart of mechanical effects from biochemical cues and 
enable us to study how HSCs biology is affected by matrices of different elasticity or 
stiffness242,244. Therefore, I set out to first estimate the stiffness in the stem cell niche followed 
by the construction of agarose/ECM composite gels that would mimic a range of stiffness close 
to this value. 
 
Material or tissue stiffness can be measured using micro-indentation atomic force microscopy 
(AFM)277. In a preliminary experiment, AFM was used to narrow down the range of elasticity 
within the bone marrow using bone marrow plugs obtained from Nestin-GFP+ mice. Areas close 
to GFP positive cells were measured, as Nestin-GFP expressing mesenchymal stromal cells 
(MSCs) are considered to be important HSCs niche cells278 (described in 1.1.2, p. 3). These 
measurements indicated that the BM elastic stiffness ranged from 300 to 450 Pa (data not 
shown), with areas of Nes-GFP+ being slightly stiffer than GFP-negative areas. This range is 
consistent with previous findings reporting a stiffness of 0.3 kPa245 and several orders of 
magnitude softer than tissue culture plastics (2–4 GPa)246. I therefore moved forward with this 
range in mind for the first screen of supportive substrates.  
 
3.3.1 HSCs can be cultured on agarose-based matrix gels  
To screen for optimal substrate stiffness conditions retaining and expanding HSCs in vitro, 
agarose based hydrogels were made covering a stiffness range of approximately 100 Pa–1 kPa. 
ECM proteins laminin and fibronectin were added to some of the gels to test whether 
extracellular matrix (ECM) components influence HSCs retention in vitro. Agarose was chosen 
for its neutral, biocompatible and scalable properties. It is non-cytotoxic in its single component 
prior to polymerisation in contrast to synthetic polymers such as poly(vinyl alcohol or 
polyacrylamide. Additionally, it is stable for extended periods of time in vitro, and importantly, 
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it is tuneable in its mechanical properties. Agarose can be functionalised with peptides and other 
small molecules and allows their diffusion-controlled release. Therefore, agarose can be used 
to form functionalised droplets encapsulating single cells to perform high throughput screenings 
of various factors279,280. 
 
In a pilot experiment 3 cells were sorted onto the agarose hydrogel. However, as seen in  
Figure 36, in some wells all three sorted cells were viable and generate clones with different 
cell cycle kinetics and diverse cell compositions, as can be determined by the different 
granularity and clone size. Furthermore, in this setting it cannot be excluded that cells of one 
clone do not produce factors that affect another clone. Additionally, it was not possible to 
physically separate these clones and analyse them individually. To avoid these caveats, single 
cells were sorted onto the hydrogels for all future experiments. Our usual liquid culture follows 
single cells for up to 10 days, from which time on cells begin to undergo apoptosis. By culturing 
cells for 14 days, I aimed to assess if softer gel mechanics extends viability compared to stiff 
tissue culture plastic.  
 
Figure 36:  Representative well that supported the development of three separate clones.  
One well at different time points shows the development of three separate clones that heterogeneous 
in cell composition as well as cell cycle kinetics. A) Day 7. B) Day 10. C) Day 14 in culture. Arrow 
heads point out the clones  
 
The proportion of HSPCs (as measured by the LSK markers), relative to the amount of viable 
cells was used as the readout for HSCs stemness retention (i.e., cultures that retain HSCs should 
also retain more primitive progenitors relative to the more mature progeny). 
Single HSCs were sorted and clonal growth was followed over time by visual inspection. Due 
to the opacity of the gel, cell division kinetics could not be carried out. As seen Figure 37 broad 
changes in clone size could be observed across the 96 different conditions on day 14.  
In liquid culture, small clone size generally correlates with retention of HSPCs. However, in 
this setting small clone size does not equate to HSPC retention as seen from clone E1 when 
compared to clone F1, with the former containing only very few LSK cells. Another factor to 
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consider, is that gel digestion conditions (30 min. trypsin at 37°C) may result in cell death of 
some cells before flow cytometry is carried out, although analysed cell number broadly 
correlated with size of colonies. 
 
The screening also gave an indication whether any of the conditions are detrimental to HSCs 
survival as no clone would grow from the single cell (e.g. well F2 in Figure 37). However, none 
of the tested conditions consistently had empty wells, suggesting that survival was not 
negatively affected as seen from Figure 38. When comparing the average survival of each well, 
60 out of 96 wells had consistently a cell survival rate >50%. A consistent >70% survival rate 
was only observed in 18 of 96 wells. Survival was enriched in lane 10 and 12, which contained 
the lowest concentration of agarose (0.5%). In both cases 3 of 18 wells had the highest survival. 
In addition both row B and F contained each 4/18 wells with >70% survival. Both these rows 
contained 0.2 mg/mL fibrinogen but differed in the amount of thrombin. Thus, softer substrate 
seems to support cell survival better than stiffer gels, while extracellular matrix components do 





Figure 37:  Day 14 visualisation of clones grown on 96 different matrix gels in Plate D. 
Broad changes in clonal growth and survival can be observed. Clone size is not necessarily 
proportional to HSPC content. The depicted LSK percentage is frequency of parent. LSK are gated 

















Figure 40:  Day 14 visualisation of clones grown on 96 different matrix gels in Plate C. 
 
On day 10 of culture, 28 of 96 wells contained clones with >70% LSK in at least one of the two 
repeats, whereas on day 21 none of the wells was found to comprise >50% LSK. Row A and F 
contained most wells (4 of 16) with an LSK content >70% on day 10. Both rows contain higher 
amounts of fibrinogen, which also enriched for improved cell survival. Lane 10 (4/16) and lane 
11 (3/16) contain most wells with LSK retention >70%, both wells are manufactured with the 
lowest concentration of agarose. These results suggest that low concentration of agarose 
supports cell survival and HSPC maintenance retention.  
 
To compare HSPC retention in 96 different conditions, LSK frequencies were displayed in a 
heat map like fashion. When focussing on the influence of agarose concentration on HSPC 
retention on day 10 it becomes evident that lower concentrations of agarose, thus gels of lower 
mechanic stiffness, tended to favour the production of HSPCs. The addition of the ECM 
proteins laminin and fibronectin seem to have a positive effect on HSPC retention but not 
consistently, this may be due to HSCs heterogeneity (Figure 41B). When the protease thrombin 
is mixed with the plasma protein fibrinogen the mixture polymerises forming a fibrin gel281. As 
seen in Figure 41C-D, it appears that gels containing a higher concentration of both thrombin 
and fibrinogen have an overall slightly higher proportion of clones retaining LSK. Altogether, 
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the main driver of differences between clonal LSK proportions seems to be the agarose 
concentration. 
 
These results indicate that matrix composition and stiffness affect HSCs fate choice and that 
soft matrices containing ECM proteins may benefit HSCs expansion. To date, very little 
research has investigated the effect of mechanical property changes on HSCs. This screen 
provides the first evidence on the single cell level, that substrate stiffness can indeed effect 
HSCs fate choice. Heterogeneity within the HSCs compartment hamper the analysis of different 
conditions on single cells as many replicates are needed to compensate for this. This concern 
may be resolved through the development of high throughput screening devices, for instance 
microfluidic chips. Nevertheless, these experiments set the stage for future experiments, which 
could test individual factor combinations to narrow down specific conditions that are optimal 
for HSCs expansion and testing of these best candidates by in vivo transplantation assays. It 
might also be possible to use the minimal medium conditions described in Chapter 3.2 to help 
identify conditions that would support in vitro survival. In the long term, beyond the scope of 
my PhD work, such HSCs expansion conditions (physical and molecular) could be applied to 




Figure 41:  Day 10 LSK retention in clones grown from single cells in 96 different matrix 
conditions. 
A-D all show the same plate but ordered according to the matrix component in focus. A) Agarose 
concentration. B) ECM additives. C) Thrombin concentration. D) Fibrinogen concentration. LSK 





Haematopoietic stem cells (HSCs) have been studied for decades. In this time a great number 
of genes have been implicated as intrinsic regulators of HSCs self-renewal and differentiation, 
yet little is known about their effects on HSCs self-renewal99-102,282. Overexpression screening 
has demonstrated that some of these genes are able to expand HSCs ex vivo, including Hoxb4, 
Fos, Prdm16 and Smarcc1283. 
Additionally, numerous extrinsic regulators, including cytokines, growth factors, and 
chemokines have been studied for their effects on HSCs123-125,128,130. Yet, there is little evidence 
on how extrinsic regulators enhance HSCs self-renewal and the molecular regulators driving 
HSCs fate choice are still poorly understood. A better understanding of the machinery that 
drives lineage priming, self-renewal, and differentiation is of medical importance as this could 
aid in the development of protocols for ex vivo HSCs expansion, production of specific mature 
cell types such as platelets, and gene therapy258. Moreover, improving our knowledge of genes 
involved in lineage differentiation may elucidate which pathways are perturbed in the 
development of blood cancers.  
 
Even though the study of HSCs has made vast progress in recent years, especially through the 
development of single cell tools, there are still many challenges to overcome to uncover what 
drives HSCs fate choice.  
For one, it is virtually impossible to study HSCs over extended periods in vitro, due to their 
propensity to differentiate. Freshly isolated HSCs only offer a snap-shot of native 
haematopoiesis and rely on the purity of the isolation strategy and the stability of the cellular 
state being assessed. Any phenotypically isolated HSCs population contains contaminating 
non-HSCs cells and vice versa, true LT-HSCs may be lost through rigid gating strategies and 
may skew interpretation if this is non-random75. In addition, even a highly purified population 
of phenotypic HSCs displays extensive heterogeneity in lineage choice and as of yet it is not 
possible to isolate specific HSCs subtypes specifically based on their surface marker expression 
alone. Moreover, any sort of gene perturbation ex vivo relies on HSCs culture, which inevitably 
alters HSCs biology.  
In vivo, the lack of reliable markers that exclusively label HSCs as well as the lack of clarity on 
the actual location and cell types comprising the HSCs niche challenge all available imaging 
technologies. In vivo gene perturbation studies using gene specific promoters are at present the 
closest we can get to understand the roles of individual genes in haematopoiesis in situ but these 
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strategies rely on targeting all HSCs and excluding any off-target effects, which is not 
necessarily possible.  
 
When studying HSCs fate choice at the single cell level, it is therefore advantageous to control 
and minimise as many variables as possible. In this thesis, I show in Chapter 3.1 that in vitro 
activation of SCF/KIT signalling in HSCs prior to first division alters clonal stem cell expansion 
without affecting initial HSCs engraftment ability. Furthermore, in Chapter 3.2 I could show 
that absence of SCF/KIT signalling can maintain HSCs function in vitro for extended periods 
of time. Finally, in Chapter 3.3, I explore the role of physical forces on HSCs retention, 
demonstrating that changes in the composition and stiffness of various matrices can also alter 
HSCs fate. 
 
Differential SCF stimulation prior to first division alters HSCs clonal expansion in 
vivo without affecting initial HSCs repopulation potential 
It has long been known that the SCF/KIT signalling pathway is crucial for functional 
haematopoiesis195 and as one of the key players in this, SCF has been one of the primary 
standard cytokines used in various growth factor combinations to maintain and expand stem 
and progenitor cells in vitro124,125,130,284. Furthermore, it has been shown that changes in SCF 
concentration in vitro can alter HSCs fate choice (self-renewal versus differentiation) in vivo 
prior to first division, with altered self-renewal frequency10. 
In this thesis, I was able to show that a concentration as low as 10 ng/mL has a negative effect 
on HSCs survival and proliferation in vitro, whereas there is virtually no difference when HSCs 
are treated with 30 ng/mL or 300 ng/mL. While this is different from previously published data, 
the input HSCs fraction I used in this thesis are a more highly purified population of HSCs with 
durable self-renewal, suggesting that the effects previously described were primarily on HSCs 
with finite self-renewal.  
In both limiting dilution and single cell transplants, no significant differences in repopulation 
ability were detected in cells treated with a high (300 ng/mL) or low (30 ng/mL) dose of SCF 
prior to first division. In both settings, ~35% of single transplanted HSCs were able to 
reconstitute the recipient mouse with similar proportions of HSCs subtypes as defined by their 
lineage output at 16 weeks. Thus 30 ng/mL SCF is sufficient to maintain HSCs function in 
culture prior to a first division. Interestingly, donor chimaerism was significantly higher in 
secondary recipients of HSCs that were stimulated with a high dose of SCF. This indicates that 
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prior to a first division, SCF stimulation alters the self-renewal activity in single cells, with 
HSCs producing more daughter HSCs following treatment with a higher dose of SCF, 
presumably in the early stages post-transplantation.  
To thoroughly assess if the increase in self-renewal activity indeed occurs in a dose-dependent 
manner, more single cell transplantations need to be carried out at different doses of SCF and 
within different time windows. HSCs expansion and number in recipients of differentially 
treated bone marrow can be quantitatively assessed by limiting dilution transplantation of the 
primary recipients bone marrow at different weekly time points within the first month of 
transplantation256. These experiments will narrow down which functional changes occur and 
when this is most evident. Concurrent RNA sequencing of these differentially treated HSCs 
may pinpoint which transcriptional changes occur driving these self-renewal divisions. SCF 
stimulation leads to the clustering of c-Kit in membrane lipid rafts121. Potentially, this occurs 
in a dose-dependent fashion and high concentrations of SCF therefore augment SCF/KIT 
signalling more than lower doses. However, it has been shown that lipid raft clustering in HSCs 
occurs as early as 30 minutes post in vitro SCF stimulation121, suggesting that after 16h lipid 
raft clustering should have reached its saturation point, even at low doses. Transplantation of 
single cells beforehand stimulated at a high dose of SCF in the presence of an inhibitor of lipid 
raft clustering may be useful to investigate if this mechanism is indeed essential for the 
improved self-renewal outcome.  
Another possibility could be that HSCs homing ability is differentially affected by SCF 
stimulation, with cells stimulated with a higher amount of SCF homing to the bone marrow at 
earlier time points thus having an earlier opportunity to undergo self-renewal divisions. This 
may happen under the assumption that SCF induces c-Kit expression on the cell surface making 
them more receptive for signals from the bone marrow, such as more SCF produced by BM 
MSCs. However, a role of SCF in bone marrow homing has not been described, in contrast to 
the CXCL12/CXCR4 axis285. Thus it would be interesting to investigate if these cells preferably 
home to putative niche cells that secrete SCF. One possible way to examine this would be the 
use of recipient transgenic mice that express fluorescent reporters in their bone marrow niche 
cells such as the Nestin-GFP+ mouse. The main caveat of this approach is the necessity of a 
high number of labelled, purified donor stem cells as only the calvarium can be imaged in a live 
animal, which represents only a small proportion of the total BM36,286.  
Another potentially more feasible approach to answer questions surrounding alterations in c-
Kit level post SCF stimulation is flow cytometric analysis or immunocytochemistry as shown 
by Yamazaki et al.121, with flow cytometry having a higher and more quantitative throughput 
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but with the caveat of requiring significantly more input material of an already rare population 
of cells. 
Measuring the levels of c-Kit on the HSCs post SCF stimulation may answer the question 
whether differentially treated cells have distinct levels of c-Kit expression that positively 
correlate with stimulation dose. Contradictory to this hypothesis would be the finding that W41 
mice, which carry a c-Kit mutation, are not reported to display any homing defects but this was 
not assessed in LT-HSCs shortly after transplantation218. A simpler way to assess the relative 
homing capacities would be to investigate this putative increased bone marrow translocation by 
transplanting differentially stimulated and labelled HSCs and assessing their homing to the 
bone marrow tracked in first days post transplantation.  
SCF has been shown to be radioprotective with the drawback that patients display severe 
allergic reactions mediated by the activation of mast cells223,225. The discussed findings show 
that on the single cell level, SCF may indeed exert some radioprotective measure onto 
transplanted HSCs in a dose dependent manner. This may be of clinical relevance, firstly in the 
pre-treatment of patients prior to stem cell transplant and secondly in stimulation of HSCs prior 
to the transplant. In patients, allergic responses may be mitigated through the use of engineered 
recombined SCF featuring an altered dimerisation interface213, which selectively activates 
HSPCs but not mast cells.  
Encouraging results from an ongoing clinical trial using stabilized Prostaglandin E2 (PGE2) 
demonstrates that treatment of HSCs prior to allogeneic transplant can indeed positively 
influence the engraftment capability of these cells. In this phase I trial it was shown that HSCs 
derived from umbilical cord blood (CB) that were pre-treated with PGE2 have higher multi-
lineage engraftment than HSCs obtained from a co-transplanted untreated umbilical cord241. 
Prior to this study, it had been shown that PGE2 enhances mouse HSCs self-renewal following 
2h ex vivo pre-treatment, but its effect on adult human HSCs has not been assessed240. 
Therefore, it is of interest to assess if pre-treatment of cord blood as well as human adult HSCs 
with SCF would yield a similar increase in self-renewal division in vivo as seen in mouse HSCs 




LT-HSCs can be maintained as single cells in vitro in the absence of SCF 
stimulation and independent of serum-supplementation 
The results discussed above suggest that the concentration of SCF does not affect the ability of 
HSCs to repopulate recipients. It was therefore of interest to investigate how SCF deprivation 
would influence HSCs survival, proliferation, and maintenance.  
It has previously been shown that activation of the gp130 receptor by IL-6 or IL-11 enhances 
HSCs expansion in vivo and in vitro231,269. The importance of gp130 signalling in stem cells has 
also been demonstrated in embryonic stem cells (ESC) and induced pluripotent stem cells 
(iPSC), where the IL-6 family member LIF (Leukaemia Inhibitory Factor) facilitates the 
maintenance of stem cell pluripotency and morphology as well as the inhibition of 
differentiation287,288. Here we could show that activation of gp130 signalling alone is sufficient 
to maintain LT-HSCs as single cells in culture for a period of 7 days. Interestingly, serum 
supplementation does not drive differentiation as is commonly believed. While 67–75% of 
sorted phenotypic HSCs die in these conditions, those that are resilient show full retention of 
multipotent long-term repopulation ability and do not show upregulation of genes associated 
with apoptosis. These results are comparable to findings showing that inhibition of lipid raft 
clustering prevents HSCs from dividing in vitro, despite activation of the c-Kit receptor111,121.  
While more differentiated progenitor fractions (LSK and SLAM) do not survive in absence of 
SCF, it has not been assessed if multipotent progenitors would survive in these conditions. 
Culture of MPP1, MPP2, MPP3 and MPP4 will determine if resiliency in these conditions is 
exclusive to LT-HSCs. Yamazaki et al. have shown that CD34+LSK do not survive for more 
than 48h in vitro upon inhibition of lipid raft clustering121, suggesting that this resilient 
phenotype may only apply to the most primitive cells.  
Two of 31 mice showed delayed onset of donor contribution, predominantly generating cells of 
the myeloid lineage but capable of producing lymphoid cells in secondary recipients. These 
mice would have been classified as not repopulated at 16 weeks as donor chimaerism was not 
detectable or equalled less than 1%. This was not due to the minimal culture conditions and is 
more likely a cell intrinsic mechanism as it has been observed by several research groups either 
through barcoding experiments or single cell transplantation64,65,289. This emphasises the need 
for new standards in the detection of successfully engrafted mice, in particular in a single cell 
transplantation setting.  
Comparison of the transcriptome of freshly isolated HSCs and those cultured for 7 days in 
absence of SCF may allow the identification of genes that are truly indispensable for the HSCs 
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state, under the premise that genes that are not expressed in the cultured population are 
dispensable for HSCs maintenance. A recent study comparing the transcriptome of several 
different phenotypically defined HSCs populations identified an overlapping molecular 
signature (MolO) in a subpopulation of HSCs suggesting that this signature can identify HSCs 
with long-term repopulation potential68. Most genes in this MolO signature were not 
differentially expressed between naïve BM HSCs and cultured HSCs, suggesting that these 
genes among others are indeed likely to be vital for HSCs biology and confirming the HSCs 
identity of cultured HSCs on the transcriptional level. The Ets1 transcription factor was found 
to be upregulated in cultured HSCs. Possibly, Ets1 is involved in stress response to minimal 
cytokine conditions. Alternatively, Ets1 may play a role in the transcriptional regulation of 
myeloid differentiation. In contrast, Gfi1b was downregulated in HSCs suggesting that this 
transcriptional regulator does not play a role in the maintenance of stemness but does not 
exclude its participation in the negative regulation of HSCs self-renewal or differentiation. To 
determine its role, transcriptional changes need to be assessed in HSCs that received SCF 
stimulation after 7 days of culture. Further transcriptional analysis and qPCR will be necessary 
to confirm these findings. Interestingly, Jun and Fos which encode for protein subunits of  
AP-1 were both downregulated in cultured HSCs. This suggests that AP-1 may play a role in 
cell proliferation although contradictory it has been shown that mice lacking JunB expression 
have an increase in cell cycle activity in addition to expansion of HSCs and myeloid cells and 
eventually develop myeloproliferative disease271. Thus, AP-1 regulation of cell proliferation 
may be dependent on the “dose” of Jun and Fos present. To assess how closely 7 day cultured 
HSCs are related to freshly isolated bone marrow HSCs and to investigate what changes occur 
post SCF stimulation, it would be interesting to sequence and compare the transcriptome of 
single cultured HSCs that either were never treated with SCF or received a pulse of SCF 
following 7 day culture. This may allow the identification of genes important for exit from 
quiescence as well as proliferation where self-renewal expansion or maintenance divisions 
occur. The described culture method allows the study of any molecule’s effect on single HSCs. 
For example, due to the discrepancy in the field about the efficacy of SCF in combination with 
TPO it would it may be of interest to study the effect TPO has on HSCs self-renewal and 
proliferation.  
Importantly, it will be essential to test if these culture conditions can be applied to human HSCs. 
As the preliminary results have shown, some phenotypic HSCs can be maintained as single 
cells for 7 days and be subsequently stimulated to proliferate, although they display a delay in 
time to entry into cell cycle. Human HSCs are isolated based on a specific set of surface 
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markers, however to date just 10% of the phenotypic cord blood HSCs population has 
repopulation potential, with even lower capacities in peripheral blood and bone marrow HSCs. 
Thus, if the minimal culture condition indeed enriches for resilient HSCs, which will need to 
be confirmed by xenotransplantation, the transcriptome of surviving HSCs may be compared 
to freshly isolated phenotypic HSCs to assess differentially expressed genes. The gene set 
overexpressed in cultured HSCs may then be probed for molecules such as surface markers that 
can aid further phenotypic enrichment of long-term repopulating human HSCs. Furthermore 
this condition could be used to extend the time window in which cells can be transduced for 
gene editing, while ensuring that exclusively HSCs are targeted. 
 
Cultured single HSCs serially engraft recipient mice and generate predominantly 
myeloid progeny 
The “hibernating” HSCs described by Yamasaki et al. were able to engraft primary recipients 
however, the study did not report if these donor HSCs exhibited any particular lineage bias121. 
In the transplantation data reported in this thesis, a striking tendency of HSCs to produce more 
myeloid cells than lymphoid cells was observed. The ratio of GM:(B+T) was >2, which are 
defined as alpha-HSCs.64. Resilient cells were enriched in the CD150high fraction of the 
phenotypic HSCs pool and prospective gating on CD150high did indeed improve 7 day HSCs 
survival. This suggests that these resilient alpha-HSCs may be phenotypically distinguishable 
from HSCs that have a more balanced lineage ratio (beta-HSCs). This is in agreement with 
previous findings that suggest CD150high enriches for cells with a myeloid lineage bias, whereas 
CD150mid HSCs produce both myeloid and lymphoid cells at similar ratios65,270, and CD150neg 
HSCs have predominantly lymphoid offspring with very little potential to engraft secondary 
recipients65,69,72,290. Additionally, MolO HSCs have been shown to have a higher than average 
expression of CD15068, which again is in line with my findings that minimal culture conditions 
select for true HSCs. 
To verify that CD150high expression indeed enriches for alpha-HSCs, more single cell 
transplantations need to be carried out. However, based on our data, CD150 alone would not be 
sufficient to prospectively isolate highly purified alpha-HSCs. Therefore, it would be useful to 
investigate if any other surface marker molecules or intracellular molecules are enriched in the 
resilient cultured HSCs fraction. This could first be performed by screening for survival in 7 
day cultures and then validated by HSCs transplantation.  
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Previous findings suggest that HSCs with a lymphoid bias proliferate faster than those with a 
predominantly myeloid output69, which may result in their premature death in minimal cytokine 
conditions as the environment is not supportive of proliferation.  
The enrichment in alpha-HSCs after 7 day minimal culture suggests that cells of this subtype 
are more resilient in culture and putatively also in vivo since myeloid-biased HSCs accumulate 
with age151. Interestingly, the distribution between HSCs generating balanced or “myeloid-
biased” HSCs resembles that of HSCs derived from aged donor mice (38–46 weeks) rather than 
young adult mice (8–16 wks) which were used as donors. It would be interesting to assess if 
aged HSCs have generally a better survival outcome in minimal culture conditions as they have 
already proven to be more resilient in vivo. Furthermore, comparison of the transcriptional 
programs in young naïve, aged, and young cultured HSCs could putatively identify pathways 
that are involved in the extended survival of the latter two cell population. 
In agreement with Morita et al. I hypothesise that alpha-HSCs represent the apex of the 
haematopoietic hierarchy, predominantly generating myeloid cells (most cells of the innate 
immune system), and transforming to beta-HSCs when cells of the adaptive immune system 
are required. This hypothesis is formed under the premise that any organism possessing both 
an innate and adaptive immune system should encounter the vast majority of pathogens in the 
early years of life. Therefore, activation of the adaptive immune response with age would be 
mediated through already existing B and T cell progenitors and would not stem from HSCs. In 
contrast, cells of the innate immune system have a limited life span and therefore require regular 
replenishing. Therefore, HSCs capable of producing a vast amount of myeloid cells are required 
until death explaining why these cells accumulate in aged individuals. Tools to test this 
hypothesis in mouse are currently not available, as a system is required in which both lymphoid 
and myeloid progenitors carry different labels, which are also distinct from a label present in 
the common ancestral HSCs and which in turn is altered with ageing. If the hypothesis holds 
true, an aged HSCs specific label should be undetectable in lymphoid cells.  
However, a recent study in an aged, healthy human individual made use of randomly occurring 
somatic mutations in both primitive and differentiated cells to track the population dynamics 
during homeostasis. While this cannot formerly prove the hypothesis on the single cell level, 
the study did show that not all HSCs contribute equally to haematopoiesis and that T cells and 
granulocytes separate earlier in life291.  
Understanding the molecular mechanisms that drive HSCs fate choice, in particular the decision 
to branch into the myeloid or lymphoid lineage may aid in the identification of molecules and 
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pathways aberrantly regulated in the development of leukaemia and present druggable targets 
for treatment.  
 
Softer hydrogels favour HSPC maintenance and survival in vitro  
HSCs reside in the bone marrow niche which is greatly different from the tissue culture plastics 
they are commonly cultured in. These differences comprise extracellular signalling molecules, 
lack of cell-to-cell interaction, and importantly a lack or change in matrix elasticity. Defining 
conditions that mimic the 3D architecture of the bone marrow niche in vitro would allow the 
teasing apart of mechanical effects from biochemical cues and enable us to study how HSCs 
biology is affected by matrices of different stiffness242,244. 
 
To investigate the role physical forces play in HSCs retention, I cultured single HSCs on 
agarose based hydrogels covering a range of matrix elasticity similar to that of the bone marrow. 
HSCs thrived better on matrices that were composed of lower concentrations of agarose, 
making them less stiff. Better retention of the HSPC population was also observed on softer 
hydrogels. This is in agreement with previous reports showing that HSCs are better maintained 
on soft tropoelastin coated plates when compared to non-coated controls247. 
 
However, other gel components such as extracellular matrix proteins and fibrin did have no 
apparent effect on HSCs survival and HPSC retention. Therefore, it may be needed to 
individually assess the impact these factors have on HSCs fate choice. Particularly, the hydrogel 
set up may not be ideal to study the effect of fibrin on HSCs, as this protein may degrade in 
culture. The addition of tranexamic acid or Aprotinin, both anti-fybrinolitic molecules, may 
extend the half-life of the fibrin network292. To assess HSCs survival in a more stringent 
manner, it may be useful to implement the minimal cytokine conditions in the culture of HSCs 
on hydrogels. Due to the great decline of HSCs on tissue culture plastic in minimal culture, any 
conditions significantly improving cell survival would certainly become apparent.  
 
Further screens are necessary to narrow down specific conditions that are optimal for HSCs 
expansion. Ideally, once the optimal conditions have been identified, these then can be 
employed to generate agarose droplets, which can be functionalised for high-throughput 
screening of factors affecting HSCs fate choice. Ultimately, HSCs expansion conditions can be 
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applied to the culture of human HSCs with the target of human HSCs expansion for clinical 
applications.  
 
Overall, in this PhD thesis I was able to show that short term ex vivo stimulation of SCF/KIT 
signalling modulates the clonal expansion of HSCs in vivo without altering HSCs engraftment 
capabilities. This shows that the SCF/KIT signalling axis is vital for HSCs self-renewal but not 
maintenance of stem cell function. The latter is also reflected in the finding that HSCs can be 
maintained as single cells in vitro for extended periods of time in the absence of SCF/KIT 
signalling while maintaining HSCs function. Additionally, I could show that HSCs are better 
retained on hydrogels with a soft matrix, similarly to the elasticity found in the bone marrow 
and thus formally prove that physical forces can alter HSCs fate choice.  
 
These findings may have great implications for the culture of human HSCs aiming at the 
expansion for autologous stem cell transplantation as well as possible pre-treatment 
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Appx-A Figure 1: Quality control parameters for single HSCs processed in batch SLX-12565.  
Red dots depicts cells excluded from analysis (62) following thresholds set for mapped reads 
(>2*105), reads mapping to genes (>0.2), and reads mapping to mitochondrial genes (<0.2). Black 
dots depicts cells that passed quality control (129). Additional parameters (individual Y axis) were 
not applied as these would not have excluded further cells and aided in ensuring quality control. Total 





Appx-A Figure 2: Quality control parameters for single HSCs processed in batch SLX-12566. 
Red dots depicts cells excluded from analysis (50) following thresholds set for mapped reads 
(>2*105), reads mapping to genes (>0.2), and reads mapping to mitochondrial genes (<0.2). Black 
dots depicts cells that passed quality control (141). Additional parameters (individual Y axis) were 
not applied as these would not have excluded further cells and aided in ensuring quality control. Total 





Appx-B Table 1: Gene ontology terms significantly enriched in HSCs stimulated with  
30 ng/mL SCF compared to freshly isolated HSCs. 
Gene ontology biological process P-value 
Adjusted 
P-value 
DNA metabolic process (GO:0006259) 3.52E-16 4.93E-13 
DNA-dependent DNA replication (GO:0006261) 1.38E-12 9.7E-10 
DNA replication (GO:0006260) 2.09E-12 9.76E-10 
DNA replication initiation (GO:0006270) 4.93E-08 1.15E-05 
G1/S transition of mitotic cell cycle (GO:0000082) 3.04E-12 1.07E-09 
cell cycle G1/S phase transition (GO:0044843) 9.2E-10 2.58E-07 
positive regulation of DNA-directed DNA polymerase activity (GO:1900264) 0.000102 0.009544 
DNA strand elongation involved in DNA replication (GO:0006271) 9E-05 0.009544 
nucleotide-excision repair, DNA incision, 5'-to lesion (GO:0006296) 0.000213 0.015936 
regulation of DNA-directed DNA polymerase activity (GO:1900262) 0.000102 0.009544 
error-prone translesion synthesis (GO:0042276) 0.000216 0.015936 
DNA repair (GO:0006281) 5.65E-06 0.000879 
cellular macromolecule biosynthetic process (GO:0034645) 8.23E-06 0.001153 
regulation of transcription involved in G1/S transition of mitotic cell cycle 
(GO:0000083) 
3.91E-05 0.004567 
nucleotide-excision repair, DNA gap filling (GO:0006297) 2.13E-05 0.002719 
error-free translesion synthesis (GO:0070987) 0.000177 0.015496 
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Appx-B Table 2: Gene ontology terms significantly enriched in HSCs stimulated with  
300 ng/mL SCF compared to freshly isolated HSCs. 
Gene ontology biological process P-value 
Adjusted 
P-value 
DNA replication (GO:0006260) 5.1E-13 2.02E-10 
regulation of transcription involved in G1/S transition of mitotic cell cycle 
(GO:0000083) 1E-10 2.38E-08 
DNA metabolic process (GO:0006259) 2.86E-14 3.41E-11 
strand displacement (GO:0000732) 1.6E-07 2.12E-05 
G1/S transition of mitotic cell cycle (GO:0000082) 6.91E-14 4.11E-11 
DNA-dependent DNA replication (GO:0006261) 1.25E-10 2.47E-08 
DNA replication checkpoint (GO:0000076) 5.4E-07 6.42E-05 
cell cycle G1/S phase transition (GO:0044843) 7.18E-11 2.14E-08 
cellular response to DNA damage stimulus (GO:0006974) 2.38E-09 3.54E-07 
DNA biosynthetic process (GO:0071897) 1.87E-06 0.000186 
mitotic cell cycle phase transition (GO:0044772) 3.46E-10 5.88E-08 
DNA repair (GO:0006281) 6.43E-07 6.96E-05 
cellular macromolecule biosynthetic process (GO:0034645) 2.21E-06 0.000202 
regulation of transcription from RNA polymerase II promoter in response to 
oxidative stress (GO:0043619) 0.00303 0.069333 
regulation of double-strand break repair (GO:2000779) 1.8E-05 0.001258 
positive regulation of mitophagy in response to mitochondrial depolarization 
(GO:0098779) 0.001789 0.048394 
positive regulation of cell cycle arrest (GO:0071158) 1.32E-05 0.001041 
DNA replication initiation (GO:0006270) 8.2E-05 0.004644 
photoperiodism (GO:0009648) 0.001104 0.033671 
double-strand break repair via homologous recombination (GO:0000724) 8.68E-05 0.004696 
DNA replication-dependent nucleosome assembly (GO:0006335) 0.000128 0.005939 
DNA recombination (GO:0006310) 1.4E-05 0.001041 
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Appx-B Table 3: Genes upregulated in HSCs treated with 300 ng/mL SCF compared to both 
30 ng/mL SCF and freshly isolated HSCs. 
Gene ID ENSEMBL ID 
Cav2 ENSMUSG00000000058 
Kdelr2 ENSMUSG00000079111 
Rnf187 ENSMUSG00000020496 
Msn ENSMUSG00000031207 
Gem ENSMUSG00000028214 
Vps35 ENSMUSG00000031696 
2810474O19Rik ENSMUSG00000032712 
Plek ENSMUSG00000020120 
Ctnna1 ENSMUSG00000037815 
Lyn ENSMUSG00000042228 
Bzw1 ENSMUSG00000051223 
Hmgcr ENSMUSG00000021670 
Naa40 ENSMUSG00000024764 
Tubb6 ENSMUSG00000001473 
Ash2l ENSMUSG00000031575 
Zdhhc13 ENSMUSG00000030471 
Galk1 ENSMUSG00000020766 
Pidd1 ENSMUSG00000025507 
Lypla1 ENSMUSG00000025903 
Tmem120a ENSMUSG00000039886 
 
